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Background: Tuberculosis (TB) is the ninth leading cause of death worldwide 
and the leading cause of death from an infectious agent. While control efforts have 
achieved gradual reductions in TB incidence globally, continuing these declines into the 
future will require the interface of many scientific and public health disciplines. 
Methods: We conducted three investigations of TB biology and epidemiology in 
a multidisciplinary approach to public health research for infectious disease control. We 
articulated a novel framework for linking individual-level TB disease progression with 
population-level clinical outcomes; we investigated the molecular mechanisms of 
pyrazinamide action on TB inhibition; and we modeled the influence of multidrug 
resistant TB (MDR-TB) transmission efficiency on long-term projections of the TB 
epidemic. 
Results: Our mathematical framework effectively links individual disease 
progression dynamics with clinical outcomes, and we demonstrate the impact of these 
dynamics on important epidemiological metrics. We identify a novel protein interaction 
between Ribosome Recycling Factor and bacterial protein RpsA, a potential target of 
pyrazinamide action. Finally, we demonstrate that predicted trends in future MDR-TB 
epidemics are highly sensitive to variations in MDR-TB transmission efficiency. 
Conclusions: This dissertation provides a unique example of how research 
through multiple lenses of public health science may provide novel insight into infectious 
disease control.  
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never do the things I do if Samantha did not do everything she does for me. Samantha, 
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 During my time here at Johns Hopkins, I have trod many paths and been part of 
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advisor and lent his support to my research with the Epidemiology department at a 
critical juncture in my studies, a seemingly small act that I will forever consider heroic. I 
must also extend my gratitude to all of the members of my thesis committee: David 
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given me over the years. Thank you. I cannot understate my thanks to the nine other PhD 
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GLOBAL TUBERCULOSIS AND PUBLIC HEALTH 
 
 Tuberculosis (TB) represents one of the most significant causes of infectious 
disease morbidity and mortality worldwide. The World Health Organization (WHO) 
estimates that, in 2016, 10.4 million new cases of TB occurred, causing 1.6 million 
deaths [1]. It is the ninth leading cause of death globally, and the leading cause of death 
from an infectious agent. (By comparison, an estimated 1.1 million deaths associated 
with HIV/AIDS occurred in 2016, of which 370,000 were related to TB [2].) The 
etiologic agent of TB, the acid fast bacterium Mycobacterium tuberculosis, is estimated 
to currently infect 1.7 billion individuals – roughly 23% of the global population – of 
which 56 million are considered at high risk of developing disease in the near future [3].  
Despite significant progress over the last half century, outcomes for TB patients 
remain inadequate. Approximately 72% of TB cases who go untreated are expected to die 
as a result [4]. Only 61% of TB cases are currently diagnosed, and still fewer are able to 
access appropriate treatment after diagnosis [1]. While many TB patients who start 
standard TB treatment regimens experience successful outcomes, such results are far 
from universal. Standardized short-course treatment regimens with directly observed 
therapy have improved cumulative treatment success for TB patients to 83% globally. 
However, in some patient populations, such as those with M. tuberculosis infections 
resistant to one or more first-line drugs, treatment success falls below 50% [1,5]. To 
address the heavy toll taken by TB worldwide and to fundamentally reduce the disability 
and loss of life caused by TB, the public health community must better understand the 
complexity of this disease from the fundamental biology of the pathogen to the epidemic 
spread of disease across vulnerable populations. 
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EPIDEMIOLOGY AND CONTROL OF TUBERCULOSIS 
 
 Infections with M. tuberculosis are transmitted through the inhalation of 
aerosolized droplet nuclei containing the bacterium; as a result, new infections are seeded 
by index cases infected with a high pulmonary burden of M. tuberculosis cells. Control of 
the TB epidemic and the prevention of new TB cases often focuses on minimizing the 
number of new infections caused through aerosol transmission, necessitating 
identification and treatment of existing infectious TB cases. Pulmonary TB cases were 
reported in 185 countries in 2016, and hundreds of thousands of cases occurred in each 
WHO region [1]. Most incident TB cases occurred in Southeast Asia, and three countries 
– India, Indonesia, and China – accounted for approximately 45% of all global TB cases. 
While the greatest numbers of TB cases occur in Asia, the greatest concentration of TB 
cases occurs in sub-Saharan Africa. There, 254 new TB cases occurred for every 100,000 
individuals in the population, and incidence rates in some areas reached over 700 per 
100,000 (e.g., in South Africa). While TB remains the leading cause of infection-related 
deaths worldwide, global TB incidence rates have declined since 2000 at an average rate 
1.4% per year, though this rate must reach 4-5% per year by 2020 to achieve TB targets 
adopted by the World Health Assembly [1]. To reach these targets, TB control programs 
must use currently available measures to prevent and treat incident cases of TB. 
 Few tools can provide adequate protection against TB. The only widely used 
vaccine for TB – Bacillus Calmette–Guerin, first developed in 1921 [6] – is only 46% 
efficacious generally and likely only 13% efficacious in areas home to populations at 
greatest risk for TB [7]. For those who have been infected but remain asymptomatic – 
4 
 
commonly termed latent TB infection – the progression to symptomatic disease can be 
prevented with isoniazid preventive therapy (IPT). Such regimens require daily or weekly 
doses of antibiotics and are recommended for six months (up to nine months in low-
burden settings), similar in duration to a treatment course for active TB [1]. IPT may 
reduce the risk of TB by more than 90% (provided that therapy is taken for 12 months or 
longer) [8]. Newer preventive regimens combining isoniazid and a rifamycin (such as 
rifampin or rifapentine) may shorten therapy for latent infection from nine months to 
twelve weeks [9]. These promising regimens demonstrate little significant reductions in 
efficacy, though at an increased cost for each TB case averted [10,11]. Importantly, such 
therapy does not prevent reinfection after the regimen is withdrawn, and in high-
incidence areas, protection may diminish within 6 months after the end of therapy [12].  
 In the absence of effective prevention measures, most TB control strategies rely 
on the detection and treatment of infectious patients to minimize the transmission of M. 
tuberculosis. For patients infected with strains of M. tuberculosis susceptible to first-line 
anti-mycobacterial antibiotics, the WHO recommends the administration of a 
standardized combination regimen daily or weekly for six months [1]. In the intensive 
phase (the first two months) of the regimen, four drugs – isoniazid (INH), rifampin (RIF), 
pyrazinamide (PZA), and ethambutol – are given; thereafter, two of the drugs – INH and 
RIF – are given throughout the continuation phase (the subsequent four months) of 
treatment. When TB patients adhere to this standard therapy, long-term treatment success 
rates can reach over 90% [13]. Success can be diminished, however, by non-adherence or 
loss to follow-up during treatment. To address these issues, treatment regimens are also 
paired with directly observed therapy – in which a second observer monitors and records 
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the consumption of each scheduled dose of antibiotic – that can lead to treatment 
completion for 90% of TB patients [14]. However, this standard treatment regimen may 
fail to adequately cure TB patients who are infected with strains of M. tuberculosis 
genetically resistant to any of the four drugs in the regimen, particularly with infections 
resistant to both INH and RIF – termed multidrug resistant TB (MDR-TB). Even under 
optimal conditions, only 25-50% of MDR-TB patients are successfully treated with the 
standard regimen, many of whom will relapse with MDR-TB within two years after the 
end of therapy [15,16].  
 Attempts to replicate the success of six-month first-line therapy using second-line 
antibiotics have not been fruitful. One factor contributing to the inadequate efficacy of 
second-line regimens is the small pool of alternative antibiotics available to replace first-
line agents [17]. A limited number of novel drugs with promising anti-tuberculosis 
activity have emerged in the last decade (e.g., bedaquiline, delaminid, and pretomanid), 
but whether they can achieve treatment success comparable with first-line agents remains 
unclear [18]. While longer (18-24 month) second-line regimens may improve treatment 
success for MDR-TB patients, such interventions place heavy financial burdens on 
patients and health systems, are associated with significant adverse side effects, and still 
fail to achieve durable cure for half of eligible patients [1,5]. A fruitful alternative may be 
the development of second-line agents which mirror the pharmacodynamics activity of 
first-line agents. For example, no single alternate agent may replace the sterilizing 
activity of PZA with comparable success [19], and no PZA analogues have been 
successfully developed. Unlike other first-line agents, the mechanism of action of PZA 
remains unclear, although recent studies suggest the involvement of a bacterial ribosomal 
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protein, RpsA [20]. Until such time when second-line regimens can effectively and 
rapidly treat drug resistant TB, these difficult cases will remain a heavy burden on TB 
control programs. As a result, control of the global TB epidemic may depend greatly on 





NATURAL HISTORY AND PATHOGENESIS OF TUBERCULOSIS 
 
M. tuberculosis exhibits a complex lifecycle in humans, often remaining clinically 
silent but occasionally manifesting in clinical pathologies. In the pre-antibiotic era, 
approximately 70% of microbiologically confirmed and clinically symptomatic infections 
led to death within 10 years of symptom onset, and most TB cases progressed to death or 
self-limited resolution of symptoms within approximately three years of symptom onset 
[4]. The complex molecular mechanisms underlying these clinical observations are 
described below, with particular emphasis on processes of initial M. tuberculosis 
infection, progression to clinical TB, and the role of HIV infection in pathogenesis. 
 
Primary Infection 
A productive M. tuberculosis infection originates following the inhalation of a 
single, aerosolized droplet nucleus containing 1-3 bacterial cells (Figure 1.1A) [21]. At 
the site of implantation, bacteria are phagocytosed by unactivated alveolar macrophages – 
which are ineffective in destroying the bacterium – where early rounds of replication 
occur in the immature phagosome (Figure 1.1B.1). If the infected macrophage is unable 
to destroy the phagocytosed bacillus, intracellular bacterial proliferation may lead to 
necrosis or apoptosis of the host cell (Figure 1.1B.2) [22].  
Before the onset of the adaptive immune response, bacterial replication occurs 
relatively uninhibited in the airspaces and in the phagosomes of myeloid dendritic cells as 
well as newly-arrived alveolar macrophages and circulating monocytes [23]. Cytokines 
such as Tumor Necrosis Factor (TNF) released by innate immune cells act to 
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permeabilize the vascular endothelium and attract additional phagocytic cells to the site 
of infection (Figure 1.1B.3, Figure 1.2) [23]. The continuous influx of innate immune 
cells at the site of bacterial replication constitutes the formation of an early granuloma, a 
defining feature of pulmonary TB (Figure 1.1B.4, reviewed in [27]). The early granuloma 
is characterized by populations of highly motile roving macrophages as well as smaller 
populations of dendritic cells and polymorphonuclear leukocytes (PMNs), creating an 




Figure 1.1: The Natural History of Tuberculosis Infection 
 
(A) M. tuberculosis is transmitted via aerosolized droplet nuclei, each with an aerodynamic diameter 
smaller than 5μm and containing 1–3 bacterial cells. The small size of the particle facilitates deposition in 
the terminal alveoli of the lungs rather than in the tissues of the larger airways. (B) Upon deposition in an 
alveolus, M. tuberculosis is phagocytosed by unactivated alveolar macrophages (part 1). The bacterium 
eventually kills the infected macrophage by either necrosis or apoptosis, escaping into the alveolar tissues 
(part 2). Replication of the bacterium continues unabated in the extracellular space and within newly 
arrived dendritic cells and macrophages (part 3). Cytokine signaling attracts further macrophages, 
monocytes, and dendritic cells, which form the early granuloma (part 4). Upon arrival of mature TH1 cells, 
macrophages become activated and can more effectively kill or contain the bacterium. Some of these 
macrophages become epithelioid, forming a capsule surrounding the necrotic region of bacterial survival 
and containing the infection from progressing further (part 5). Following immunologic suppression, the 
bacterial population may destroy immune cells at the luminal surface of the granuloma, causing the 











In some cases, bacteria are phagocytosed by macrophages or dendritic cells which 
traffic to the draining hilar lymph nodes, leading to lymphohematogenous dissemination 
and seeding of distal sites of infection [27,29]. At this time, approximately 3-8 weeks 
following initial implantation, dendritic cells presenting M. tuberculosis antigens via 
MHC-II molecules to immature CD4+ T cells in the context of IL-12 and a costimulatory 
signal from B7:CD28 interactions triggers T cell maturation into TH1 cells (Figure 1.2). 
As mature TH1 cells traffic from the lymph nodes to the pulmonary and extrapulmonary 
sites of infection, they release IFN-γ which, with costimulation through CD40:CD40L 
interactions, activates local macrophages and monocytes and triggers oxidative bursts, 
phagolysosomal maturation, production of antimicrobial molecules (ROS, RNI, NO, 
NOS2, defensins, surfactants, etc.), secondary granule fusion, and epithelioid 
macrophage differentiation (Figure 1.2)  
The cumulative effects of the onset of the adaptive immune response are to 
substantially reduce the net rate of bacterial growth to an equilibrium at the site of 
infection, limit extracellular survival of bacteria, and cause maturation of the granuloma 
to a fibro-epithelioid lesion (Figure 1.1B.5) [33–35]. In certain individuals, the adaptive 
immune response and concomitant granuloma maturation is sufficient to sterilize the 
infection, leaving only a healed, calcified lesion; in most cases, however, the bacterial 
population continues to survive. For a small number of individuals (~5% of those 
recently infected) [36], the infection will progress rapidly to active, symptomatic disease 
(termed primary progressive TB) within approximately 15-30 weeks [37] but potentially 




clinically silent, long-term latent state, of which 5-10% will eventually reactivate to cause 
symptomatic secondary TB [39,40]. 
 
Primary Progressive Tuberculosis 
In roughly 5% of infections with M. tuberculosis, the infection is never 
sufficiently contained in the maturing granuloma [36]. As a result, these patients will 
rapidly develop symptomatic disease, termed primary progressive TB, over the course of 
weeks or months following the initial infection. In low-incidence settings, such disease 
makes up only 14% of prevalent cases of TB [41], but this may increase to 72% in high-
incidence settings [42,43]. While this has been hypothesized to occur due to insufficient 
cellular immunity at the time of initial infection (particularly in children), further research 
is required to robustly test this hypothesis. Because the bacterial population is never 
contained in a mature granulomatous lesion, disease may disseminate diffusely 
throughout the lung or into the vasculature and throughout the body in a condition known 
as miliary TB. 
 
Secondary Tuberculosis 
Once an initial infection has been contained in a latent state, it can remain latent 
for years or decades and many patients will never report symptoms of TB during their 
lifetimes. In roughly 5-10% of latent infections, the infection may reactivate leading to 
gross necrosis in affected regions of the lung [49]. Many cases of reactivated secondary 
TB follow an insult to the immunological system responsible for continuously controlling 




(inhibition of TNF) or adaptive immunity (reduction in CD4+ T cells), and a nontrivial 
contributing role of multiple host genetic variants has also been identified (Figure 1.2) 
[31]. The following dysregulation may provide an advantage for bacterial cells to 
proliferate and destroy populations of macrophages at the luminal surface of the 
granuloma, leading to accumulation of caseous necrosis as nearby lesions enlarge and 
merge (Figure 1.1B.6) [34]. Key in this process is the secretion of host matrix 
metalloproteinases (MMPs) in response to the accumulation of mycobacterial products 
such as ESAT-6 which function to continuously degrade pulmonary collagen as well as 
to modulate host immune chemokines [50,51]. Eventually, these lesions may erode into 
larger respiratory airways, discharging the liquefied caseum from the necrotic cavities 
into the bronchial tree. Once the liquefied necrotic material has been evacuated, this 
material may seed bacteria in other sites of the lung and may lead to the aerosolization of 
droplet nuclei, continuing the chain of transmission. 
 
Interactions with HIV 
Following the emergence of HIV as a global pandemic in the 1980s, co-infection 
has appeared as one of the leading risk factors driving TB epidemiology. The most 
important effects of HIV infection are indirect: depletion of CD4+ TH1 cells leads to an 
increased risk of secondary TB in individuals with latent infection [47,55]. However, 
HIV infection may also have more direct effects on the pathophysiology of tuberculosis 
infections [56]. HIV has been shown to preferentially infect CD4+ T cells specific to M. 
tuberculosis peptides, even in comparison with T cells specific for other opportunistic 




coreceptors CCR5 and CXCR4, HIV can also co-infect M. tuberculosis-infected 
macrophages leading to macrophage dysfunction and inhibited killing [58,59]. Within the 
granulomatous environment, HIV may interfere with TNF expression and lead to 
increased caseous necrosis [60,61]. Circulating monocytes infected with HIV upregulate 
production of the macrophage-attractant chemokine CCL2 and can skew the cellular 
immune response to a TH2 phenotype [62,63]. Finally, because the typical immune 
response to TB involves production of proinflammatory cytokines (such as TNF, IL-1β, 
and IL-6) which favor replication of HIV, coinfection may trigger reciprocal effects 




Figure 1.2: Immunologic Responses to M. tuberculosis 
 
Following initial infection with M. tuberculosis, alveolar macrophages secrete the pro-inflammatory 
cytokine TNF. As the early granuloma forms, dendritic cells sample M. tuberculosis antigens and traffic to 
the secondary lymphatic tissues to begin antigen presentation. When an immature CD4+ T cell successfully 
and specifically binds the dendritic cell’s antigen/MHC-II complex and B7, the cell may mature into one of 
two phenotypes. In the presence of the costimulatory molecule IL-12, the cell will mature into an IFN-γ-
producing TH1 cell, while in the presence of IL-6 and TGF-β molecules, the cell will mature into an IL-17-
producing TH17 cell. The arrival of TH1 cells carrying CD40L and secreting IFN-γ activates macrophages 
at the site of infection, producing an oxidative burst leading to the destruction of bacterial cells and 
maturation of the granuloma. As the infection progresses, a deficiency in the TH1 response (particularly 
through reductions in TNF or IFN-γ signaling) may result in caseous necrosis, destruction of immune cells 
throughout the granuloma, and bacterial escape. TH17 cells may contribute to the pathological damage of 
M. tuberculosis through secretion of IL-17, which stimulates the migration of PMNs, which produce a 
variety of oxidative species capable of damaging host cells. In addition, IL-17 contributes to the secretion 
of several matrix metalloproteinases by macrophages, PMNs, and epithelial cells. TNF, tumor necrosis 
factor; MMP, matrix metalloproteinase; ROS, reactive oxygen species; RNI, reactive nitrogen 
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EXPERIMENTAL ANIMAL MODELS OF TUBERCULOSIS 
 
 Animal models represent important methodological tools in understanding – and 
ultimately controlling – human TB. Key insights from such studies have informed our 
understanding of TB transmission [21], immunology [25], pathogenesis [65], and 
treatment. The most common experimental model of M. tuberculosis infection is the 
mouse, which offers several distinct advantages in the study of TB: mice are inexpensive, 
can tolerate high infectious doses used in many experimental approaches, and a plethora 
of genetic and immunological tools exists for the manipulation and interrogation of 
biological processes in mice [66,67]. Despite these advantages, in several ways mice are 
poorly representative of TB pathology in humans. Most murine models do not develop 
caseating granulomas – a defining characteristic of human TB related to the production of 
infectious aerosols – and instead develop non-caseating necrotic lesions [68,69]; mice fail 
to develop true latent infections and instead develop long-term chronic pathology [70,71]; 
mice progress from initial infection to death much more rapidly than humans [72]; and 
mice are not known to self-resolve infections with M. tuberculosis, eventually 
progressing to death regardless of inoculating dose [72].  
Alternative animal models are occasionally used in place of mice. Guinea pigs are 
particularly susceptible to infection and routinely develop caseating granulomas, making 
them a useful model for the study of TB inhalation and implantation [21,73]; however, 
relatively few molecular or immunological tools have been developed for the 
experimental manipulation of guinea pig immunology [66–68]. Rabbits similarly develop 
caseating granulomas as well as cavitary lesions but are relatively resistant to TB 
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infection – often substituted by infection with M. bovis in experimental studies – and 
most rabbits experience self-limited disease before spontaneously resolving [66–68]. 
Still, none of these animal models faithfully represent human sensitivity to infectious 
exposure; latent infection progressing to active disease; long durations between 
characteristic stages of infection; and heterogeneity in outcome (ranging from possible 
self-resolution or progression to death). Most of these distinct features of human disease 
are recapitulated by nonhuman primate models, but such models are prohibitively 
expensive for most experimental questions and inferences drawn from such studies are 
limited by small sample sizes. Despite the wealth of information about specific aspects of 
the pathological process learned from animal models, there remains a critical gap in 
connecting these processes to clinically-relevant outcomes in human populations. 
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DRUG RESISTANT TUBERCULOSIS 
 
 In M. tuberculosis, drug resistance emerges through the stepwise acquisition of 
individual chromosomal mutations, with no apparent acquisition through horizontal gene 
transfer [74]. As a result, a TB patient may be initially infected with an MDR-TB strain 
(termed primary resistance), or she may be initially infected with a drug susceptible strain 
which progressively develops into MDR-TB through de novo acquisition of mutations 
conferring resistance to INH and RIF (secondary resistance). Such secondary resistance 
may develop as a result of subtherapeutic drug regimens due to patient nonadherence, 
poor drug quality, and/or patient-dependent pharmacokinetic properties [75]. While 
improved treatment regimens for drug susceptible TB can minimize the probability of 
developing secondary resistance, the impact of primary resistance and the transmission of 
MDR-TB between patients remains widely debated. 
Traditional TB dogma holds that phenotypic drug resistance in a bacterial 
population carries a physiological tradeoff [76,77]; therefore, mutations conferring drug 
resistance are likely to be accompanied by a reduction in reproductive fitness in the 
absence of the drug. This dogma dates to observations made in the 1950s that INH 
resistant clinical and laboratory strains of TB caused disease less frequently in guinea 
pigs than drug sensitive strains, and that this loss in virulence was inversely correlated 
with minimum inhibitory concentrations of INH [78,79]. These observations were 
corroborated in the following decades with both clinical isolates and laboratory mutants 
resistant to INH and/or RIF [80–82]. However, experimental evidence has also accrued 
which contradicts the fitness cost hypothesis. Screens of clinical isolates with varying 
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degrees of resistance to INH, RIF, and other antibiotics demonstrate that different isolates 
can be less virulent, equally virulent, or more virulent than drug sensitive strains in mice, 
and that the degree of virulence is not necessarily associated with any trends in drug 
resistance [83]. Multiple studies have confirmed that – within a given phenotype of drug 
resistance – the degree of laboratory fitness is highly dependent on the specific 
resistance-conferring chromosomal mutations present [77,82,84]. Genetic epistasis – in 
which secondary mutations (unrelated to antibiotic resistance) confer physiological 
benefits in the presence of resistance-conferring mutations – has also been shown to 
compensate physiological fitness costs [85–87].  
Most studies of the fitness costs of drug resistance in M. tuberculosis have been 
conducted by assessing the growth of resistant organisms in co-culture with drug 
susceptible organisms, or by comparing the virulence of each strain in laboratory animals 
infected under controlled conditions. Yet for the purposes of public health, these assays 
do not capture many characteristics of the complex natural history of infection: the 
successful transmission of M. tuberculosis from an initial host to a secondary host in 
whom it establishes infection, replicates, and subsequently transmits again [88,89]. 
Extrapolating laboratory findings to humans is further limited by the animal models 
commonly used in the study of TB which, as described above, may fail to faithfully 
represent the TB disease process of humans [68]. In vitro or in vivo growth rates may or 
may not represent growth rates in situ, which in turn may not correlate with clinical 
virulence or population-level transmission dynamics. 
 To complement studies of physiological fitness costs in laboratory models, 
molecular epidemiological methods have also been employed. Studies of genetic 
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clustering investigate TB cases with genetically related M. tuberculosis infections as 
evidence of recent TB transmission. Such studies have found that MDR-TB strains 
cluster anywhere from 10-fold more to 10-fold less than drug sensitive TB strains in 
various studies and settings [90]. Phylogenetic analyses have been used to reconstruct 
extensive chains of MDR-TB transmission [91,92], and even extensively drug resistant 
TB (resistant to INH, RIF, as well as a fluoroquinolone and a second-line injectable 
agent) has been observed to cause explosive outbreaks [93].  
How these characteristics may contribute to long-term MDR trends in the global 
TB epidemic are difficult to evaluate empirically, and thus dynamic mathematical models 
using differential calculus have been used to estimate the impacts of fitness costs on the 
spread of MDR-TB. Mathematical models developed assuming a significant fitness cost 
associated with drug resistant TB predict that such strains are unlikely to ever displace 
sensitive strains as the dominant burden of disease, provided drug sensitive TB is treated 
effectively [94], and that MDR-TB will remain a localized problem in areas where it 
develops [95]. However, when MDR-TB strains are considered to have variable fitness 
costs, MDR-TB may eventually outnumber drug sensitive cases [96,97], consistent with 
recent estimates which suggest that 95% of incident MDR-TB cases in recent years were 









 The effective control of the global TB epidemic in coming decades will require 
the integration of both fundamental biology and epidemiology to develop novel tools for 
TB control and to effectively optimize and implement those tools already available. This 
work aims to provide an example of how these disciplines, often divided by methods and 
expertise, may be effectively linked in the practice of public health science. In Chapter II, 
we develop a theoretical framework for linking host-level pathogen dynamics with 
population-level clinical outcomes, demonstrating the utility of interrelating pathogen and 
epidemiological characteristics in understanding clinical TB. In Chapter III, we 
investigate the role of the bacterial ribosomal protein RpsA in the action of PZA and 
report a novel interaction with Ribosome Recycling Factor, representing a possible 
conserved bacterial function inhibited by PZA. In Chapter IV, we investigate how 
competing assumptions about the fitness costs of drug resistance influence long-term 
projections of the MDR-TB epidemic and demonstrate that the future of MDR-TB 
depends on the relative efficiency with which MDR-TB transmits infection. Finally, in 
Chapter V, we summarize these results in the context of current TB control and future 
scientific inquiry. Cumulatively, these studies offer an innovative approach to answering 
questions of public health relevance through the lenses of multiple scientific disciplines 
and provide a model for investigations in the field of TB control and beyond. 
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Background: Substantial individual heterogeneity exists in the clinical 
manifestations and duration of active tuberculosis. We sought to link the individual-level 
characteristics of TB disease to observed population-level outcomes. 
Methods: We developed an individual-based, stochastic model of TB disease in a 
hypothetical cohort of patients with smear-positive TB. We conceptualized the disease 
process as consisting of two states – progression and recovery – including transitions 
between the two. We then used a Bayesian process to calibrate the model to clinical data 
from the pre-chemotherapy era, thus identifying the rates of progression and recovery 
(and probabilities of transition) consistent with observed population-level clinical 
outcomes. 
Results: Observed outcomes are consistent with slow rates of disease progression 
(median doubling time: 84 days, 95% uncertainty range 62-104) and a low, but nonzero, 
probability of transition from disease progression to recovery (median 16% per year, 95% 
uncertainty range 11%-21%). Other individual-level dynamics were less influential in 
determining observed outcomes.  
Conclusions: This simplified model identifies individual-level dynamics – 
including a long doubling time and low probability of immune recovery – that 
recapitulate population-level clinical outcomes of untreated TB patients. This framework 
may facilitate better understanding of the population-level impact of interventions acting 
at the individual host level. 
  





Tuberculosis (TB) remains one of the leading causes of death worldwide, with an 
estimated 23% of the world’s population infected and 1.4 million individuals dying of TB 
in 2015 [1,2]. The spectrum of disease caused by Mycobacterium tuberculosis 
demonstrates marked heterogeneity in terms of pathological presentation [3], incubation 
period [4], infectiousness [5], treatment responses [6], and other key clinical 
characteristics. While experimental studies have described underpinning biological 
mechanisms [7], and epidemiological studies have identified risk factors for TB 
progression at the population level [8], integrating these distinct approaches remains a 
complex task. 
Epidemiological models are often utilized to make inferences about dynamics of 
complex systems, such as transmission of drug-resistant TB [9] and population-level 
impacts of various interventions [10]. In many such models, however, individual-level 
temporal dynamics and pathological processes (such as disease onset, progression, cure, 
and death) are simplified as population-level rates or probabilities. In contrast, within-
host models can help disentangle individual-level dynamics of M. tuberculosis 
replication, host immune cell responses, cytokine signaling, pathology, and bacterial 
metapopulations [11–15]. Most within-host models of TB have uncertain applicability to 
human epidemics, however, as they draw on biological observations of experimental 
animal infection that have important dissimilarities with key aspects of human disease – 
including long-term asymptomatic latency, spontaneous self-resolution, and 
heterogeneity in disease outcome [16]. There is therefore a critical gap in our 
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understanding, namely the linkage of individual-level pathological processes to 
population-level clinical outcomes. Filling this gap could help to better predict the 
population-level effects of interventions – from better treatment for drug-resistant TB to 
earlier diagnosis and linkage to care – for which individual-level biological effects may 
be easier to measure. 
In this study, we present a mathematical framework to address this knowledge 
gap using a simplified biological representation of TB progression across a population of 
individuals with incipient active TB. In developing this framework, we aimed to create 
the simplest possible representation of biological processes that could be compared 
against observed population-level clinical outcomes. We then calibrate this system to 
characteristics of the natural history of TB observed in empirical studies of patients in the 
pre-chemotherapy era. The primary objective of this study is to identify individual-level 
characteristics of TB disease progression which could – when simulated in a simplified 
system over large populations of immunocompetent individuals – successfully 
recapitulate clinical outcomes of untreated TB at the population level. 
  






To better simulate the temporal dynamics and heterogeneous outcomes of disease 
progression in clinical populations, we developed an individual-based, stochastic 
mathematical model of pulmonary tuberculosis progression in the human host. To link 
this model to population-level clinical outcomes, we drew upon data from 
epidemiological studies describing the natural history of TB before the worldwide 
introduction of modern anti-mycobacterial therapy (or the emergence of the HIV/AIDS 
pandemic) [17]. A systematic review of these studies estimated that, among adults 
diagnosed with sputum smear-positive TB, the average duration of disease was three 
years, 55% would die within five years, and 28% would eventually spontaneously resolve 
without chemotherapy [17]. We therefore sought to ascertain the individual-level 
characteristics of TB progression and resolution that could replicate similar clinical 
outcomes in large simulated populations. 
 
Conceptual Framework  
To construct a conceptual framework to address the primary objective, we made 
the simplifying assumption that, once infected, individuals exist in one of two clinical 
phases: disease progression or stabilization/recovery (Figure 2.1A). During these phases, 
the disease burden may increase and symptoms worsen (progression), or the disease 
burden may stabilize and symptoms either improve or worsen only slowly (recovery). To 
capture the myriad host and pathogen modifiers which influence an individual’s disease 
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phenotype [18–20], rates of progression and recovery are modeled at the individual level 
to allow for variability from one individual to the next (see rate distributions in Figure 
2.1B). Each individual’s course of disease may then be simulated as a rate of progression, 
a rate of recovery, and a set of Markov probabilities which define the transitions between 
these two phases (see Figure 2.1C).  
While these conceptual phases of progression and recovery are simplifications of 
the complex pathophysiology of TB infection [21], they are analogous to experimentally 
observable dynamics of bacterial replication and immune responses in vivo [7]. Unlike 
biological within-host models of TB [11–14,22], this model does not attempt to capture 
the complex and diverse immunological and pathophysiological mechanisms which 
influence clinical outcomes in any given individual. Rather, for simplicity and ease of 
understanding, we use “disease burden” as a mathematical benchmark that is likely 
associated with clinical outcomes (e.g., individuals who develop a higher burden may 
experience more severe symptoms, increased risk of mortality, and other pathological 
characteristics such as increased infectiousness) [18,23,24]. In this framework, “disease 
burden” should not be interpreted as a direct representation of bacillary load; instead, 
disease burden in this model represents a composite measure of characteristics of TB 
disease – such as pulmonary pathology, cough frequency, immunological exhaustion, 
chronic weight loss, etc., in addition to bacillary load – that correlate with the progression 
of clinical disease in patients. In this context, the simulated disease burden is not a 
verifiable quantity per se, but rather an instrument to relate the observable rates of 
progression and recovery in human populations to potentially measurable analogues of 
bacillary growth and decline in experimental systems.  
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We next define a conceptual “symptom threshold” as the disease burden above 
which active TB becomes symptomatic and clinically recognizable (i.e., as would be 
observable in pre-chemotherapy studies of smear-positive TB patients) [17]. Inversely, an 
infection in which the disease burden falls below this threshold represents an apparent 
self-resolution of symptomatic TB. Similarly, we define a “death threshold” – another 
conceptual construct – as the disease burden beyond which death would occur. (Similar 
techniques have been used to define “detectability” and “life-threatening” thresholds in 
models of cancer progression [25].) Using disease burden as a reference frame for clinical 




Each patient is assumed to start at a disease burden of 1 (arbitrary) unit in the 
progression phase. The start of each simulation therefore represents the time at which a 
pathophysiological process toward progression to symptomatic, active disease (i.e., 
“incipient” TB) begins. Therefore, each patient is considered clinically silent and 
epidemiologically undetectable in our analyses until the patient’s disease burden exceeds 
the symptom threshold for the first time. In calculating the disease burden at each discrete 
time step, we assume that progression and recovery follow the properties of a simple 
exponential process, with a single rate constant describing net growth (or decay) over 
time for a given individual in a given phase. We assume that the range of plausible 
growth rates during the progression phase (Figure 2.1B, purple distribution) is higher 
than the range of plausible growth (or decay) rates during the recovery phase (Figure 
   
42 
 
2.1B, blue distribution). While the disease progression of two simulated patients may 
exhibit different exponential growth and decay rates, the simulated disease within each 
individual host is assigned a single representative rate for the progression phase and a 
single representative rate for the recovery phase, sampled from the plausible ranges of 
each distribution (illustrated as the vertical lines on each curve in Figure 2.1B). 
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Figure 2.1: Individual-Level Model Framework of Progression and Recovery in 
Tuberculosis 
(A) Each patient’s disease is modeled through time as a sequence of transitions between disease 
progression and disease recovery. (B) A patient may take her rate of progression and her rate of recovery 
from a range of plausible rates, represented by probability densities across possible values of progression 
(purple density) and recovery (blue density). The shape of these densities is determined by the specific 
value of the rate mode parameters. Within each cohort, a value from each of these densities (depicted by 
vertical lines in the plot) is stochastically sampled to characterize each patient’s infection. (C) In the case of 
an arbitrary simulated Patient A, disease development begins in the progression phase during which growth 
is characterized by the patient’s sampled rate of progression. At any time (with a given weekly probability), 
the infection may transition to recovery, during which growth/decay is characterized by the patient’s 
sampled rate of recovery. Similarly, at any subsequent time, the infection may transition from recovery to 
the progression phase, with the same rate of progression as sampled previously. The concomitant changes 
in Patient A’s disease burden are represented in Figure 2.2. 
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As a simulated course of disease progresses, each individual may transition 
between progression and recovery phases (illustrated for an arbitrary simulated “Patient 
A” in Figure 2.1C). Mathematically, these transitions occur probabilistically, independent 
of disease burden or history, and correspond to switches from the progression rate to the 
recovery rate, or vice versa (blue and purple arrows in Figure 2.1B-C). If, at any point, 
the disease burden of a symptomatic patient exceeds the “death threshold”, the patient is 
classified as having died of TB. Conversely, a patient whose burden declines below the 
“symptom threshold” is classified as an apparently self-resolved case; these cases may 
relapse with symptomatic TB during the five years of simulation (see “Patient A” in 
Figure 2.2). Patients whose disease burden declines below the starting value of 1 unit are 
classified as cured, with no further possibility of disease progression. Thus, for each 
patient the duration of disease can be calculated as the continuous time spent with a 
disease burden between the “symptom threshold” and the “death threshold.” A cohort of 
simulated patients is then assembled to estimate population-level clinical characteristics 
such as TB mortality, spontaneous resolution, and disease duration, accounting for 
variation in progression/recovery rates from one patient to the next as well as stochastic 
transition events from progression to recovery and back. A representative cohort of 250 
simulated patient trajectories (representing a single set of population-level parameter 
distributions) is illustrated in Figure 2.2; emphasized is the infection trajectory of “Patient 
A" (diagramed qualitatively in Figure 2.1C). 
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Figure 2.2: Disease Burdens of a Simulated Population over Time 
 
 
Patients whose infections exceed the “symptom threshold” (a mathematical benchmark) are tracked until 
death (when the bacillary burden exceeds a mathematical “death threshold”, colored in red) or self-
resolution (when the burden falls below the “symptom threshold”, colored in green). Patients who continue 
to experience active TB (i.e., without exceeding the death threshold or experiencing self-resolution) after 
five years are colored in blue. Patients who never develop symptomatic disease (i.e., never surpass the 
symptom threshold) are plotted in grey. All disease burdens depicted were generated using the same model 
parameters and represent the population variability in progression/recovery rates as well as stochastic 
transitions between phases of infection. The disease burden of an arbitrary Patient A quantitatively depicts 
the progression of disease diagrammed graphically in Figure 2.1C; note that the rate (slope) of progression 
for Patient A is the same throughout her life (i.e., both before and after recovery). 
 




To evaluate the likely values of model parameters (progression/recovery rates and 
phase transition probabilities), we implemented a Bayesian sampling-importance-
resampling algorithm [26]. In this approach, a range of reasonable (“prior”) values was 
defined for each model parameter (see Table 1). These prior ranges were taken as 
uniform distributions, on either the logarithmic- or log-modulus-transformed scales [27], 
bounded as shown in Table 1. Latin hypercube sampling [28] was then utilized to 
randomly draw two million sets of parameter values; each set was subsequently used to 
simulate a population of 1,000 patients with untreated TB using the drawn values for the 
two transition probabilities to inform stochastic realizations of the sequence of 
progression and recovery in each individual patient. The drawn values of the progression 
rate and recovery rate for the cohort represented the cohort’s population modal 
progression and recovery rate, respectively, with each individual’s rates drawn from a 
beta distribution (chosen to provide central tendency within defined upper and lower 
bounds) around each mode. Beta distributions were parameterized by the modal value 
and a concentration parameter of κ=20 to maintain a clear central tendency in each 
population. Individuals who never reached the symptom threshold over five years were 
dropped from the analysis. All other individuals were simulated until death (reaching the 
death threshold, colored in red in Figure 2.2), spontaneous recovery (again falling below 
the symptom threshold, colored in green in Figure 2.2), or five years of symptomatic 
disease (colored in blue in Figure 2.2) – reflecting the five-year mortality/recovery data to 
which our model was calibrated [17]. Outcomes in each cohort were aggregated to 
calculate the population-level simulated outcomes described below.  
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Table 2.1: Parameter Values Used to Define Upper and Lower Bounds of Sampling Ranges 
 
Parameter Sampled Range References Notes 
Death threshold  7.0-10.0a (log10 
units)b 
[37–39] Burdens in animal models rarely measure greater than 109 units per lung.  
Width of the window between 
symptom and death thresholds 
4.0-7.0a (log10 
units)b 
[39–41] Burdens in animals with asymptomatic infection may be as high as 103 
units. 
Progression to Recovery transition rate  0.001-0.35 per 
weeka,c 
Derived Assume 5% transition per year, and no more than 75% transition per 
month.  
Recovery to Progression transition rate  10-5-10-4 per weeka,d [42] Probability of reactivation in latent infections estimated to be 0.8% per 
year. 




[39–41] Assume patients progress from onset to death in 3-60 months, assuming 104 
unit symptom window. 




[43] Assume patients self-resolve at ¼ the rate of chemotherapeutic recovery (as 
defined by time to sputum conversion). 
 
aRange sampled uniformly on the log10 scale 
bThe symptom threshold in a given simulation is derived by value of the death threshold and the value of the symptom window width. 
cA 0.35 weekly rate of transition is equivalent to a 75% monthly probability of transition 
 dRates in this range are equivalent to 0.05-5.0% probabilities of transition 
eRange sampled uniformly on the log-modulus scale 
fProgression rates in this range are equivalent to net population doubling times in the range of 6-137 days 




To identify those parameter values most consistent with observed population-
level data, we assigned each cohort a pseudo-likelihood, defined as the joint probability 
density of the simulated cohort’s population-level characteristics according to estimated 
density functions for three key summary statistics of observed pre-chemotherapy era 
cohorts: 55% case-fatality ratio within 5 years of symptom onset, median symptom 
duration of 3 years, and spontaneous resolution of ≥10% of cases [17]. (For further 
details, see “Importance Resampling” in the Supplementary Methods.) After assigning a 
pseudo-likelihood to each simulated cohort, we resampled two million cohorts, with 
replacement, proportional to the pseudo-likelihood [26]. The resampled (posterior) 
distribution therefore represents – in weighted fashion – those cohorts (and their 
corresponding parameter values) with the best fit to historical data. We define 95% 
uncertainty ranges (UR) as the 2.5th and 97.5th percentiles of each parameter’s value, 
across the posterior distribution. 
A multivariate sensitivity analysis was performed by computing the partial rank 
correlation coefficient (PRCC) between each of the six input parameters (two transition 
probabilities, modal progression rate, modal recovery rate, symptom threshold, and death 
threshold) and the pseudo-likelihood of each plausible cohort. This analysis identifies 
those parameters that most strongly influence the ability of the simulated data to fit the 
observed data, adjusting for all other parameters simultaneously. Based on the results of 
this sensitivity analysis, an additional post-hoc non-parametric Spearman correlation was 
tested between the probability of transitioning from progression to recovery and the 
modal progression rate.  
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Mathematical formulae, prior distributions, likelihood functions, importance 
resampling, and further technical details are provided in the Supplementary Methods. All 
statistical computing was performed using R version 3.2.2 (R Foundation for Statistical 
Computing, Vienna, Austria). 
  





Of the two million simulated patient cohorts, 551,100 (27%) had results deemed 
consistent with historical estimates of TB natural history (i.e., non-zero pseudo-
likelihoods, see the Supplementary Results for further details). Figure 2.3 presents the 
case-fatality ratios and median durations of disease of all simulated cohorts; the 551,100 
plausible cohorts are colored according to the pseudo-likelihood of each. After weighting 
(resampling) cohorts according to these pseudo-likelihoods, the median case fatality ratio 
was 55% [Interquartile range (IQR): 54%, 56%], the median duration of disease for the 
50th percentile of cohorts was 2.5 years [IQR: 2.1, 2.8], and the median proportion of 
self-resolving cases was 28% [IQR: 19%, 37%] – consistent with empirical calibration 
targets (55% case fatality, mean three-year symptom duration, 28% self-resolved over 10 
years) [17]. 
The correlation between each input parameter value and the fit between simulated 
and observed data is presented in Figure 2.4. The probability of transition from the 
progression phase to the recovery was also strongly correlated with model fit, and 
plausible models are consistent with a median yearly transition probability of 16% [95% 
UR: 11%, 21%; Figure 2.5A] The most important determinant of model fit was the rate 
of disease progression, and plausible results indicate a median progression rate of 0.0083 
per day [95% UR: 0.0066, 0.011], equivalent to an exponential doubling time of 84 days 
[95% UR: 62, 104; Figure 2.5B, purple posterior]. This range can be interpreted as the 
doubling times of TB “disease burden” that are consistent with observed data on case-
fatality, duration of clinical disease, and probability of self-resolution [17]. The rate of 
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disease progression and the probability of transition from progression to recovery were 
correlated among plausible cohorts (Spearman’s ρ = 0.68, p<0.01).  
The association between the rate of recovery and model fit to observed data was 
less strong (Figure 2.4). Model results suggest a median recovery rate of -0.014 per day 
[95% UR: -0.032, -0.0052], equivalent to an exponential half-life of 48 days [95% UR: 
22, 133; Figure 2.5A, blue posterior]. Sensitivity analysis indicated that model fit was not 
associated with the value of the symptom threshold, death threshold, or probability of 
transition from recovery to progression ( |PRCC|<0.02 for each, see also Supplementary 
Figures S1.1-S1.3). 
To illustrate the potential application of this framework for investigating the 
impacts of individual-level interventions, we simulated cohorts with various diagnostic 
strategies (detailed further in the Supplementary Methods). In this example, our model 
was able to recapitulate global estimates of case fatality in the presence of partial 
diagnosis and treatment coverage (17.3%) [2] and illustrate how those gains in mortality 
could be achieved without observing substantial reductions in incidence (see the 
Supplementary Results for further details). 
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Figure 2.3:Weighting Process of Two Million Simulated Cohorts, According to Fit 
with Observed Clinical Data 
 
Each point represents the results of a cohort of 1,000 simulated patients, plotted according to the 5-year 
case fatality ratio and median duration of disease amongst symptomatic patients who die or self-resolve. 
Each point is colored according to its weight (probability of being resampled to generate the final, or 
posterior, distribution), measured from 0 to 1 (the maximum likelihood of cohort results). Points colored in 
grey represent those cohorts with joint likelihoods equal to zero. (Not depicted are the 5% of simulations in 





Figure 2.3:Weighting Process of Two Million Simulated Cohorts, According to Fit with Observed Clinical Data 
 




Figure 2.4: Association between Key Model Parameters and Population-Level 
Clinical Results 
 
Each bar represents the partial rank correlation coefficient of the association between each model parameter 
and the joint likelihood of cohort results (i.e., how closely each cohort fits the observed data). Beneath each 
parameter label is the sampling range from which parameter values were sampled. 
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Figure 2.5: Values of Key Parameters Consistent with Observed Cohort Data 
 
Model input values (prior distributions) were sampled uniformly on log-transformed or log-modulus-
transformed scales between reasonable bounds selected on an a-priori basis (denoted by vertical dashed 
lines). Histogram densities show the proportion of 2 million weighted parameter values that were most 
consistent with observed cohort data from the pre-chemotherapy era (posterior distributions). (A) 
Distributions of probabilities of transition from progression phase to recovery phase on weekly and 
annualized scales. Simulations most consistent with observed data therefore primarily contain transition 
probabilities in the lower half of the initially sampled range (i.e., left-hand portion of the graph). The 
median transition probability among these data-consistent simulations (16% per year) implies that 50% of 
patients transition within 4.2 years (0.5=e-0.16×4.2), provided they survive that long. (B) Distributions of 
progression rates and recovery rates during the progression phase (purple) and the recovery phase (blue). In 
this graph, a progression/recovery rate of zero implies no change in disease burden with time. Recovery 
rates less than zero are therefore also displayed as half-lives (i.e., duration of time required for the disease 
burden to be cut in half), while progression rates are displayed as doubling times (i.e., duration of time 
required for the disease burden to double). 
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This study sought to identify individual-level TB disease characteristics that were 
consistent with historical population-level clinical outcomes, using a simplified model. 
As our model is calibrated to clinical characteristics of symptomatic TB, it should be 
interpreted as representative of incipient and active TB (but not long-term latency). The 
simulated case-fatality (median 55%), duration of disease (median 129 weeks), and 
proportion of self-resolved cases (median 28%) indicate that this simplified structure can 
capture the basic dynamics of clinical TB progression in human populations. Our primary 
results suggest that, under physiological conditions in realistic populations, active TB 
may reasonably be represented as a slow rate of disease progression (median 84-day 
doubling time) and a low probability of transitioning from progression to recovery (16% 
per year).  
This modeling approach deliberately utilized a minimal parameterization of 
complex disease processes, but many possible complex models may also be consistent 
with observed clinical characteristics of TB progression. Therefore, the results presented 
here must be interpreted in the context of this framework and the analytical approach 
utilized. 
It may be useful to provide intuitive context for these results. For example, we fit 
our model to a review of pre-chemotherapy era studies suggesting that TB patients 
experienced symptoms for an average of 3 years before death or symptom resolution 
[17]. Our estimated median doubling time of 84 days (Figure 2.5A, purple posterior) 
would generate a net 104 unit increase in disease burden (the minimum difference 
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between the “symptom threshold” and “death threshold”) in 3.1 years of continuous 
progression. Our estimated 16% yearly probability – equivalent to a 29% probability of 
transition in the first two years – likewise reflects the empirical estimate (to which our 
data were fit) that 28% of untreated TB patients experience spontaneous resolution [17]. 
The data from this model also offer useful context with which to view 
experimental results from in vitro and in vivo models. For example, murine data suggest 
much faster disease progression (physiological doubling times of 2-3 days [29,30]) and 
shorter duration of disease (median durations of 31 weeks [31]) compared to our results 
(doubling times of 84 days and median disease duration of 2.5 years). Additionally, our 
results indicate that most patients who transition from progression to recovery experience 
sustained reductions in disease burden whereas bacillary burden in murine models may 
eventually plateau [29,30] but never declines. This discrepancy illustrates some of the 
implicit limitations of murine models in the study of human TB: without treatment, all 
mice eventually die from TB, whereas many human patients may naturally self-resolve 
[17]. Our simulation framework – with parameter values calibrated to clinical data in 
human populations – thus provides an important complement to data from animal 
models. 
A primary limitation of this model framework is its simplification of the complex 
internal pathophysiological mechanisms of host-pathogen interactions. For example, 
changes in disease burden are simplified as generalized exponential growth and decay, 
and transitions between progression and recovery are represented as stochastic processes 
depending only on the current phase of disease. These simplifications necessarily limit 
the ability to draw precise mechanistic inference; however, they also allow for simulation 
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of a conceptually tractable measure (disease burden), thereby quantitatively linking 
individual-level data on disease progression and recovery with observable population-
level clinical outcomes. Similarly, we also use mathematical constructs of symptom and 
death thresholds that have no direct physiological meaning. Importantly, these constructs 
were not significant determinants of our primary outcome (see Figure 2.4 and 
Supplementary Figures S1.1-S1.3). Our model is also not capable of calculating the 
single (“identifiable”) parameter values that are most likely to result in the observed 
clinical data to which our model was fit. Rather, we sampled from a priori defined ranges 
and evaluated multiple sets of parameter values that might be consistent. Finally, our 
calibration strategy used data from historical studies with distinct demographic and 
epidemiological characteristics; while use of data-driven evidence is an advantage of the 
methodology, differences in these characteristics between historical and modern 
populations may limit the generalizability of these results in the contemporary 
epidemiology of TB (e.g., including HIV, diabetes, and changing age structures).  
The development of a model linking individual-level and population-level 
outcomes opens a variety of avenues for future research and may also help to ground 
predictions of the population-level impacts of interventions which hinge on the temporal 
dynamics of individual-level TB outcomes. For example, the impact of scale-up of 
screening and diagnostic interventions may be heavily influenced by the distribution of 
individuals detectable by such interventions, as demonstrated in our simulation of 
diagnostic and treatment interventions. When patients with high simulated disease 
burdens are more likely to be diagnosed and treated than patients with low disease 
burdens, our model accurately reproduced 2015 global estimates of case fatality with 
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high precision, without predicting a major reduction in transmission (see the 
Supplementary Results). Linking clinical data with this mathematical framework may 
also be relevant to the transmission of TB, where a small number of patients (with 
prolonged symptoms and/or large disease burdens) may generate a majority of new 
infections [32]. For example, our simulation of diagnosis and treatment implied passive 
clinical interventions alone may not significantly reduce disease morbidity (as measured 
by disease burden over time), which may correlate with infectious potential in a 
population. Identifying such patients with measurable correlates of “disease burden” – 
such as cough frequency, cavitary lesions, sputum grade, aerosol dispersion, and time to 
positivity of cultures [33–35] – may augment the impact of diagnostic and treatment 
interventions on transmission, an effect our model may be able to quantitatively 
characterize. Finally, this framework holds potential for application to other infections 
which can be conceptualized as a sequence of transitions between states of varying 
pathogenesis [36]. 
In summary, this novel model linking individual-level and population-level 
outcomes suggests a range of parameters related to TB progression and recovery that 
might be consistent with observed clinical outcomes. Among these, we estimate the 
doubling time of disease burden as 84 days during the progression phase, a half-life of 47 
days during recovery, and a probability of transition to recovery of 16% per year. Thus, 
in human populations, TB disease burden is likely to grow at a very slow rate, with a 
relatively low probability of switching from progression to recovery in the absence of 
intervention. While limited by pathological and mechanistic simplifications, this model 
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links within-host and population-level processes to better understand the complex 
interactions which influence human pathology and disease.  
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 Background: The mechanism of action of PZA in TB chemotherapy remains 
unsettled, though evidence suggests it inhibits the action of the bacterial protein RpsA. 
We reviewed the evidence for different models of PZA action and investigated protein 
binding partners of RpsA. 
 Methods: Recombinant RpsA was expressed and purified in E. coli. M. 
tuberculosis cells were lysed via sonication or French Press methods to obtain whole cell 
lysate. Purified bait RpsA was used to isolate putative binding partners using affinity 
chromatography. Protein identities were confirmed by mass spectrometry. Binding 
partners were overexpressed in M. tuberculosis culture and the minimal inhibitory 
concentration of POA was measured. 
 Results: RpsA bound several M. tuberculosis whole cell lysate proteins with high 
affinity. The most significant binding partner was found in lysate obtained via sonication 
but not by French Press and was identified as Ribosome Recycling Factor (RRF). When 
overexpressed in M. tuberculosis culture, RRF did not increase the sensitivity of cells to 
inhibition by POA. 
 Conclusions: These observations offer the first suggestion of a role of PZA in the 
inhibition of multiple conserved ribosome stress response pathways.   





 While infections with strains of Mycobacterium tuberculosis susceptible to 
antibiotics may be successfully treated with a standardized short-course combination 
regimen, treatment of drug resistant tuberculosis (TB) requires longer regimens with 
additional, more expensive antibiotics often administered by injection [1]. Even after 18-
24 months of combination treatment with second-line drugs, multidrug resistant TB 
(MDR-TB, resistant to at least two first-line drugs – rifampin and isoniazid) remains 
uncured in roughly half of treated patients [1]. Such treatments are complicated by the 
difficulty in detecting clinically meaningful drug resistance at the time of TB diagnosis. 
A critical component of long-term TB control programs will be the development and 
implementation of novel agents with anti-mycobacterial activity [2]. One strategy in the 
development of novel drugs and improvement in the detection of drug resistance involves 
identifying the mechanisms of action of current antibiotics used in the first-line treatment 
of TB. In the introduction of Chapter III, mechanisms of action of current first-line drugs 
are reviewed and the unique role of pyrazinamide in this regimen is explored for future 
study.  
  
Short-course Chemotherapy for TB 
 Resistance to anti-mycobacterial therapies has existed as long as such antibiotics 
have been in use. In the first clinical trial of streptomycin for use in treating pulmonary 
tuberculosis (TB) in 1947, 35 of 41 surviving patients who received the antibiotic were 
later found to have developed infections that were insensitive to clinical concentrations of 
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streptomycin [3]. Much of the clinical research that followed those early studies was 
devoted to maximizing the effectiveness of TB treatment regimens, in large part by 
reducing the probability of acquiring drug resistance during treatment. Combining 
streptomycin and para-amino salicylic acid was found to reduce the probability of 
developing resistance to either drug individually, the first use of combination therapy to 
treat TB [4]. Isoniazid (INH), a more potent bactericidal drug, soon became a cornerstone 
of any first-line combination therapy [5]. While combinations of fast-acting bactericidal 
drugs like INH and ethambutol [6] were able to rapidly kill large bacterial populations in 
the first weeks of therapy [6,7], treatment courses of 12 months or longer were required 
to achieve adequate rates of long-term, relapse-free survival [8]. Rifampin (RIF), when 
included in combination with other bactericidal agents , could reduce the duration of 
treatment needed to achieve relapse-free cure from 12 months to 9 months [5,9].  
 
Bacterial Populations and Drug Action 
 Of the four drugs utilized in the standard short-course first-line treatment of TB – 
INH, RIF, ethambutol, and pyrazinamide – three may be replaced with other agents that 
act in similar pharmacodynamics fashion. Actively replicating cells, targeted by the 
bactericidal actions of INH and ethambutol, may alternatively be killed by 
fluoroquinolones such as levofloxacin or moxifloxacin which inhibit DNA gyrase [10]. 
Rifampin may be effectively replaced by rifabutin when needed to avoid interactions with 
non-nucleoside reverse transcriptase inhibitors or protease inhibitors [11], and additional 
drug classes which mimic the activity of RIF continue to be developed for clinical use 
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[12]. Pyrazinamide (PZA), however, targets a unique population of cells unlike any other 
known class of antibiotics.  
PZA demonstrates low bactericidal activity in clinical trials. At doses required to 
demonstrate appreciable rates of sputum conversion, PZA proved too hepatotoxic and 
was therefore removed from standard regimens [13]. However, in combination with more 
bactericidal drugs, lower-dose PZA improved rates of long-term relapse-free cure, 
demonstrating its sterilizing activity [5]. This sterilizing activity is likely accomplished 
through an altogether different modality than that of RIF. When PZA was added to 
combination regimens already containing RIF, rather than providing redundant 
sterilization without added effect, PZA was able to further shorten regimens from nine 
months to the six-month regimen still recommended today [5]. Despite the improvement 
provided by PZA in a six-month regimen, it was found that no benefit was gained when 
adding PZA beyond the first two months, suggesting that the bacterial population which 
is sterilized by PZA is effectively neutralized in the first eight weeks of therapy [14].  
Experimental evidence further supports the assertion that PZA acts on a unique 
population of bacterial cells. Under laboratory conditions, PZA demonstrates poor 
inhibitory activity against M. tuberculosis in broth cultures at neutral pH [15], similar to 
the expected environment for actively replicating cells in lung cavities and interstitium. 
Similar observations are noted in commonly used murine models of TB [7,16]. However, 
at acid pH, PZA activity is greatly enhanced [17]. Recent data indicate that the minimal 
effect observed in murine models may result from crucial differences in pathology 
between TB in mouse and humans. While humans develop characteristic caseating 
necrosis and cavitary lesions, most mouse models develop a more diffuse (and non-
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caseating) cellular infiltration [18,19]. Unlike other murine models, in C3HeB/FeJ mice – 
an inbred mouse strain which develops caseating necrosis in response to M. tuberculosis 
infection – PZA demonstrates significant antibiotic effect, albeit with notable inter-
animal variability [16,20,21]. This observation has been explained by variability in 
caseum pH, with animals that exhibit more acidic caseum also demonstrating a greater 
dose-response to PZA [22]. Cumulatively, these findings define the role of PZA in 
accelerating sterilization in clinical regimens: by targeting a unique population of 
bacterial cells in a discrete acid compartment incompletely sterilized by RIF alone, PZA 
hastens the elimination of subsets of the bacterial population that would otherwise 
survive in an inactive state through the intensive bactericidal phases of therapy until the 
acidic environment of the caseum is eliminated [23]. Considering that there are no 
effective alternatives to PZA for sterilizing bacterial populations in acidic environments, 
it is vital to better understand the mechanism of action of PZA if we are to identify novel 
drugs to emulate its activity in cases of PZA-resistant infections. 
 
Models of Pyrazinamide Action: Membrane Disequilibrium 
Speculation about the specific molecular mechanism through which PZA exerts 
its antibiotic effects has persisted for several decades. Pyrazinamide, like INH, is 
administered as a prodrug which is converted to its active form, pyrazinoic acid (POA) 
by the bacterial nicotinamidase pncA [24,25]. As a result, most genetic resistance to PZA 
occurs through inactivating mutations to pncA, and a collection of various pncA 
mutations have been observed in clinical isolates [26]. The precise site and mode of 
action of POA, however, remains uncertain. 
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After PZA is converted to POA within M. tuberculosis cells, POA accumulates 
extracellularly at neutral pH, possibly through active transport efflux mechanisms [27]. 
Only when cells are treated with PZA in weakly acidic media (pH≤5.5) does POA begin 
to accumulate intracellularly, and the peak intracellular concentration is inversely 
proportional to pH [27]. Notably, this intracellular accumulation is not observed in 
inherently PZA-resistant M. smegmatis at acid pH, suggesting the antibiotic effect of 
PZA is dependent on the inability of M. tuberculosis cells to maintain low intracellular 
concentrations of POA in acid conditions. Efflux pump inhibitors such as reserpine and 
ion transport inhibitors (hence ATP production inhibitors) such as valinomycin increase 
the intracellular accumulation of POA in both M. tuberculosis and M. smegmatis at 
neutral pH [27,28], furthering the hypothesis that PZA activity is dependent on active 
efflux mechanisms which falter in acid conditions. These observations led to a model of 
POA action through a cascade of nonspecific toxic effects due to membrane 
disequilibrium. This framework asserts that the accumulation of protonated HPOA in an 
acidic extracellular environment at equilibrium results in an imbalanced influx of HPOA, 
resulting in disrupted membrane function, cytoplasmic acidification, and energy 
depletion due to loss in proton motive force across the membrane [13,29]. Consistent 
with this hypothesis are observations that the accumulation of intracellular POA is 
associated with reduced cross-membrane potential and that inhibitors of membrane-
bound ATPases and cytochrome c oxidases enhance the activity of PZA in acid 
conditions [28].  
This model, however, is incomplete. The dependence of intracellular POA 
accumulation on diffusion of protonated HPOA has not been confirmed experimentally, 
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and recent findings indicate that – unlike known ionophores CCCP and monensin – POA 
and PZA have no effect on cytoplasmic pH in acidic media [30]. The extracellular 
accumulation of HPOA has only been deduced theoretically using the Henderson-
Hasselbach equation, assuming equilibrium between anionic POA- and HPOA [31]. The 
hypothetical equilibrium conditions required for the Henderson-Hasselbach relationship 
to hold have not been empirically tested in vitro and are unlikely to hold in vivo. The 
extracellular accumulation of HPOA, which could provide evidence in favor of this 
hypothesis, has not been demonstrated experimentally. Recent studies have contested the 
finding that POA exposure reduces membrane potential [30]. Finally, nonspecific effects 
related to intracellular POA accumulation – such as reduced uptake of environmental 
amino acids and nucleotides [28] and increased sensitivity to weak acids and ultraviolet 
radiation [32] – may also be consistent with alternative models of PZA action.  
 
Models of Pyrazinamide Action: Fatty Acid Pathways 
Several additional models of PZA/POA action have been postulated. In multiple 
mycobacterial species, resistance to a PZA derivative, 5-chloro-pyrazinamide, may be 
conferred through overexpression of the Fatty Acid Synthase I gene fas1, a component in 
lipid biogenesis pathways [33]. Further investigation has demonstrated that both PZA and 
POA exert an inhibitory effect on FASI pathway products in acidic but not neutral pH 
[33,34]. Interestingly, in a cell-free assay, M. smegmatis FASI was inhibited by both 
POA and unmetabolized PZA, suggesting a possible direct antibiotic effect of PZA itself 
[35], though these results were contradicted in an M. tuberculosis system [36]. In a 
saturation transfer difference NMR system, POA and PZA were found to compete with 
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NADH for multiple binding sites on purified M. tuberculosis FASI [37]. Further support 
for a fatty acid synthesis model is provided by studies of Coenzyme A (CoA) 
metabolism, a precursor in long-chain fatty acid synthesis. Isolates of PZA-resistant M. 
tuberculosis generated through experimental culture have been shown to occasionally 
possess mutations in panD, an enzyme involved in biosynthesis of pantothenate and CoA 
[38,39], and intrinsically PZA-resistant M. bovis BCG displays POA sensitivity upon 
disruption of the long-chain fatty acyl-CoA ligase fadD2 [40]. However, while 
supplemental pantothenate and CoA metabolites were found to mitigate the effects of 
PZA and POA [41,42], PZA remained active against M. tuberculosis strains lacking 
functional panD, indicating that PZA does not function primarily through panD 
inhibition [42]. Nevertheless, POA treatment was found to deplete CoA levels 
downstream of PanD action [39,43] and, more directly, POA was found to bind directly 
with purified PanD by isothermal titration calorimetry [43]. Despite the promise of these 
findings in molecular investigations, the direct connection between inhibition of fatty 
acid synthesis and the specific sterilizing effects on unique bacterial subpopulations – the 
critical role fulfilled by PZA in clinical regimens [23] – remains unrefined. A novel 
model, however, may serve to better articulate the mechanism of action of POA in 
fulfilling this specific role. 
 
Models of Pyrazinamide Action: Trans-Translation 
In light of the limitations of existing models of PZA/POA action, alternative 
methods of investigation have been pursued. A POA derivative, 5-hydroxyl-2-pyrazine 
carboxylic acid, linked to a sepharose matrix was found to bind specifically to several 
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novel protein partners in M. tuberculosis whole cell lysate [44]. Mass spectrometric 
analysis subsequently identified one of these partners as the small ribosomal subunit 
protein S1 encoded by the gene RpsA. No fatty acid synthesis pathway enzymes were 
detected in the same pull-down experiment. Furthermore, POA was found to bind 
specifically to purified wild-type RpsA with a Ka>7×107 M-1 as measured by isothermal 
titration calorimetry [44]. Later studies would identify two POA binding sites on M. 
tuberculosis RpsA using X-ray crystallography [45]. Overexpression of RpsA on a 
plasmid vector increased the minimum inhibitory concentration (MIC) – the 
concentration of drug required to prevent visible bacterial growth on solid media – of 
PZA five-fold in acidic in vitro conditions [44]. Several clinically PZA-resistant M. 
tuberculosis isolates carrying wild-type pncA genes were found to carry RpsA mutations 
at either N-terminal or C-terminal amino acid positions, and one such RpsA mutant (as 
well as RpsA from intrinsically PZA-resistant M. smegmatis) failed to bind specifically 
with POA by titration calorimetry. Cumulatively, these observations provided convincing 
evidence that, once POA has sufficiently accumulated intracellularly in acidic conditions, 
its antibiotic effect may be exerted through binding RpsA; when RpsA is mutated and 
POA cannot bind, the antibiotic effect is lost. 
Functional studies provide a more detailed mechanism of inhibition through RpsA 
than alternative models suggested. While RpsA is an essential component of canonical 
translation and ribosome function, studies in other bacteria such as Escherichia coli have 
found that RpsA also plays a critical role in rescuing ribosomes under unique conditions 
[46]. When a ribosome stalls on a truncated mRNA, in the absence of a stop codon 
termination complexes cannot act to release the incomplete peptide or disengage the 
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ribosomal subunits. Specialized RNA complexes which possess dual transfer and 
messenger characteristics (hence referred to as transfer-messenger RNAs or tmRNAs) 
may enter the ribosomal A-site, tag the incomplete peptide for degradation using a poly-
alanine sequence, and subsequently rescue the stalled ribosome for recycle and re-use 
[47]. This process is known as trans-translation or ribosome rescue. Cell-free translation 
assays and in vitro depletion experiments indicate that RpsA is an essential component of 
trans-translation and may bind tmRNA outside the ribosome [48].  
On the basis of these observations, interactions between RpsA and tmRNA in M. 
tuberculosis were assessed. When purified RpsA and tmRNA are co-incubated, gel 
mobility assays reveal tmRNA migrates at a much larger molecular weight than expected, 
suggesting it is bound by RpsA [44]. When these complexes are incubated in the 
presence of POA, tmRNA migrates closer to its expected molecular weight (proportional 
to the concentration of POA present), indicating that POA inhibits the interaction of 
RpsA and tmRNA. No comparable inhibition is observed when tmRNA is incubated with 
mutant RpsA from POA-resistant clinical isolates [44,45]. Peptide assays of cell-free 
translation systems confirmed that trans-translated peptides from M. tuberculosis 
ribosomes are not produced in the presence of POA, but canonical translation is 
unaffected. These data illustrate a direct and detailed mechanistic description of PZA’s 
antibiotic effect through the inhibition of ribosome rescue. That some bacteria implement 
ribosome stalling and rescue as a form of metabolic regulation under stress conditions 
[49] lends further credence to this model as the mechanism through which PZA functions 
to sterilize specific bacterial subpopulations in acidic or other stress conditions [23].  
 




Pyrazinamide is an essential component of first-line short course regimens used to 
treat TB. No other drug or drug class acts to sterilize bacterial populations in acidic 
compartments, and no effective replacement for PZA can reduce TB treatment from nine 
to six months while maintaining low rates of relapse. If novel chemotherapies are to be 
developed which can emulate the therapeutic role of PZA in combination therapy, it is 
essential to better understand the mechanism of action of PZA in M. tuberculosis. The 
most detailed model of PZA action indicates its ability to inhibit the rescue of stalled 
ribosomes under stress conditions, specifically by inhibiting the interactions between 
RpsA and tmRNA. As the function of RpsA has never been investigated thoroughly in M. 
tuberculosis, RpsA may offer novel targets for agents which could one day supplement 
PZA and further hasten therapy or replace PZA in the case of drug resistance. We 
therefore proposed to identify to protein binding partners of RpsA in M. tuberculosis. 
 
  






Based on X-ray crystallographic findings that POA binds RpsA in the protein’s C-
terminal region (residues K303, F307, F310, and R357) [45], we restricted our 
investigation to binding partners of the C-terminal domain of RpsA comprising the 
protein’s fourth RNA-binding S1 domain and a flexible alpha-helix of unknown function 
(residues 292-481), denoted RpsA292. Polymerase chain reaction was used to amplify M. 
tuberculosis genomic RpsA292 with an N-terminal hexa-histidine tag which was cloned 
into an IPTG-inducible pET-SUMO vector as previously described [44]. This vector was 
transformed into E. coli DH5α chemically competent cells according to the 
manufacturer’s protocol. Transformed cultures were plated on LB agar containing 
50μg/mL kanamycin to identify transformed clones. Correct RpsA292 insertion was 
confirmed by Sanger DNA sequencing.  
Prior to overexpression, clones were grown to stationary phase overnight in liquid 
LB media with kanamycin at 35°C and shaking at 250rpm. Cultures were then transferred 
1:100 into fresh media and grown to mid-log phase under the same conditions, at which 
point 400μg/mL isopropyl β-D-1-thiogalactopyranoside (IPTG) was used to induce 
protein overexpression. Cultures were then grown for four hours under the same 
conditions. 
Induced cells were harvested by centrifugation at 4000rpm and washed with PBS. 
Resuspended cells were lysed via sonication. Homogenates were separated by 
centrifugation at 16000rpm for 20 minutes at 4°C. Cell lysate supernatants were 
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incubated with nickel-nitrilotriacetic acid (Ni-NTA) resin for 60 minutes at 4°C. Charged 
resin was then washed with PBS plus 20mM imidazole to remove contaminants. Purified 
RpsA292 was then eluted from the resin using PBS plus 250mM imidazole. Purity was 
confirmed by SDS-PAGE. Imidazole was removed from purified protein buffers using 
dialysis cassettes 1:1000 in PBS overnight. 
 
Cell Lysis 
Single colonies of wild-type M. tuberculosis strain H37Ra (ATCC 25177) were 
inoculated into Middlebrook 7H9 liquid media with 0.2% (v/v) glycerol, 0.05% Tween 
80, and 10% filtered albumin-dextrose-catalase. Cultures were grown to mid-log phase 
over 14-21 days. Cells were harvested via centrifugation at 9000rpm for 10 minutes at 
4°C. Pellets were washed three times in PBS and resuspended. Cells were lysed either 
through sonication or French press lysis [50]. Lysis using sonication followed the 
protocol described above for E. coli. 
In its native state, RpsA is associated with the 30S ribosomal subunit, a large 
macromolecular complex composed of both protein and nucleic acids [51]. Sonication, a 
common method of obtaining cell lysate which was utilized above, exposes whole cells to 
high energy ultrasonic pulses causing cytoplasmic cavitation and cell rupture [50]. As a 
result of these forces, large non-covalently-bound complexes may be separated into their 
constituent components and unique binding properties of the joint complex may be lost. 
French press lysis is an alternative method which ruptures cell walls and membranes 
through mechanical shearing and barotrauma but leaves larger complexes intact [50]. We 
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therefore also tested the binding partners of purified RpsA292 in M. tuberculosis lysates 
obtained through French press lysis 
For French press lysis, a Thermo Scientific Pressure Homogenizer was used. Cell 
suspensions were loaded into the pressure chamber at 4°C, pressure was gradually 
increased to 2000 PSI and ejected homogenate was collected. Pressurization was repeated 
three times total. After either lysis method, homogenates were centrifuged for 30 minutes 
at 20,000rpm at 4°C and lysate supernatants were collected. 
 
Protein Interactions 
Protein binding partners of RpsA292 were assessed via Ni-NTA pulldown. A total 
of 5mg of M. tuberculosis H37Ra cell lysate supernatant were incubated with 200μg 
purified RpsA292 for 2.5 hours at 4°C with gentle rocking. In experiments with POA, 
either 300μg/mL POA or DMSO as control was incubated with lysate supernatants for 15 
minutes prior to the addition of RpsA292. Then, Ni-NTA resin was added to the mixture 
1:10 by volume and incubated for one hour further. As controls, RpsA292 alone, cell 
lysate alone, and PBS alone were incubated with resin under the same conditions. 
Unbound lysate products were removed from the resin using microfuge columns spun at 
800rpm or using gravity columns, depending on the size of the preparation. Resin was 
then washed twice with PBS plus 20mM imidazole. Products bound to RpsA or to the 
resin matrix were eluted with PBS plus 250mM imidazole. Eluents were mixed with 
sodium dodecyl sulfate and heated to 100°C for 10 minutes to denature protein products, 
and precipitates were removed by centrifugation. Samples were then loaded into 1% 
polyacrylamide gels and electrophoresed at 100V for 1.5 hours. PAGE gels were 
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developed using colloidal Coomassie Blue stains at room temperature for 10 minutes. 
Bands of interest were excised from gels and submitted to the Johns Hopkins Mass 
Spectrometry and Proteomic facility for liquid chromatography FTFT tandem mass 
spectrometric analysis. Data was processed using Proteome Discoverer (v1.4 Thermo 
Fisher Scientific) and analyzed using Mascot v.2.5 Matrix Science. 
 
Genetic Cloning 
Wild-type M. tuberculosis genomic ribosome recycling factor (Rv2882c) was 
amplified via polymerase chain reaction using the following primers: 5’ – GGT 
TTAATTAA GAA GGA GAT ATA CAT ATG ATT GAT GAG GCT CTC – 3’ 
(forward) and 5’ – GATATC CTA GAC CTC CAG CAG CTC – 3’ (reverse). Purified 
PCR products were confirmed by Sanger DNA sequencing. Products were digested using 
NEB PacI and EcoRV double digestion restriction endonucleases in CutSmart Buffer for 
15 minutes at 37°C according to manufacturer instructions. The tetracycline-inducible 
vector pUV15tetORM (ATCC Plasmid # 17975) was digested under the same conditions. 
Ligation of PCR products into the digested vector was performed using NEB T4 DNA 
Ligase at room temperature overnight, followed by inactivation at 65°C for 15 minutes 
according to manufacturer instructions. Ligation products were transformed into E. coli 
DH5α chemically competent cells according to the protocol described above. Plasmids 
were isolated from transformed cells and correct insertion and orientation was confirmed 
by Sanger DNA sequencing.  
Purified pUV15tetORM-RRF isolated from E. coli was subsequently transformed 
into M. tuberculosis H37Ra and H37Rv cells according to standard protocols [52]. All 
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work involving live M. tuberculosis H37Rv was performed in the Johns Hopkins 
Bloomberg School of Public Health Biosafety Level 3 facility according to standard 
operating procedures. Competent cells were created by inoculating starter cultures into 
Middlebrook 7H9 liquid media with glycerol, Tween 80, and filtered albumin-dextrose-
catalase and incubating at 37°C to log phase for 7 days. Cells were harvested by 
centrifugation at 4000rpm for 10 minutes. Cell pellets were resuspended in sterile 
distilled water and washed three times with 10% glycerol in water, and finally 
resuspended 100:1 in 10% glycerol in water. Purified plasmids (containing cloned RRF 
or empty vector) were added to cell suspensions for 1 minute at room temperature before 
electroporation (one pulse at 2.5kV). Transformed suspensions were then incubated in 
fresh Middlebrook 7H9 liquid media at 37°C overnight, before plating on Middlebrook 
7H11 solid media with 50 μg/mL hygromycin. Plates were incubated at 37°C until single 
colonies were visible (approximately 3 weeks). 
 
Antibiotic Sensitivity Testing 
Transformed single colonies of M. tuberculosis were grown to log phase in 
sequential cultures of Middlebrook 7H9 liquid media with glycerol, Tween 80, filtered 
albumin-dextrose-catalase, and hygromycin. Agar plates containing Middlebrook 7H11 
solid media with glycerol, Tween 80, and filtered albumin-dextrose-catalase were 
prepared containing increasing concentrations of POA up to 600μg/mL and/or increasing 
concentrations of the inducing agent anhydrotetracycline (ATc) up to 100ng/mL. Log 
phase transformed cultures were then spread uniformly on solid media and incubated at 
37°C for up to 6 weeks. Growth on all plates was assessed on the same day. 





Based on the observations that POA interacts with RpsA in its C-terminal domain 
[44,45], we purified an N-truncated recombinant M. tuberculosis RpsA (residues 292 to 
481). To facilitate our affinity chromatography methodology, we included an N-terminal 
polyhistidine tag on the truncated peptide. Sample purity was confirmed by SDS-PAGE 
(Figure 3.1), indicating a band of high intensity at the expected fragment size of 21.6kDa.  
To identify novel putative binding partners of RpsA not previously observed in 
fast-growing Gram-negative systems, purified RpsA292 was incubated with M. 
tuberculosis H37Ra whole cell lysate. Lysate components with significant binding 
affinity for RpsA are expected to associate with the peptide during this incubation step. 
When added to a Ni-NTA matrix, the polyhistidine-tagged RpsA292 becomes bound to the 
matrix along with any associated bound partners, while other lysate components are 
washed away. Initial pulldown results are presented in Figure 3.2A. Eluents from 
RpsA292 incubated with cell lysate obtained through sonication are shown in lane 6. 
Because lysate components may bind directly with the Ni-NTA matrix due to native 
histidine-rich domains or nonspecific binding [53], eluents from lysate incubated with 
PBS as control are included in lane 7. Notably, five bands of high intensity appear in 
eluents of lysate incubated with RpsA292 that are not observed in eluents of either lysate 
alone or RpsA292 alone (enlarged and annotated in Figure 3.2B) in the size range of 
approximately 17-22kDa. 
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As described in the Methods, a truncated peptide of M. tuberculosis RpsA was amplified with an N-
terminal polyhistidine affinity tag and cloned into a pET-SUMO vector. Expression was induced by IPTG 
and cells were lysed via sonication. Lysate supernatants were incubated with Ni-NTA resin and unbound 
constituents were washed with 20mM imidazole. Lanes 1-5 represent five sequential eluent fractions after 
wash. 
  





Figure 3.2: RpsA292 Cell Lysate Pulldown  
 
Purified RpsA292 was incubated with M. tuberculosis cell lysate, after which Ni-NTA resin was added to 
the mixture. The results of the pulldown experiment wash and elution fractions, run on an SDS-PAGE gel, 
are presented in 3.2A. Lane 1: Lysate alone (before wash); Lane 2: Purified RpsA292 alone (before wash); 
Lane 3: RpsA292 with Lysate, wash; Lane 4: Lysate alone, wash; Lane 5: RpsA292 alone, eluent; Lane 6: 
RpsA292 plus Lysate, eluent; Lane 7: Lysate alone, eluent. Putative protein binding partners may be 
identified by comparing bands in the RpsA292 alone eluent (Lane 5) and Lysate alone eluent (Lane 7) to 
those bands with increased intensity in the mixture of RpsA292 and Lysate (Lane 6). These lanes are 
enlarged in 3.2B, and bands which were excised for identification through mass spectrometry are annotated 
as boxes B through F (Box A indicates the band of RpsA292 present in the eluent of both samples). 




Figure 3.2: RpsA292 Cell Lysate Pulldown  
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We also tested the binding partners of purified RpsA292 in M. tuberculosis lysates 
obtained through French press lysis (Figure 3.3). Rather than observing additional 
pulldown partners in the French press lysates, we found that the bands of highest 
intensity found from sonication lysates were not found in French press lysates (lane 3 vs. 
lane 6). This suggests that this binding partner may itself be a component of a large 
macromolecular complex which precipitates out of solution when French Press lysates 
are centrifuged to obtain lysate supernatant. 
To definitively identify the putative binding partners of RpsA identified through 
pulldown, we excised these SDS-PAGE gel bands (Figure 3.2B) and submitted them for 
analysis via LC-MS/MS by the Johns Hopkins Mass Spectrometry and Proteomics 
facility. The identities of the highest-likelihood candidate peptides from each band are 
presented in Table 3.1. Interestingly, the SDS-PAGE band of highest intensity from 
Figure 3.2 (band B) is consistent with ribosome recycling factor (RRF, Rv2882c), a 185-
residue, 20.8kDa protein. Because RRF may play a role in ribosome rescue independent 
of tmRNA in E. coli (discussed below), we sought to test the effects of POA on the 
putative interactions between RpsA and RRF. 
We repeated our pulldown experiment using RpsA292 and M. tuberculosis lysates 
obtained from sonication. In this iteration, we also incubated samples with either 
300μg/mL POA or DMSO as control (Figure 3.4). While the 21kDa band attributed to 
RRF appeared to show diminished intensity in the presence of POA (lane 3 vs. lane 5), 
this may be attributed to variations in the amount of total protein loaded in each lane and 
is not a definitive finding.  
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Purified RpsA292 was incubated with M. tuberculosis cell lysate obtained through either sonication (Lanes 
2-4) or French press (Lanes 5-7), and eluents run on an SDS-PAGE gel are presented. Lane 1: RpsA292 
alone, eluent; Lane 2: Sonication Lysate (before wash); Lane 3: RpsA292 plus sonication Lysate, eluent; 
Lane 4: Sonication Lysate, eluent; Lane 5: French press Lysate (before wash); Lane 6: RpsA292 plus French 
press Lysate, eluent; Lane 7: French press Lysate alone, eluent. Lanes 2-4 represent a replicate of the 
experiment performed in Figure 3.2. Protein binding partners present in the sonication Lysate but absent in 
the French press Lysate may be identified by comparing bands of increased intensity in Lane 3 to Lane 6. 
(Boxes have been added at the same molecular weight position in both lanes for comparison.) 
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Purified RpsA292 was incubated with M. tuberculosis cell lysate (obtained through sonication) in the 
presence of either DMSO (as control, Lanes 2-3) or 300μg/mL POA (Lanes 5-6), and eluents run on an 
SDS-PAGE gel are presented. Lane 1: Lysate alone (before wash); Lane 2: Lysate alone with DMSO, 
eluent; Lane 3: RpsA292 and Lysate with DMSO, eluent; Lane 4: RpsA292 alone (before wash); Lane 5: 
RpsA292 and Lysate with POA, eluent; Lane 6: Lysate alone with POA, eluent. The potential effects of 
POA on RpsA292 binding partners may be assessed by comparing the intensity of bands present in the 
DMSO sample (Lane 3) with those present in the POA sample (Lane 5). (Boxes have been added at the 
same molecular weight position in both lanes for comparison.) 
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To explore physiological and phenotypic changes associated with RRF 
expression, we cloned wild-type M. tuberculosis rrf into a pUV15tetORM vector under 
control of an ATc-inducible promoter element. (As rrf is an essential gene, deletion is 
infeasible and knockdown or genomic mutation is methodologically problematic in slow-
growing mycobacteria.) This vector was transformed into both M. tuberculosis H37Ra 
and H37Rv strains. Overexpression of RRF was induced using increasing concentrations 
of ATc and colonies were grown on solid media containing increasing concentrations of 
POA to determine the MIC (Figure 3.5). In both strains of M. tuberculosis, no detectable 
differences were observed in the MIC of POA in any concentration of inducing agent, 
suggesting that overexpression of RRF does not increase the sensitivity of M. 
tuberculosis to POA. 
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Wild-type M. tuberculosis RRF was cloned into a pUV15tetORM vector and transformed into competent 
M. tuberculosis H37Ra cells. Overexpression was induced using either 30ng/mL ATc (middle column) or 
100ng/mL ATc (right column), and colonies were plated on Middlebrook 7H11 media containing 50μg/mL 
hygromycin (as a selective marker for the vector) and between 0 and 600μg/mL POA. The effects of RRF 
overexpression may be assessed by comparing the MIC of colonies containing the recombinant vector 
(containing cloned RRF, pUV-RRF) and that of colonies containing the empty vector (pUV-Empty) at each 
concentration of ATc. In all samples and replicates, no significant differences were noted in MIC between 









In this study, we investigated the putative binding partners of RpsA in M. 
tuberculosis. We found that purified, truncated RpsA292 associated with several cell 
lysate proteins in a Ni-NTA pulldown. The most significantly enriched protein from 
sonicated lysates was depleted in French press lysates, indicating that it is possibly 
associated with large, insoluble complexes intracellularly. By mass spectrometric 
analysis, the identity of this protein was found to be ribosome recycling factor (RRF), a 
protein known to bind the ribosomal 50S subunit in bacteria [54]. Incubation of RpsA292 
and sonicated lysates in the presence of POA did not noticeably inhibit the association of 
RpsA292 with RRF as assessed by pulldown. Overexpression of RRF in M. tuberculosis 
cells did not alter the sensitivity of cells to POA. Cumulatively, these observations 
suggest that RpsA may bind RRF in bacterial cells – a novel finding – and that this 
interaction is not likely to be meaningfully impacted by the antibiotic actions of POA. 
Ribosome recycling factor plays a core role in translation across bacterial species. 
Originally termed ribosome releasing factor, RRF was first described in 1970 and soon 
after its essential role (alongside elongation factor G) in disassembly of the post-
termination complex was documented [55,56]. After an mRNA stop codon has entered 
the ribosomal A-site, release factors 1 and 2 act to hydrolyze the final peptidyl-tRNA 
ester bond and release the nascent peptide, leaving two uncharged tRNA molecules, the 
mRNA, and the ribosomal subunits associated as a post-translation complex [57]. 
Elongation factor G and RRF then act in the P-site to eject the release factors from the 
occupied A-site, and subsequently dissociate the ribosomal subunits allowing them to be 
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recycled or degraded [58]. The ribosome/mRNA complex has been co-crystallized with 
RRF, and on the basis of these structural studies, RRF has been predicted to associate 
primarily with 50S subunit 23S RNA and possibly proteins L5, L16, and L27 [54,59], but 
this has not been confirmed in vivo. However, due to the flexibility of its C-terminal 
domain, RpsA is routinely excluded from X-ray crystallographic studies of the ribosome 
and it is unclear whether it may plausibly interact with the RRF binding position. Our 
study may present the first evidence of a novel binding partner for RRF in the M. 
tuberculosis post-termination complex. In addition to its traditional role in releasing the 
post-termination complex, RRF may also play a non-canonical role in ribosome rescue. 
In E. coli, certain short reading frames have been shown to produce toxic effects 
when transcribed, and these effects are related to codons cognate for rare tRNAs [60]. As 
these tRNAs are rapidly depleted, ribosomes stall mid-translation leading to a global halt 
in protein synthesis [61–64]. Similar to its role in rescuing ribosomes stalled on truncated 
peptides, overexpression of tmRNA can act to alleviate the toxic effects of ribosomes 
stalling on these rare codons [65]. Notably, overexpression of RRF demonstrates the 
same resuscitation phenotype. This observation does not necessarily discount canonical 
RRF function, as RRF may be recycling ribosomes rescued and terminated through trans-
translation. However, when the tmRNA gene is interrupted and rendered nonfunctional, 
overexpression of RRF still demonstrates a rescue phenotype [65]. This implies that, on a 
stalled ribosome which cannot be terminated by tmRNA, RRF may still assist in 
ribosome release even though the peptide chain has not yet been released and the P-site is 
occupied by peptidyl-tRNA instead of release factors 1 and 2. This non-canonical role for 
RRF mirrors the phenotypic rescue demonstrated by tmRNA; that this occurs even in the 
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absence of functional tmRNA suggests that RRF may serve a redundant or 
complimentary rescue function. Importantly, it suggests that RpsA may play a vital role 
in interacting with multiple molecules which salvage stalled ribosomes under stress 
conditions. This would reinforce the existing model that POA’s primary mechanism of 
antibiotic action is to disrupt ribosome rescue [44,66]. Importantly, all such work on 
RRF-mediated ribosome rescue has been investigated in E. coli, and mycobacterial 
proteins in this pathway may have important functional differences between those in E. 
coli [67,68]. Only further investigation of these pathways in M. tuberculosis will confirm 
or refute this hypothesis. 
This experimental methodology is not without its limitations. Our primary finding 
was detected using a Ni-NTA pulldown and a polyhistidine-tagged bait protein. Such 
methods of affinity chromatography are subject to several known shortcomings: they are 
biased to towards interactions with high affinity and slow dissociation; post-translational 
modifications of RpsA expressed in E. coli may not reflect modifications in native M. 
tuberculosis; the binding conditions in buffer are unlikely to reflect intracellular binding 
conditions; affinities of purified bait proteins (RpsA) may not reflect the binding 
affinities of proteins in the native cellular niche (i.e., in complex with other ribosomal 
proteins and nucleotides); and affinity tags may interfere with native protein folding and 
may disrupt (or enhance) binding affinities [69–71]. It should be noted that these 
limitations are more likely to reduce the sensitivity of the assay than its specificity, and 
therefore false positive results are less likely than false negative results (i.e., some true 
binding partners may not have been captured in our assay, but it is less likely that RRF is 
a falsely positive binding partner). As discussed above, different cell lysis methods affect 
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the specific proteins contained in lysate supernatant, and as a result our lysates are 
unlikely to be fully representative of all potential intracellular binding partners of RpsA. 
Again, this limitation is more likely to produce false negatives than false positives. For 
these experiments, we deliberately elected to use a truncation of the full length RpsA as 
our bait protein, which may not represent all potential binding sites (or obstructions to 
RRF binding) found in wild-type RpsA. This truncation was selected based on data that 
POA binding sites occur at residues K307 and later [45], and therefore we were primarily 
interested in proteins which bound specifically to the C-terminal domain of RpsA. To 
validate our identification of RRF as a potential binding partner of RpsA292, we utilized 
an overexpression/MIC experimental approach as has been used previously [44]. 
However, this approach could only confirm if a greater molar concentration of RRF could 
reduce the sensitivity of M. tuberculosis to POA (hypothetically by ensuring excess RRF 
could access RpsA during ribosomal rescue); negative results (i.e., no change in MIC) 
cannot distinguish between whether a) RRF binds to RpsA and this interaction is 
unaffected by POA; or b) RRF does not bind to RpsA regardless of the presence/absence 
of POA. Additionally, while M. tuberculosis cells were confirmed to carry the pUV 
vector (through selective resistance to hygromycin), we did not confirm that induction 
with ATc resulted in increased RRF protein levels (e.g., by western blot); as an essential 
protein used in translation termination, RRF may simply be constitutively expressed at 
high levels at its genomic locus. Furthermore, studies have demonstrated fundamental 
flaws in this approach, that overexpression of proteins targeted by antibiotics may 
counterintuitively lead to a reduction or no change in detectable MIC in vitro, depending 
on the specific kinetics of interactions between pro-drug, activating enzyme, activated 
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drug, drug target, and drug target binding partners [72]. These limitations suggest that 
while RpsA may bind RRF under buffered cell-free conditions, they remain inconclusive 
as to whether this actually occurs in living M. tuberculosis cells and to what extent this is 
inhibited by POA. 
Alternative approaches and future experiments may well resolve these 
outstanding questions. Affinity chromatography (which detects interactions between 
proteins in cell-free systems) may be validated by an array of additional biochemical 
assays, such as tandem affinity purification, co-immunoprecipitation, or far western 
blotting [69–71]. More quantitative information of binding characteristics may be 
obtained from biochemical and biophysical methods such as isothermal titration 
calorimetry, surface plasmon resonance, or NMR spectrometry. Just as important as 
demonstrating a capacity for binding is the demonstration of protein-protein interactions 
in the intracellular environment. Two hybrid assays, fluorescence resonance energy 
transfer, and fluorescence co-localization microscopy may be versatile tools to this end. 
Synthetic lethality and genetic mutagenesis may also be insightful, though recombinant 
manipulation of genomic RpsA or RRF may be difficult as both are essential genes and 
may not tolerate significant alteration or disruption. Whether or not RpsA and RRF 
interact in vivo, the clinical relevance of these interactions remains unestablished. 
Sequencing of RRF from clinical M. tuberculosis isolates (particularly PZA-resistant 
isolates containing no pncA mutations and/or containing RpsA C-terminal domain 
mutations) may identify informative mutations to better understand the physiological role 
of RRF. Again, its function as a conserved, essential gene may make this approach 
unwieldy, and a search of whole-genome sequences from a library of 498 clinical M. 
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tuberculosis isolates from South Africa and China found no mutations in RRF [73]. 
Finally, the general hypothesis that POA interferes with one or more aspects of ribosome 
rescue deserves interrogation using the most powerful and sophisticated techniques 
available. Transcriptomic sequencing of M. tuberculosis cells exposed to POA may 
reveal changes in transcriptional and regulatory programming in response to antibiotic 
exposure. Even more powerful, ribosome profiling paired with RNA-seq experiments can 
reveal a) whether bacterial cells experience increased global ribosomal stalling and arrest 
when exposed to POA; and b) if specific transcripts experience greater rates of ribosomal 
stalling which contribute specifically to the antibiotic effects of POA [74,75]. These 
approaches, individually and in combination, provide exciting opportunities to further 
interrogate the interactions between RpsA and RRF and what role POA may play in that 
interaction.  
 For the purposes of this investigation, we limited our examination of RpsA 
interactions to the most abundant protein identified by mass spectrometry, RRF. That this 
protein also possesses functionality analogous to known binding partners of RpsA (e.g., 
tmRNA) encouraged further characterization of RRF. However, several other candidate 
proteins were identified by mass spectrometry as putative binding partners of RpsA (see 
Table 3.1), namely inorganic pyrophosphatase (PPiase, GI: 494694055), 50S ribosomal 
protein L6 (Rpl6, GI: 148660494), and ribose-5-phosphate isomerase B (Rv2465c, GI: 
148662300). The presence of RpsA-RRF interactions does not necessarily preclude the 
possibility of concomitant interactions between RpsA and one or more of these 
candidates. While we did not further evaluate putative interactions between these proteins 
and RpsA, these interactions may offer promising opportunities for future research.  
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PPiases are ubiquitous proteins that are essential enzymes across bacterial phyla 
which function to hydrolyze pyrophosphate into inorganic phosphate, a function needed 
for a variety of metabolic processes including DNA replication, transcription, membrane 
biosynthesis, etc. [91]. In M. tuberculosis, PPiase is constitutively expressed under 
nutrient rich conditions as well as a variety of stress conditions, making it an attractive 
target for the development of bactericidal agents [92], and several promising allosteric 
inhibitors have been identified with activity specific to the PPiase of M. tuberculosis [93]. 
However, PPiase activity is primarily confined to catalysis of pyrophosphate and no 
interactions with ribosomal subunits or transcriptional substrates or products have been 
reported in the scientific literature. While this does not preclude the possibility of true 
interactions with RpsA, a high index of suspicion would be appropriate in follow-up 
studies.  
In contrast with PPiase, Rpl6 is a known ribosomal protein that is likely to be 
intracellularly co-located with RpsA and may represent more promising interactions. 
While RRF functions in ribosome disassembly and release, Rpl6 functions in late-stage 
ribosome assembly and is essential for the functional initiation of translation and is a 
target for several antibiotics [94,95]. In Gram-positive organisms, mutations of Rpl6 have 
been associated with the generation of small colony variants, a heterogeneous 
subpopulation of cells which may tolerate stress conditions and antibiotics [96]. This may 
offer an alternative explanation of the unique clinical function of PZA (sterilization of 
small populations of bacteria in acid compartments): inhibition of Rpl6 may deplete a 
subpopulation of small colony variants which may be induced by acid stress and can 
tolerate inhibition by other first-line drugs. However, there have been no reports of small 
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colony variants in the M. tuberculosis literature, and most such literature is confined to 
fast-growing organisms such as Staphylococcus and species of Enterobacteriaceae.  
Finally, a limited literature of ribose-5-phosphate isomerase B (which catalyzes 
the reaction of ribulose 5-phosphate and ribose 5-phosphate) exists for the bacterial 
kingdom. Of those published studies, the function of this protein in M. tuberculosis 
differs from that of E. coli [97], but how this may interact with RpsA in M. tuberculosis 
remains unclear. However, as competitive inhibitors of this enzyme have been developed 
[98,99 ], it may be relevant to investigate the function of RpsA in the presence of ribose-
5-phosphate isomerase B inhibitors. Ultimately, each of these proteins may offer 
alternative, novel pathways involved in the activity of RpsA and potentially PZA and 
may merit further research. 
In light of our finding that RRF does not increase the sensitivity of M. 
tuberculosis to POA, it may be productive to reexamine the premise that POA functions 
primarily by binding RpsA and inhibiting trans-translation. As yet, all mechanistic data 
indicating that POA binds RpsA have been collected in cell-free systems. These data are 
convincing: affinity chromatography, isothermal titration calorimetry, X-ray 
crystallography, and NMR spectrometry all indicate a nontrivial binding affinity between 
POA and RpsA [44,45]. These findings are corroborated by the detection of RpsA 
mutations in clinically PZA-resistant M. tuberculosis isolates containing wild-type pncA 
[76,77]. Similar findings that POA inhibits interactions between RpsA and tmRNA have 
also been observed exclusively in cell-free systems: gel mobility assays and cell-free 
translation systems [44,45]. However, no in vivo system has corroborated these findings.  
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Recent studies have begun to question the trans-translation model of POA action. 
An attempt to reproduce earlier findings that RpsA overexpression increased the 
sensitivity of M. tuberculosis to POA could not replicate these results, instead finding 
that the sensitivity of M. tuberculosis to PZA was unchanged [78]. Re-analysis of 
microarray data from PZA exposure experiments [79] found no change in RpsA transcript 
levels following drug exposure [78]. While binding affinities measured through 
isothermal titration calorimetry were found to approximate those measured in earlier 
studies when the pH of RpsA diluent is neutral [44], no energy of dissociation was 
measured when both solutions (POA and RpsA) were at equal acidic pH [78]. This 
suggests that the energy of dissociation measured in earlier reports represents proton 
dissociation as a neutral solution is titrated into an acidic buffer, but does not characterize 
the affinity of interactions between RpsA and POA. Finally, the POA-associated 
inhibition of trans-translation in a gel mobility assay and a cell-free system in the 
presence of POA could not be replicated [78]. In the absence of in vivo corroboration of 
POA-RpsA interactions, these failures to replicate early findings cast doubt over the 
trans-translation model of POA action.  
While, if true, the POA-RpsA model may be informative for novel drug 
development, evidence suggests it bears little relevance on the detection of clinical drug 
resistance. Because of its role in activating PZA to POA, upwards of 80% of clinical 
PZA-resistant isolates have been attributed to mutations in pncA [80]. In thirteen 
publications reporting RpsA sequences from clinical isolates, only 33 PZA-resistant 
isolates (5%) demonstrated non-synonymous RpsA mutations out of over 614 PZA-
resistant isolates reportedly sequenced with wild-type pncA [44,76,81–90]. This indicates 
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that, at best, RpsA mutations may explain only 5% of clinical PZA-resistance not 
attributable to pncA, and incorporating RpsA (with or without panD) sequencing into 
molecular PZA-resistance diagnosis algorithms only improves sensitivity 2-5% [82,89]. 
While any improvement in the detection of antibiotic resistance is important, these 
modest improvements in sensitivity suggest that still more can be done to understand 
mutations associated with clinical resistance.  
This chapter has endeavored to review the microbiological basis for first-line TB 
combination therapy and the importance of PZA’s sterilizing activity. To that end, it has 
examined proposed models for the mechanism of action of PZA (including membrane 
disequilibrium, inhibition of fatty acid synthesis, and inhibition of trans-translation), and 
discussed experimental evidence for those models. Based on the observation that POA 
binds and inhibits RpsA, we investigated the putative binding partners of RpsA in M. 
tuberculosis. We found that RpsA may bind RRF in vitro, but could not demonstrate that 
this interaction was inhibited by POA. This is the first report of potential interactions 
between RpsA and RRF in the scientific literature, and could imply that RpsA may serve 
a key function in several ribosome rescue pathways. These findings should be validated 
with further investigation and several such methodologies are proposed here. Finally, this 
article concludes by critically evaluating the evidence that RpsA may not be an important 
site of action for PZA’s antibiotic effects, both microbiologically and clinically. While 
PZA remains a critical and indispensable component of first-line TB regimens globally, 
the mechanism through which it exerts its unique sterilizing effects is still a source of 
contentious debate. Only through further investigation may we better understand sources 
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of PZA resistance and develop novel chemotherapeutic agents to enhance or replace 
pyrazinamide. 
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 Background: The extent to which MDR-TB can transmit infection relative to 
drug sensitive TB is unclear. We assessed the impacts of competing assumptions about 
the transmission efficiency of MDR-TB on long-term trends in MDR-TB epidemics in 
South Africa and Vietnam. 
 Methods: We formulated a deterministic mathematical model of DS-TB and 
MDR-TB. Using this structure, we compared three scenarios with different assumptions 
about the efficiency with which MDR-TB transmits: MDR-TB transmits less efficiently 
than DS-TB; it transmits equally as efficiently as DS-TB; or it initially transmits at a 
deficit which gradually shrinks over time. We calibrated these scenarios with data from 
national drug resistance surveys and projected epidemic trends to 2040. 
 Results: Long-term trends in MDR-TB epidemiology are highly dependent on its 
transmission efficiency. Current trends in MDR-TB are consistent with MDR-TB 
incidence rates in South Africa increasing by either 5% (assuming a constant efficiency 
deficit) or by 226% (assuming a shrinking efficiency deficit) by 2040, and by either 84% 
or 465% (respectively) in Vietnam. The most significant determinants of long-term 
MDR-TB incidence were the transmission efficiency of MDR-TB, and the rate with 
which deficits in MDR-TB transmission may be reduced over time. 
 Conclusions: Whether MDR-TB remains a small proportion of global TB cases 
will depend on the transmission efficiency of MDR-TB relative to that of DS-TB. A 
better understanding of these characteristics is necessary to more precisely predict long-
term TB trends.  





 The global epidemic of multidrug resistant tuberculosis (MDR-TB) represents a 
significant challenge to worldwide TB control efforts. In 2016, an estimated 490,000 
cases of MDR-TB occurred, representing 4% of new TB cases and 19% of previously-
treated TB cases globally [1]. While significant efforts have been made to improve the 
accurate and timely detection of patients suffering from drug resistant TB and to provide 
these patients with effective second-line therapies, the global burden of MDR-TB has not 
abated [1]. In the face of myriad challenges posed by TB epidemics, the World Health 
Organization has adopted the END TB strategy to reduce global TB incidence by 90% (to 
less than 10 per 100,000 annually) and TB deaths by 95% between 2015 and 2035 [2]. In 
light of the poor clinical outcomes, economic burden, and human cost associated with 
detecting and treating patients suffering from MDR-TB, the success of efforts to reach 
these goals will likely depend to an important extent on the future trajectory of MDR-TB 
epidemics around the world. However, predicting the trajectory of these epidemics 
remains a challenge. Mathematical epidemic models may assist in understanding these 
trends and predicting the effects of TB interventions. 
 Strategies to control MDR-TB often emphasize the prevention of drug resistance 
through detection and effective treatment of drug sensitive TB (DS-TB), assuming that 
MDR-TB fails to spread efficiently [3]. Early microbiological studies found that highly 
isoniazid (INH) resistant isolates of Mycobacterium tuberculosis were associated with 
reduced virulence in animal models of TB [4,5], suggesting that resistance-conferring 
mutations carry with them a physiological fitness cost in the absence of antimicrobial 
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pressure. According to this classical dogma that MDR-TB suffers a fitness cost compared 
to DS-TB, the appropriate management of DS-TB cases should be sufficient to contain 
epidemics of MDR-TB [3,6]. Therefore, several leading public health organizations have 
made effective management of DS-TB the cornerstone of MDR-TB control [2,7,8].  
The extent to which trends in MDR-TB incidence may be reversed through 
effective control of DS-TB is likely to depend significantly on the ability of MDR-TB 
cases to transmit infection and generate secondary cases [9]. In contrast with early studies 
of INH-resistant M. tuberculosis, more recent in vitro and in vivo studies have cast doubt 
over the consistency of the fitness cost hypothesis [10,11]. Further studies have 
demonstrated that drug resistant mutants with reduced physiological fitness may be 
restored to full virulence over time through secondary compensatory mutations and 
evolutionary selection [12,13]. While it is unclear to what extent in vitro fitness and 
compensatory evolution relates to the relative efficiency of MDR-TB transmission at the 
population level, epidemiological time-series studies indicate that the prevalence of 
MDR-TB isolates carrying these low-cost or compensatory mutations has increased over 
time in several settings [14,15]. Simultaneously, evidence has accumulated that modern 
MDR-TB epidemics are driven primarily by transmission rather than by the acquisition of 
drug resistance during treatment [16,17]. Therefore, the future trajectory of MDR-TB 
epidemics (and the long-term success of control efforts which prioritize DS-TB control) 
is likely to depend significantly on the relative efficiency with which MDR-TB cases 
transmit infection to others and cause disease in the secondary host. 
 In light of the varied approaches used to model MDR-TB transmission efficiency 
and given the complexity of empirical evidence about MDR-TB dynamics, we sought to 
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compare the impacts of different assumptions about MDR-TB transmission efficiency on 
projections of long-term MDR-TB incidence. We used a mathematical model of DS-TB 
and MDR-TB in two high burden settings to project future trajectories of MDR-TB 
epidemics under three competing assumptions about the relative transmission efficiency 
of MDR-TB. Within this framework, we demonstrate the ability of different modeling 
scenarios to recapitulate empirical epidemic characteristics with varying degrees of 
success. We further show that such scenarios forecast highly divergent trajectories of 
MDR-TB epidemics. 
  





TB Dynamics and Natural History 
To explore the evolutionary impact of differential transmissibility, we formulated 
a deterministic compartmental model of adult TB transmission [18] in two high burden 
settings: South Africa and Vietnam. Our model represents the natural history of DS-TB 
and MDR-TB as follows (Figure 4.1A): susceptible populations who become infected 
with either DS-TB or MDR-TB may develop latent TB infection (followed by a slow rate 
of progression to active TB disease) or rapidly progress to active TB. Regardless of 
whether populations progress rapidly or slowly, all experience a subclinical (and less 
infectious) period of disease before developing clinically detectable (and fully infectious) 
TB. The emergence of MDR-TB occurs initially through the natural selection of 
spontaneous mutations during first-line treatment of DS-TB but subsequently spreads 
through person-to-person transmission (see Supplemental Methods for a detailed 
description of modeling methods and ordinary differential equations).  
Our model incorporates a simplified interaction of HIV and TB co-epidemics 
(Figure 4.1B) without explicitly incorporating HIV transmission, but rather with the 
annual incidence of HIV fitted to setting-specific UNAIDS estimates [19] of adult HIV 
incidence (independent of TB status; see Supplemental Methods for full details). 
Populations living with HIV are classified into three states: High CD4 (representative of 
populations with CD4+ T cell levels above approximately 250 cells/mL), Low CD4 
(representative of populations with CD4 levels below approximately 250 cells/mL), and 
Receiving antiretroviral therapy (ART; representative of a weighted population average 
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of CD4 levels among those receiving ART). An individual’s HIV status may then 
influence rates of TB mortality, infectiousness, rapid progression, reactivation, diagnosis, 
etc.  
 
Diagnosis & Treatment 
Upon diagnosis, TB patients initiate either effective therapy or ineffective 
therapy. Those receiving effective therapy demonstrate a rapid cessation of infectiousness 
[20], a reduction in mortality, and – upon treatment completion – long-term cure or 
eventual relapse. Those receiving ineffective therapy experience continued infectiousness 
and TB-associated mortality. Patients with MDR-TB receive drug susceptibility testing 
(DST) at a rate determined by setting-specific national estimates of DST coverage over 
time (since 2006; see Supplemental Methods for full details) [1,21,22]. Those who do not 
receive DST may only initiate ineffective first-line therapy (6 months in duration), while 
those who receive DST may initiate effective or ineffective second-line therapy (20 
months in duration). Additionally, patients may default from any treatment regimen 
(correlated with the length of each regimen, see Table 1) and MDR-TB patients may fail 
to initiate treatment following DST. Rates of ART initiation are calculated from setting- 
and time-dependent data on ART coverage and, to reflect the integration of TB and HIV 
care in these settings, co-infected patients in whom either disease is detected experience 
increased rates of treatment initiation for their coinfections. 
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Figure 4.1: Model Structure  
 
States of TB infection and possible transitions between them are represented in panel A. Upon initial 
infection, populations develop latent infection or incipient (preclinical) disease. After developing fully 
infectious active TB, populations initiate treatment at a specified rate, and treatment may be effective 
(eventually achieving sputum conversion) or ineffective. For those who complete an effective treatment 
course, they may either achieve durable cure or are rendered temporarily non-infectious but with future 
relapse anticipated. Those receiving an ineffective first-line regimen may re-initiate treatment after failure. 
MDR-TB may be acquired during first-line treatment (without cure) or as a result of transmission. 
Populations with MDR-TB may initiate ineffective first-line treatment or, following DST, effective or 
ineffective second-line treatments. Compartment colors correspond to the respective infectiousnes and TB-
associated mortality of each state (see Methods and Supplementary Methods for more details). In addition 
to TB natural history, populations are also classified by treatment history (treatment-naïve or previously-
treated, not shown), and HIV status (represented in panel B). Following HIV infection, populations 
transition through states of increasing immunosuppression or to antiretroviral therapy (ART) at defined 
rates.  
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Figure 4.1: Model Structure  
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Approach to TB Transmission 
We investigated the impact of transmission-related differences between DS-TB 
and MDR-TB by varying initial assumptions about the transmission efficiency of each 
strain over time. We define the coefficient of transmission efficiency as the number of 
new TB infections that result from each infectious person-year of active TB. 
Transmission efficiency captures the biological processes of TB transmission (aerosol 
production, infectious doses, bacterial virulence, etc.) as well as non-biological processes 
that influence transmission (contact rates, population mixing, etc.). Therefore, the 
transmission efficiency of either DS- or MDR-TB strain may be increased through 
changes in underlying biology (e.g., compensatory mutation) or through population-level 
influences (e.g., hospital housing of MDR-TB patients). In all cases, we assume the 
transmission efficiency of DS-TB declines slowly after 2000 to capture the roughly 2% 
annual decline in overall TB incidence (due to various secular trends in improved health 
status, living conditions, etc., and unrelated to improvements in MDR-TB case 
management) [1].  
To reflect divergent hypotheses concerning the transmission of MDR-TB relative 
to DS-TB, we constructed three scenarios regarding the transmission efficiency of MDR-
TB over time (Figure 4.2). In the first scenario (“Constant Efficiency Deficit”), we 
assume that MDR-TB emerges historically with a deficit in transmission efficiency 
(relative to that of DS-TB) which remains constant through the present and into the future 
(i.e., with no opportunity for compensatory mutations, increased cohorting of MDR-TB 
patients in congregate settings, or other processes to increase the transmission efficiency 
of MDR-TB over time). While the transmission efficiency of DS-TB declines slowly 
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over time in this scenario, we conservatively assume that the transmission efficiency of 
MDR-TB remains constant. In the second scenario (“Shrinking Efficiency Deficit”), we 
assume that MDR-TB emerges with a deficit in transmission efficiency which gradually 
shrinks until the efficiency of MDR-TB equals that of DS-TB (through, for example, 
compensatory evolution, natural selection of “high fitness” MDR-TB strains, or social 
processes such as recurrent imprisonment that concentrate MDR-TB in high-transmission 
settings). In the third scenario (“No Efficiency Deficit”), we assume that MDR-TB 
emerges historically with a transmission efficiency equal to that of DS-TB. In all 
scenarios, the transmission efficiency of MDR-TB is modeled independently from that of 
DS-TB, such that declines in DS-TB transmission do not necessarily cause declines in 
MDR-TB, although the efficiency of MDR-TB may never exceed that of DS-TB.  
As described below, a range of possible values was defined for parameters related 
to MDR-TB transmission, and calibration was used to identify those values most 
consistent with empirical MDR-TB epidemic observations. The emergence of modern 
MDR-TB was allowed to range from 1971 to 1996 (see Supplementary Table 1). The 
initial transmission efficiency of MDR-TB relative to that of was allowed to range from 
39-94% in the Constant Deficit and Shrinking Deficit scenarios (and was fixed at 1.0 for 
the No Deficit scenario). In the Shrinking Deficit scenario, the annual rate of reduction in 
the MDR-TB transmission efficiency deficit was allowed to range from 0 to 1.5% per 
year. (Further details on the parameterization of each scenario may be found in the 
Supplementary Methods.) 
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The assumed transmission efficiency (transmission events per 1,000 infectious person-years) of DS-TB 
over time is drawn in green; the downward slope recapitulates reductions in TB transmission efficiency due 
to secular trends unrelated to MDR-TB diagnosis and treatment (for example, reductions in crowding, 
improved socioeconomic conditions, etc.). In our three model scenarios, we assume either that the 
transmission efficiency of MDR-TB is at a perpetual defict compared to that of DS-TB (Constant Deficit 
Scenario, drawn in orange); that the transmission efficiency of MDR-TB is consistently the same as that of 
DS-TB (No Deficit Scenario, drawn in magenta); or that MDR-TB has lower transmission efficiency than 
DS-TB initially but gradually converges towards that of DS-TB over time (Shrinking Deficit Scenario, 
drawn in red). Years are shown for illustrative purposes; dates of MDR-TB emergence and rates of 
increase/decrease in transmission efficiency are sampled from defined ranges; see Sampling & Calibration 
for further details.  
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Sampling & Calibration 
For each input parameter used in the formation of our model, we defined a range 
of plausible values based on the scientific literature (Table 4.1 and Supplementary Table 
S2.1). These ranges were parameterized as lognormal (for continuous ranges bounded at 
0), logit-normal (for continuous ranges bounded between 0 and 1), or uniform probability 
distributions (for parameters on continuous ranges with sparse support in empirical 
literature). To capture the uncertainty in these parameter values, we utilized a two-stage, 
semi-Bayesian Sampling/Importance Resampling algorithm [23] to simulate epidemics 
consistent with empirical data. 
 Using Latin hypercube sampling [24], we generated 135,000 sets of initial 
parameters, each set composed of one value for each parameter related to DS-TB drawn 
from the probability density defined in Table 1. Each parameter set was then used to 
simulate a DS-TB epidemic to 1990 followed by a DS-TB/HIV epidemic to 2016. In the 
first stage of calibration, these simulations were fitted to the WHO estimates of total TB 
incidence in each setting and setting-specific estimates of the proportion of HIV-positive 
patients among incident TB cases (using national survey data in South Africa and WHO 
estimates in Vietnam) [1,25]. Each calibration point was defined as a bounded beta 
distribution and a pseudo-likelihood weight for each initial parameter set was defined as 
the joint probability density of the set’s simulated DS-TB epidemic incidence and 
proportion of HIV-positive patients.  
In the second stage of sampling, 135,000 DS-TB/HIV parameter sets were 
resampled (with replacement) according to their pseudo-likelihood weights (as described 
above) and accompanying values for MDR-TB parameters in each set were drawn from 
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their defined distributions (Table 4.1), again using Latin hypercube sampling. These 
parameter sets were used to simulate new DS-TB/HIV/MDR-TB epidemics from the date 
of the emergence of MDR-TB (itself a sampled parameter value) until 2016. In the 
second stage of calibration, these simulations were fitted to the proportion of MDR-TB 
among recently-diagnosed TB in new and – separately – in previously-treated patients (as 
measured in national drug resistance surveys) [26–28]. Each calibration point (proportion 
MDR among recently-diagnosed new and previously-treated TB cases) was defined as an 
independent normal distribution and a new pseudo-likelihood weight for each parameter 
set was calculated from the MDR-TB calibration targets. These pseudo-likelihood 
weights were used to resample those DS-TB/HIV/MDR-TB parameter sets most 
consistent with historical MDR-TB epidemics before projecting outcomes into the future. 
 
Outcomes and Statistical Analysis 
 Our primary outcomes in each setting were the absolute incidence of MDR-TB in 
2040; the incidence of MDR-TB relative to all incident TB in 2040; and the fold change 
in absolute and relative MDR-TB incidence between 2016 and 2040. For projections of 
these primary outcomes we report median values as well as Uncertainty Ranges (UR), 
defined by the 5th and 95th percentiles of posterior distributions. The three scenarios 
related to MDR-TB transmission efficiency were compared in terms of fit to the observed 
epidemiological data by calculating Bayes Factors. (A Bayes Factor (BF) is calculated as 
the ratio of the cumulative posterior probabilities of two models, and can be interpreted 
as the calibration data’s support for one model over another [46].) Unless otherwise 
stated in the text, Bayes Factors were calculated in support of the Constant Deficit 
scenario over other models. We investigated the sensitivity of the primary outcomes to 
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individual input parameters by comparing the primary outcome in those simulations 
sampling within the lowest quintile of each input parameter’s (posterior) range against 
those simulations sampling within the highest quintile. Nonparametric partial rank 
correlation coefficients are also presented in the Supplementary Results.  
 
Replication of Previous Findings 
 A recently-published mathematical model of MDR-TB in several countries 
implemented an approach to MDR-TB transmission conceptually comparable to our No 
Deficit scenario [17]. Despite the similar approach utilized, our results demonstrate 
qualitatively different trends in MDR-TB incidence (see below). Therefore, we sought to 
replicate the findings of this previous study by altering assumptions about a small number 
of key input parameters (see Supplementary Methods for further details). 
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Table 4.1: Selected* Parameter Values 
Description Medi
an 
Sampling Range† Distribution References 
Probability of rapid progression after initial tuberculosis infection 0.14 0.08-0.25 Logit-normal [29] 
Reactivation rate from latent to incipient (preclinical) active 
tuberculosis, per year 
0.001 0.0005-0.002 Lognormal [30–33] 
Rate of tuberculosis diagnosis and treatment initiation, per year 1.0 0.7-1.5 Lognormal [1,34,35] 
Proportion failing to initiate treatment for multidrug-resistant 
tuberculosis after diagnosis (in excess of loss to follow-up of patients 
with drug-susceptible tuberculosis) 
0.05 0.02-0.10 Logit-normal [1,35] 
Proportion of treated patients who have an apparent treatment response     
Newly diagnosed patients with drug-susceptible tuberculosis, 
first-line therapy 
0.98 0.96-0.99 Logit-normal [1,36–38] 
Patients with multidrug-resistant tuberculosis, longer therapy 0.77 0.66-0.85 Logit-normal [39–41] 
Proportion who relapse, among those with apparent treatment response     
Newly diagnosed patients with drug-susceptible tuberculosis, 
first-line therapy 
0.04 0.026-0.06 Logit-normal [41,42] 
Patients with multidrug-resistant tuberculosis, longer therapy 0.04 0.015-0.10 Logit-normal [42,43] 
Probability of loss to follow-up during therapy     
First-line therapy 0.06 0.03-0.10 Logit-normal [1] 
Longer therapy for multidrug-resistant tuberculosis 0.11 0.04-0.25 Logit-normal [44,45] 
Risk of acquiring multidrug resistance during first-line therapy 0.004 0.0015-0.01 Logit-normal [40] 
*See the Supplementary Methods for a full listing of all parameters, sampling distributions, and references. †Sampling ranges represent the 2.5th to 97.5th 
percentiles of unbounded distributions and lower to upper bounds of uniform distributions. 





Calibration and Model Fit 
 After calibration, we compared the ability of each of our MDR-TB transmission 
models to accurately reproduce empirical observations of MDR-TB prevalence among 
treatment-naïve and previously-treated patients in South Africa and Vietnam. In South 
Africa, while Constant Deficit and Shrinking Deficit models were similarly supported by 
the data (BF=2.6), the No Deficit model was supported far more poorly relative to either 
model (BF<10-8) (Figure 4.3A).  
Similar findings were obtained from Constant Deficit and Shrinking Deficit 
models in Vietnam (BF=2.1, Figure 4.3B). In this setting, where the MDR-TB epidemic 
has been growing faster than in South Africa, the No Deficit model was better supported 
by empirical data but was nonetheless less supported than either of the other models 
(BF<10-3). Due to the poor performance of the No Deficit model in both settings, we only 
considered Constant Deficit and Shrinking Deficit models in our primary results (see 
Supplementary Results for further details).  
These results differ importantly from those of a recent publication implementing 
an approach similar to our No Deficit scenario [17]. We were able to successfully 
reproduce the findings of that publication by altering several assumptions about TB 
natural history and treatment availability (see Supplemental Results for more details). 
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Figure 4.3: Calibration Performance 
 
Simulated epidemics are weighted according to how well each reproduced empirical calibration targets 
(historical estimates of MDR in new and previously-treated TB cases). Recent TB diagnoses were used 
(instead of incident TB cases) to better represent the sampling methodologies used in national drug resistant 
surveys which were used for calibration. Recent diagnoses are defined as any populations transitioning 
from active, untreated TB into any diagnosis/treatment state. Red points represent median and 95% 
confidence intervals for calibration targets drawn from national survey data. (The 1996 prevalence survey 
in Vietnam measured the proportion MDR in new cases only.) IQR represents 25th to 75th percentiles and 
the 90% range represents the 5th to 95th percentiles of posterior simulations. 
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Figure 4.3: Calibration Performance 
A – South Africa 
 
B – Vietnam 
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Projections of MDR-TB Burden 
  When projecting these simulations to 2040, the potential epidemics predicted by 
the Constant Deficit and Shrinking Deficit models diverge significantly. In South Africa 
(Figure 4.4), the Constant Deficit scenario predicts the incidence of MDR-TB at 26 cases 
per 100,000 (IQR: 17-41), comprising 5% (IQR: 4-9%) of all incident TB by 2040. These 
results indicate a median 2.0-fold increase in the relative incidence of MDR-TB from 
2016 to 2040. Projections from the Shrinking Deficit scenario predict much higher 
potential increases in MDR-TB, reaching a median of 69 cases per 100,000 (IQR: 38-
131) by 2040 and accounting for 15% of incident TB (IQR: 8-27%) by that time: a 
median 5.1-fold increase in relative incidence from 2016 to 2040 (IQR 2.8-fold to 7.7-
fold). Similar trends were predicted in Vietnam (Figure 4.5), where the Constant Deficit 
scenario predicts a 2.2-fold increase (IQR: 1.6-3.6-fold) over 2016 and the Shrinking 
Deficit scenario predicts a 5.4-fold increase (IQR: 3.6-7.4-fold) in the relative incidence 
of MDR-TB.  
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Figure 4.4: Projections of the MDR-TB Burden in South Africa 
 
 
Simulated MDR-TB epidemics in South Africa were and projected from 2010 to 2040. Row A illustrates 
the projected absolute MDR-TB incidence in each scenario, while Row B illustrates MDR-TB as a 
proportion of all incident TB. The 2040 projected median (IQR) values are included in the upper right of 
each panel. IQR represents 25th to 75th percentiles and the 90% range represents the 5th to 95th percentiles 
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Figure 4.5: Projections of the MDR-TB Burden in Vietnam 
 
 
Simulated MDR-TB epidemics in Vietnam were and projected from 2010 to 2040. Row A illustrates the 
projected absolute MDR-TB incidence in each scenario, while Row B illustrates MDR-TB as a proportion 
of all incident TB. The 2040 projected median (IQR) values are included in the upper right of each panel. 










 The variability in these MDR-TB outcomes was influenced most strongly by 
parameters determining the transmission and mortality of MDR-TB. The distributions of 
2040 MDR-TB incidence projections in South Africa, separated by parameter quintile 
values, are presented in Figure 4.6. More influential parameters demonstrate a greater 
separation of outcome distributions between the upper and lower quintiles of their values. 
(Similar results were observed for the relative increase in MDR-TB incidence and for 
outcomes in Vietnam, presented in the Supplementary Results). In the Shrinking Deficit 
model, the rate of reduction in the MDR-TB transmission efficiency deficit remained 
highly correlated with 2040 incidence (upper vs. lower quintile medians: 117 vs. 38 per 
100,000). Similar correlations were observed for rates of TB mortality and loss during 
first-line treatment (which determine infectious MDR-TB person-time in the absence of 
second-line therapy). In the Constant Deficit model, the efficiency of MDR-TB 
transmission remained correlated with future incidence (upper vs. lower quintile medians, 
32 vs. 19 per 100,000), as were rates of TB mortality and loss during first-line treatment. 
Outcomes in both models were similarly influenced by parameters related to TB natural 
history, diagnosis and treatment, and HIV interactions (see Supplementary Results). 
Additional parametric and nonparametric sensitivities analyses for projections in South 
Africa and Vietnam are included in the Supplementary Results. 
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Figure 4.6: Sensitivity Analysis – Influence of Key Model Parameters on Projections 
of MDR-TB Incidence in South Africa  
 
Each boxplot represents the distribution of values for the primary outcome (the incidence of MDR-TB in 
2040) within a given set of simulations. Pairs of boxplots represent groups of simulations categorized by 
values of a single input parameter: red boxplots represent the outcomes of those simulations with parameter 
values in the upper 20% of all simulations; blue boxplots represent the outcomes of those simulations with 
parameter values in the lower 20% of all simulations. More influential parameters demonstrate a greater 
separation of the distributions of outcome between simulations in the upper quintile and simulations in the 
lower quintile of parameter values. To the left of each panel are included the input parameter values 
corresponding to the accompanying quintile. In black is represented the overall distribution of the outcome 
across all simulations and the median estimate is drawn as a vertical dotted line. Boxes represent the 
median, 25th, and 75th percentiles of the distribution of outcomes; whiskers represent the 5th and 95th 
percentiles of the distribution of outcomes. In the Constant Deficit model, parameters involving the 
reduction in MDR-TB transmission efficiency deficit are excluded. 




Figure 4.6: Sensitivity Analysis – Influence of Key Model Parameters on Projections of MDR-TB Incidence in Vietnam  
 





 This analysis illustrates that the future trajectory of MDR-TB in South Africa and 
Vietnam remains highly uncertain, with the absolute incidence of MDR-TB increasing by 
either 5% or 226% in South Africa by 2040 and by either 85% or 465% in Vietnam, 
depending on the transmission efficiency of MDR-TB. A major determinant of this 
uncertainty reflects our current lack of knowledge as to whether any deficit in 
transmission efficiency of MDR-TB relative to DS-TB currently exists, and whether such 
a deficit is likely to be reduced into the future. If one assumes that the transmission 
efficiency of MDR-TB is unlikely to change over time, we project that the relative 
incidence of MDR-TB will increase over time with median projected increases of 98% in 
South Africa and 120% in Vietnam by 2040. However, if one assumes that the 
transmission efficiency of MDR-TB may increase over time, we project that the relative 
incidence of MDR-TB may increase dramatically, with median increases of 410% in 
South Africa (ranging upwards of 670%) and 437% in Vietnam (ranging up to 636%). 
This raises the critical question: what evidence exists to suggest that the transmission 
efficiency of MDR-TB may increase over time, and how quickly may this occur? 
 Unfortunately, clear evidence of the potential for increases in the transmission 
efficiency of MDR-TB remains sparse. Much of the scientific literature examining the 
fitness costs and compensatory evolution of drug resistant M. tuberculosis originates 
from laboratory studies which are imperfect models of human transmission. Initial studies 
demonstrated that mutations in the promoter of ahpC may improve in vitro peroxide 
tolerance of INH resistance-conferring katG mutations [12,47]. Such ahpC mutations, 
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however, are uncommon in clinical INH-resistant M. tuberculosis isolates, raising 
questions of the clinical relevance of such adaptations [48]. Similar laboratory 
observations have been noted in the associations of ethambutol resistance and secondary 
mutations in Rv3792 [49], while the ability of rpoA and rpoC mutations to compensate 
rifampin resistance-conferring mutations have been documented in vivo and in human 
populations [13,50].  
Biological compensatory evolution only partially represents epidemiological 
transmission efficiency and experimental assays used to study compensatory evolution 
are prone to methodologically overestimating the benefit of compensatory mutations 
[51]. For the purposes of projecting future trends in MDR-TB epidemics, more important 
than laboratory measures of physiological fitness are estimates of what we have termed 
transmission efficiency; by this we mean the capacity of a case of TB to transmit 
infection and propagate disease in secondary hosts, best represented by the number of 
new TB infections that result from an infectious-person year of active disease. No 
reasonable laboratory systems are capable of quantifying transmission efficiency, and 
therefore we must rely primarily on studies of incident and prevalent TB in human 
populations [52]. Epidemiological studies examining household contacts of DS-TB and 
MDR-TB patients have suggested that fewer secondary cases arise from index MDR-TB 
patients than from DS-TB patients when adjusted for infectious person-time of exposure, 
though the risk of secondary infection (rather than secondary disease) from MDR-TB 
may actually be higher than from DS-TB [53,54]. Importantly, while physiological 
fitness and adaptation of MDR-TB may increase transmission efficiency, the 
transmission efficiency of MDR-TB may also increase as a result of changes in contact 
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rates, mixing patterns, contact susceptibility, and other population-level characteristics 
which influence TB transmission. For example, the clustering of MDR-TB in 
incarcerated populations – where cases and contacts are confined in close quarters with 
inadequate ventilation or access to MDR-TB diagnosis and second-line treatment – is 
well documented [55]. Both MDR-TB and extensively drug resistant TB have also 
demonstrated dramatic clustering in hospital settings, where infectious source cases are 
concentrated and typical contacts – hospitalized patients, often living with HIV or other 
immunosuppressive conditions – are more susceptible to TB infection [56,57]. How these 
heterogeneous mixing and contact patterns influence the transmission efficiency of 
MDR-TB across a large population (and in relation to DS-TB transmission) remains an 
unsettled question. Outside institutional settings, the transmission efficiency of MDR-TB 
may also increase in communities as the result of increasing urbanization which can 
mimic the same risk factors as cohorting in hospitals or prisons [58]. Increased 
population density and rural-to-urban migration have been identified as significant risk 
factors for MDR-TB transmission in cities across Asia and Africa [59,60]. That the urban 
populations of Asia and Africa are expected to double and triple, respectively, by 2050 
[61] suggests that the transmission efficiency of MDR-TB may potentially increase (or 
continue increasing) in countries already hardest hit by DS-TB epidemics. 
 Considering the importance of changes in the transmission efficiency of MDR-TB 
in influencing long-term trends in MDR-TB incidence, the scientific community must 
better understand these characteristics at the population level. Some existing study 
designs have laid the foundations for understanding MDR-TB transmission efficiency. 
Molecular clustering studies have been used for a number of years to characterize how 
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phenotypic and genetic traits of pathogen and hosts associate with the transmission of TB 
[62]. Such studies, however, require costly molecular surveillance programs and at least 
two years of follow-up, and are subject to a number of biases in sampling and inference 
[63–65]. More recent phylogenetic approaches utilizing the high resolution afforded by 
whole genome sequencing of M. tuberculosis isolates have also been utilized to 
reconstruct chains of transmission influenced by putative high- or low-fitness mutations 
[66]. The utility of such studies to draw inferences regarding the transmission efficiency 
of MDR-TB relative to DS-TB may be limited, as transmission chains may not be 
directly or quantitatively compared. Nested case-control studies may improve sampling 
efficiency and shorten surveillance duration over traditional cluster analyses [67]. Cross-
sectional designs combined with whole genome sequencing may offer unique insight in 
characterizing the transmission of MDR-TB in vulnerable patient populations [68]. 
Ultimately, the most important sources of data will be the continuation and expansion of 
repeated national drug resistance surveys [26–28].  
Each of the study designs described above has improved our understanding of 
MDR-TB transmission relative to DS-TB transmission. Despite the utility of these 
studies, none have fully characterized population-level relative transmission efficiency 
(specifically examining exposure time-adjusted transmission and secondary case 
generation). An idealized design to accomplish this might be described in the following 
manner: a large, population-representative cohort of MDR-TB and DS-TB patients 
enrolled, for whom the time of onset of infectiousness could be identified with precision, 
whose secondary contacts (confirmed to be previously TB-uninfected) are exhaustively 
investigated for the new acquisition of infection. With such a study, the denominator of 
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transmission efficiency – total infectious person-time – could be quantified and well-
defined, and the numerator – the number of new infections which result – could be 
measured with little error. Further, such a study would need to be conducted repeatedly to 
assess whether the transmission efficiency of MDR-TB is changing over time (a critical 
determinant of long-term MDR-TB epidemiology).  
Such an idealized design is unrealistic and infeasible for a number of reasons: 
MDR-TB would be a relatively rare event in a population-representative sample 
(currently less than 10% of all TB cases in South Africa) [1,27]; it is difficult to ascertain 
the time of onset of infectiousness; exposed secondary contacts may not be identified or 
may not consent to study participation; confirmation of previous infection history is 
difficult to ascertain; and biological diagnosis of new infection is imperfect [69,70]. 
However, existing study designs and novel epidemiological tools may assist in assessing 
different components of the idealized study design described. Cross-sectional survey 
designs can characterize which demographic groups would compose a representative 
population of TB patients and/or contacts. Novel biomarkers and diagnostic assays may 
help determine the onset of infectiousness (and its trajectory over the course of disease 
[71,72]) as well as newly acquired infections [73,74], while genotypic surveillance and 
cluster studies can link index cases with secondary contacts. Combining several of these 
strategies (e.g., nesting genotypic or biomarker studies within larger cohorts or clinical 
trials [75]) may further improve our ability to inform the existing gaps in our 
understanding of the complex characteristics of MDR-TB transmission efficiency. Until 
such studies provide a more clear understanding of current trends in TB transmission 
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efficiency, our results indicate that the future of MDR-TB epidemics will remain, 
necessarily, uncertain. 
Our approach in this analysis was intended to demonstrate the importance of 
assumptions about the transmission efficiency of MDR-TB in projecting the long-term 
burden of drug resistant TB in two high burden settings. In South Africa, where the 
burden of MDR-TB remained relatively stable between 2002 and 2013, we found little 
support for a model in which the transmission efficiency of MDR-TB has historically 
equaled that of DS-TB. In Vietnam, where the relative incidence of MDR-TB has risen 
significantly between 1996 and 2011, possibly suggesting a greater role for the 
transmission of MDR-TB, there was somewhat better support for the highly transmission-
driven MDR-TB epidemics necessitated in the No Deficit model. Nevertheless, in both 
settings, this was the most poorly-supported model examined.  
 Our results offer an important complement to MDR-TB modeling projections 
published previously. Our previous studies have projected that acquired drug resistance 
accounted for less than 10% of MDR-TB cases in 2013, consistent with the results 
presented here (see Supplementary Results for further details) [16]. Estimates of MDR-
TB incidence using our Constant Deficit and Shrinking Deficit models are comparable to 
those estimated by Blower and colleagues, though our calibration methodology leads to 
significantly less variance in these estimates [76]. Importantly, we found our No Deficit 
model was poorly supported by empirical data in South Africa and projected greater 
increases in the burden of MDR-TB than was recently reported by Sharma and colleagues 
using a similar approach [17]. We were able to reproduce the findings of that report by 
implementing a more slowly-developing TB epidemic than used in our primary analysis 
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and a delay of many years between the onset of infectiousness and treatment initiation, as 
was assumed in that study (see Supplementary Methods and Supplementary Results).  
 Our methodology is not without its limitations. South Africa and Vietnam are 
countries with unique DS-TB, MDR-TB, and HIV epidemics that are not generalizeable 
to all settings but were chosen based on the availability of repeated national drug 
resistance survey data. Uncertainty in our projections may reflect uncertainty in the 
underlying data (e.g., only two national MDR-TB surveys in South Africa) and 
uncertainty in underlying natural history parameters. Our sensitivity analyses suggest 
that, while our results were largely robust to uncertainty in these parameters, our 
estimates were importantly influenced by parameters determining the infectious person-
time of untreated MDR-TB cases (TB mortality and loss during first-line treatment). 
More complete consensus around these estimates would likely reduce the variance of 
long term projections, while significant future improvements in MDR-TB detection 
(particularly in Vietnam, where DST remains unavailable to more than 80% of new TB 
cases [1]) or treatment of MDR-TB (e.g., access to effective short-course second-line 
regimens) are not captured in our projections and could possibly curtail long term 
increases in MDR-TB incidence. Finally, in the absence of unambiguous empirical data 
describing changes in MDR-TB transmission efficiency, we used a simple model of a 
linear increase over time (see Shrinking Deficit Scenario in Figure 4.2) with rates of 
change (i.e., the range of possible slopes in Figure 4.2, from very slow to rapid increases) 
sampled from a broad uniform distribution. Therefore, estimating the future of MDR-TB 
critically depends on better understanding the transmission efficiency of MDR-TB and 
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both the magnitude and shape by which that transmission efficiency may change over 
time. 
 Global efforts to control TB are likely to hinge on the future trajectory of MDR-
TB epidemics. While MDR-TB is often described as carrying a fitness cost associated 
with drug resistance, this characterization may be inaccurate. Alternative arguments 
suggest that the transmission efficiency of MDR-TB may equal that of DS-TB already or 
in the future. We investigated the importance of these assumptions in influencing 
mathematical projections of MDR-TB epidemics. We found that while there was little 
empirical support for models in which there is No Deficit in transmission efficiency 
between MDR-TB and DS-TB, there was roughly comparable support for models in 
which MDR-TB emerges with limited transmission efficiency with or without a 
subsequent increase in transmission efficiency over time. Our results indicate that the 
future of MDR-TB epidemics depends significantly on whether the transmission 
efficiency of MDR-TB may increase over time. A better understanding of these dynamics 
in human populations will improve our ability to predict (and possibly prevent) increases 
in the burden of MDR-TB into the future.  
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 This dissertation represents a series of investigations of tuberculosis (TB) through 
a variety of methodological and substantive lenses: microbiological, epidemiological, and 
theoretical. While much has been accomplished in recent years to improve the diagnosis, 
treatment, and prevention of TB, the disease remains one of the most significant causes of 
disease morbidity and mortality worldwide. To ensure these improvements continue and 
accelerate in coming decades, control of the global TB epidemic will require the optimal 
use of currently available public health tools today, as well as the development of new 
tools for tomorrow. As scientific training becomes increasingly specialized, so too may 
expertise become increasingly segmented and insular. Advances in TB control efforts 
into the future are unlikely to be accomplished by isolated disciplines, but will require the 
interface of scientific experts and public health professionals with a variety of 
backgrounds and areas of expertise. The studies described here offer a unique approach 
of multidisciplinary training and research in public health science. Such a cross-
fertilization of scientific fields may offer a new avenue to generate or hasten new insights 
into infectious disease control. In this section, we contextualize the findings of these 
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SUMMARY OF RESULTS 
 
The translation of laboratory findings – particularly from animal models – is a 
complex dilemma facing many fields of biomedicine [1]. We recognize this issue in the 
TB field and, in Chapter II, offer a new perspective. We introduce a novel theoretical 
framework for linking observations of individual-level pathogenesis, disease progression, 
and recovery with population-level clinical outcomes in humans. Our analysis 
demonstrates that TB progression in humans is decisively slower than is predicted by 
animal models. We also successfully implemented this approach to provide evidence – 
based on individual-level disease progression – that improved TB detection and treatment 
alone may not effectively improve population-level morbidity, as has been observed with 
the rollout of the DOTS strategy as well as Xpert® MTB/RIF [2,3].  
In Chapter III, we investigate the bacterium M. tuberculosis and the intracellular 
mechanisms underlying drug action and the detection of drug resistance, key elements in 
epidemic multidrug resistant TB (MDR-TB). Based on previous findings that the first-
line drug pyrazinamide (PZA) interacts with the bacterial protein RpsA [4], we sought to 
characterize the protein binding partners of RpsA which may be involved in this 
interaction. We identified the essential protein Ribosome Recycling Factor (RRF) as a 
high-affinity binding partner through affinity chromatography amongst a handful of other 
proteins, presenting the first evidence of RpsA-RRF interactions. While laboratory 
findings are critical in the study of TB, in some cases it is difficult to draw clear 
conclusions of their impacts on the TB epidemic. We discuss the contradictory laboratory 
and epidemiological evidence for fitness costs associated with drug resistance.  
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Experimental evidence has accumulated for several decades strengthening the 
hypothesis that mutations which confer drug resistance also carry physiological and 
evolutionary tradeoffs in the absence of drug pressure. More recent molecular studies 
have demonstrated the potential of compensatory evolution and genetic epistasis to 
overcome these tradeoffs. Yet, how these principles translate to the transmission and 
epidemic spread of MDR-TB remains unclear. In Chapter IV, we explore how these 
molecular and evolutionary principles may influence the global TB epidemic in the 
coming decades. We compare competing assumptions about the efficiency with which 
MDR-TB transmits infection, whether with a persistent deficit in efficiency, with a deficit 
that is gradually eliminated, or with no deficit at all. Our findings demonstrate that long-
term trends in MDR-TB incidence vary dramatically depending on the assumptions made 
about biological fitness and transmission efficiency. Additionally, we effectively 
reproduced the contradictory findings of a recently published analysis [5] and were able 
to demonstrate that the discrepancies in our results are attributable to questionable 
assumptions contained in that study. Our analyses provide important context for any 
attempt to predict long-term trends in the MDR-TB epidemic, and highlight important 
characteristics of the TB epidemic about which there remains much uncertainty. 
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STRENGTHS AND LIMITATIONS 
 
These findings offer novel insights into the biology and epidemiology of TB. Our 
individual-level model uses a mathematical and theoretical framework to translate studies 
of individual-level disease progression with large-scale population impacts. This 
framework can accurately recapitulate key characteristics of human TB and can robustly 
predict the population-level impacts of individual interventions (e.g., passive case 
detection and improved diagnostic sensitivity). In this study, we intentionally adopted a 
modeling framework as simple as possible at the individual-level while accurately 
recapitulating human clinical TB. As a result, in its current form, this model cannot 
capture complex pathophysiology and mechanistic interactions which underlie clinical 
progression. However, the simplicity of this framework may serve as a useful platform 
for the community of TB researchers to build upon in complexity and application.  
Our molecular findings, that RpsA may interact with RRF in M. tuberculosis, 
present important clues to better understanding the role of PZA in sterilizing infection 
during first-line treatment. However, these findings were not confirmed in vivo. 
Nevertheless, the chromatography methods utilized are prone to lower sensitivity than 
specificity, and this observed interaction was unlikely falsely-positive or an experimental 
artefact. While RpsA and RRF may indeed interact biochemically, overexpression of rrf 
did not affect the sensitivity of M. tuberculosis to pyrazinoic acid, and therefore this 
interaction may not be relevant in the mechanism of PZA action. Furthermore, recent 
studies have raised critical questions about the role of RpsA in mediating the effects of 
PZA [6], and the prospects of this field remains in flux. 
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Our projections of the MDR-TB epidemic illustrate the importance of carefully 
translating experimental findings to human populations, as they can dramatically 
influence estimates of long-term epidemic trends. While our results differ importantly 
from those of a recent publication [5], we were able to accurately replicate those findings 
and demonstrate the methodological nature of these discrepancies. Nonetheless, our 
findings are intended to compare a series of competing assumptions about the 
transmission efficiency of MDR-TB, and cannot be interpreted as rigorous predictions of 
national or global TB epidemics. Furthermore, as a modeling exercise, our model makes 
many simplifying assumptions about the complex nature of ongoing TB epidemics 
around the world. Our sensitivity analyses demonstrate that these findings are largely 
robust to model parameterization, though it is possible that our model structure or 
parameter selection do not fully capture some critical details of TB transmission and 
treatment. 
Despite the above limitations, these investigations represent important, novel, and 
robust approaches to the epidemiological analysis and microbiological study of TB.  
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OPPORTUNITIES FOR FUTURE STUDY 
 
As with many scientific endeavors, these studies are not self-contained and may 
lay the foundations for further research which can enhance, elaborate, confirm, or even 
contradict the findings presented here.  
Our theoretical framework for linking individual-level and population-level 
outcomes is intended as a novel tool for the TB research community. Several studies have 
already built detailed within-host models of TB immunology and pathogenesis [7,8], but 
these models are restricted to the study and prediction of TB pathology in animal models. 
Populating our framework’s simplified Markov probabilities with a detailed within-host 
model may elucidate key differences in the dynamics of M. tuberculosis infection in 
animal models and humans. Additionally, our framework may prove useful for improving 
population-level epidemic models which often make simplifying assumptions about the 
course of TB pathology and the inter-person heterogeneity of disease. For example, 
compartmental models assume that populations transition from being asymptomatic to 
being fully infectious and detectable. Yet, ignoring preclinical/incipient disease is likely 
to greatly overestimate the impact of interventions on TB incidence [9]. Our framework 
may provide an important tool to study and simulate this period of disease (which is 
inherently difficult to characterize empirically). Incorporating these dynamics may assist 
us in predicting the outcomes of interventions which influence individual-level dynamics 
(such as time-to-diagnosis, etc.) or in understanding how the transmission dynamics of 
TB change over time (e.g., when individuals become more infectious as their course of 
disease progresses) [10,9].  
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The molecular findings we describe – a novel role for RRF in RpsA activity – 
offer several promising routes for future research. Previous studies indicate that PZA acts 
by inhibiting the tmRNA-mediated trans-translation response of M. tuberculosis [4,11]. 
Studies in Escherichia coli have demonstrated that RRF may play a non-canonical role in 
ribosome rescue, supplementary to and independent of the role of tmRNA [12–15]. These 
observations, in combination with our findings, suggest an exciting hypothesis that PZA 
may act by inhibiting several ribosome stress-response pathways (i.e., mediated by 
tmRNA and RRF). Confirmation of this hypothesis will require an in-depth evaluation of 
the cellular (and ribosomal) function of RRF in mycobacterial species, an area of limited 
previous research.  
Finally, our projections of MDR-TB epidemics recommend both short-term 
methodological responses and long-term research priorities. Our study demonstrates that 
building mathematical epidemic models of drug resistance upon assumptions of fitness 
costs (or the absence thereof) can critically alter long-term outcomes; in the absence of 
strong empirical data about the transmission efficiency of MDR-TB, modelling studies 
must address this uncertainty in their initial assumptions and in the sensitivity of their 
results to changes in transmission efficiency. More fundamentally, future trends in the 
MDR-TB epidemic will depend highly on the transmission efficiency of MDR-TB 
relative to DS-TB and whether it may change over time. This critical quantity remains 
highly uncertain, and characterizing transmission efficiency will require integrating 
several epidemiological approaches as we have described.  
Cumulatively, our work presents exciting opportunities (as well as fundamental 
challenges) for furthering our understanding of M. tuberculosis biology and TB 
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epidemiology at large, which may – directly or indirectly – contribute to control of the 
global TB epidemic. 
  





Despite the heavy losses of life and health that can be attributed to tuberculosis 
throughout history, today, TB is on the decline. Global incidence of TB has fallen 
continuously since the turn of the millennium, despite alarming increases in some high 
burden settings [16]. Mortality due to TB has dropped even faster, falling by 37% in this 
period. This progress, while encouraging, is too slow for the many millions who die or 
fall ill with TB each year. It will not be sufficient to achieve the current global targets for 
TB control (reducing incidence by 90% between 2015 and 2035) without more rapid 
declines [16].  
The future of TB control remains a challenge both daunting and promising. To 
face this challenge effectively, the public health community will need new tools and new 
techniques drawn from myriad sources of scientific inquiry and public health practice. It 
is our hope that multidisciplinary approaches like those presented here will improve 
public health science and fortify efforts to control the heavy burden and human cost of 
infectious diseases now and in the future. 
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SUPPLEMENTARY INFORMATION FOR CHAPTER 2 
 
  





This modeling strategy utilizes an agent-based, stochastic approach to simulate 
the clinical progression of symptomatic TB in individual patients over a course of 
infection. The clinical progression of disease is parameterized as the simulated disease 
burden of the infected patient. The individual-level dynamics through which this model 
functions are conceived as the consequence of two components: a sequence of states of 
infection, and the progression or recovery of disease during each element of the 
sequence. 
 
The Sequence of Infection States 
In clinical populations, a qualitative dichotomy is often observed between TB 
patients who are experiencing decompensation and concomitant worsening of symptoms 
and prognosis versus patients who are experiencing improvement in symptom resolution 
and prognosis whether due to successful treatment or spontaneous self-resolution [1]. 
Additionally, individual patients may experience one or both of these trends over the 
course of infection. While these general trends are the manifestations of complex 
immunological and pathophysiological processes, the trends themselves hold important 
prognostic information about the likely outcome of the patient. 
To quantitatively capture these prognostic qualitative phases, a simplifying 
assumption is made that, at each discrete time step during the course of a single infection, 
the disease burden of a patient exists in one of two mutually exclusive states . ( ) ∈
{ 	, }. Between any two time steps ( ), ( )  , the infection can 
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freely transition between these states. The probability of transition in any time step is 
dependent only on the current state of infection: 
( ), ( )	~	i. i. d. Pr	 ( ) ( )  (1) 
Therefore, the sequence of states that composes any individual infection ( ), ⋯ , ( )  
has the properties of a simple Markov Chain. 
 
Infection Growth and Decay 
One of the most significant prognostic determinants of TB mortality is pulmonary 
bacillary burden [2–4]. While experimentally unfeasible to measure in TB patients, 
bacillary burden is commonly measured in time course studies of infection in animals. 
Empirical data of changes in bacillary burden has been successfully modeled according to 
exponential dynamics of bacterial populations, consistent with the underlying biology of 
bacterial replication [5,6]. Therefore, this within-host model assumes that patient “disease 
burden” is analogous to, though an indirect instrument of, bacillary burden size. 
During any single time step ∆ , the disease burden of a patient is assumed to 
follow the properties of a simple exponentially reproducing population: =
( )∆  where Nt represents the disease burden at time t and ( )represents the 
exponential rate constant during the interval ∆ = [ , + 1) in which the infection exists 
in state ( ). Therefore, when ( ) > 0, the disease burden is increasing exponentially; 
when ( ) < 0, the disease burden is decaying exponentially. When ( ) = 0, the disease 
burden is stationary during the interval ∆  and = . The cumulative dynamics of 
the bacillary burden of any infection can then be summarized as: 
= ∏ ( )∆ 	 	 = ( ), ⋯ , ( )  (2) 





It is notable that, in clinical populations, certain patients are particularly 
vulnerable to progression once infected while other patients are particularly resilient. This 
between-host heterogeneity may result from the specific interactions between each 
human host, the quality of his or her immune response, and the genetic and epigenetic 
characteristics of the inciting strain/genotype of M. tuberculosis [3,7,8]. While 
recognizing the significant between-host heterogeneity that exists in a population of TB 
patients, the population as a whole exhibits characteristic trends in disease progression 
and resolution. For example, relatively few patients progress from symptom onset to 
death in less than 10 weeks or more than 10 years; the average duration of disease in TB 
patients has been estimated at 3 years [9]. These population-level characteristics can be 
used to inform the likely amount of between-host variability in the population. 
This between-host variability is captured mathematically as the distribution of 
exponential rate constants of infections in the population. For each possible state 
( ) ∈ { 	, }, the corresponding rate constant ( ) is modeled as a 
beta distribution with parameters ( ), = 20  transformed over the interval 
( ), ( )  where ( )  represents the mode of exponential rate constants in the 
population of infections in state ( ) ,  represents the beta distribution concentration 
parameter, ( ) represents the minimum allowable exponential rate constant in state ( ) 
, and ( ) represents the maximum allowable exponential rate constant in state ( ). This 
concentration value was chosen to maintain a clear central tendency in any simulated 
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population, with a standard deviation less than 11% the sampling range (max =
( . )
( )
 ). For any individual infection in the population:  
~	 . . . , = 20, ,   (3) 
and 
 ~	 . . . , = 20, , .  (4) 
 
Clinical Characteristics 
For the purposes of this model, population outcomes of infection simulations are 
calibrated to empirical estimates of the clinical characteristics of TB patients in the pre-
chemotherapy era [9],notably the case fatality ratio, disease duration, and proportion of 
cases resolved amongst symptomatic TB patients. To parameterize the disease burden for 
calibration, conceptual thresholds are imposed on the disease burden to define the 
onset/resolution of symptoms and the point of death. Such thresholds have been used in 
other within-host mathematical models as instruments for analyzing the transition from 
subclinical to detectable disease in ovarian cancer [10]. The mathematical “symptom 
threshold”, , is defined as the disease burden above which the patient is considered to 
experience severe enough symptoms for clinical presentation and diagnosis and below 
which the patient experiences a clinically inapparent infection and/or a resolution of 
symptoms. The mathematical “death threshold”, , is defined as the disease burden above 
which the patient expires. For any individual infection, the duration of disease 
(specifically, the duration of symptomatic disease) can then be calculated as: 
( ) = [	(min	( | ∈ ℕ	, ≥ )) ∨ (min	( | ∈ ℕ	, ≥ 	, < 	))] − [min	( | ∈ ℕ	, ≥
)] (5) 




For a population ℙ ∈ {1, ⋯ , }, each member with a disease burden ( ), the case-
fatality ratio can be calculated as: 
(ℙ) = ℙ ( )
ℙ ( )
 (6) 
and the proportion of cases which self-resolve can be calculated as: 




Parameterization and Sampling 
Ranges of values for each parameter that were deemed plausible on an a-priori 
basis are detailed in Table 1. The probability of transition from progression to recovery 
Pr ( ) = ( ) =  was defined by the limits of 0.1%-
29.29% per week. The lower bound of this range, equivalent to a 5% probability that 
individuals transition in the first year of progression, was used considering that roughly 
45% of patients survive the first five years of disease [9]; therefore, we speculated at least 
10% of those survivors would begin to recover within the first year. The upper bound of 
this range, equivalent to a 75% probability that individuals transition in the first month of 
progression, was used considering that patients delay seeking treatment for an average of 
25-32 days after symptom onset [11] and that clinical diagnostic criteria of pulmonary 
TB include a history of cough for 2-3 weeks [12,13]; therefore we speculated that at least 
one quarter of TB patients experience a continuous worsening of disease over the first 
month of symptoms. The probability of transition from recovery to progression 
Pr ( ) = ( ) = , analogous to the reactivation of latent 
TB infection, was defined by the limits of 0.001% to 0.00001% per week, equivalent to 
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the benchmarks that minimum of 0.05% and a maximum of 5% of patients transition in 
the first year of recovery . These limits were defined with consideration that the yearly 
probability of reactivation latent TB infection has been estimated as 0.084% per year in 
asymptomatic individuals [14]. In light of these estimates, we assumed that the 
probability of symptomatic (recovering) patients experiencing symptom recrudescence 
would not be substantially less than the probability of reactivation from latency in 
immunocompetent adults but could be as high as two orders of magnitude greater.  
The “death threshold” ( ) was allowed to vary from 107 to 1010 units, using an 
analogous reference frame estimated from the maximum measured bacillary burdens of 
non-human primates suffering from asymptomatic and fulminant TB disease [15]. To 
ensure there is always a plausible separation between the “death threshold” and the 
“symptom threshold” ( ), the latter was defined by the log-difference log ( ) −
log ( ), a “window width” parameter which defined the extent of disease progression 
between the onset of symptoms and death. The “window width” was allowed to vary 
between benchmarks of 104 to 107 units informed by the typical variations between 
bacillary burdens of asymptomatic/latent and symptomatic non-human primates. 
Therefore, deriving the “symptom threshold” from this log-difference allowed the 
“symptom threshold” to vary between 1 to 106 units [15–18]. 
The bounds of the distribution of exponential rate constants in the progression 
phase ([ , ]) were defined according to the benchmarks that no 
patient in the progression phase would progress from asymptomatic/subclinical disease to 
death in less than 90 days – informed by the slow pathophysiology of clinical TB and 
early studies which found overall mortality in the first year of disease to be no greater 
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than 30% [19]. We define the partition of “progression” and “recovery” phases according 
to the boundary of their exponential rate constants such that any patient who remains 
continuously in the progression phase would die in a maximum of 5 years of 





 and thus 





. Assuming a reasonable value of = 10 , 
the limits of the distribution of exponential rate constants in the progression phase were 
specified as 0.005 and 0.102 per day, equivalent to population doubling times in the of 
137 days to 6 days, respectively.  
The upper bound of the recovery phase exponential rate constant  was 
similarly defined according to the above definition such that any patient continuously 
progressing would die in a maximum of 5 years; consequentially, we define that, if any 
patient continuously in the recovery phase were to die, it would occur after no less than 5 
years of symptomatic disease. The lower bound of the recovery phase exponential rate 
constant ( ) – the fastest allowable rate of spontaneous recovery – was informed 
by data on the average rate of recovery with the assistance of bactericidal therapies. It has 
been estimated that a patient receiving effective drug therapy will experience sputum 
conversion no sooner than an average of 35 days after initiation [20]. If one assumes that 
a symptomatic (spontaneously recovering) patient receiving no drug therapy will recover 









. Assuming a 
reasonable value of = 10 , the limits of the distribution of exponential rate constants in 
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the recovery phase were specified as -0.066 and 0.005 per day, equivalent to a population 
half-life of 11 days and a population doubling time in the range of 137 days, respectively. 
Modes of the population distributions of these exponential rate constants 
,  were allowed to vary across the full range of allowable values 
for each respective phase.  
For each of the 2,000,000 simulations of the individual-level model, Latin 
hypercube sampling was used to draw one value from the specified ranges of each 
parameter to create 2,000,000 six-parameter sets. Transition probabilities from 
progression to recovery and vice versa were conceptualized as characteristics of the 
cohort (i.e., one value per cohort), with each individual patient trajectory comprised as 
stochastic realizations of these probabilities. Additionally, symptom and death thresholds 
were conceptualized as reference frames with which to compare individuals’ progression, 
and were therefore fixed for all patients (i.e., one value each per cohort). Parameter 
values for these transition probabilities and thresholds were uniformly sampled on log10-
transformed scales. By contrast, rate constants of progression and recovery were 
conceptualized as distributional values – the mode was selected for a given cohort, and 
each individual’s personal rate of progression and recovery was drawn from a beta 
distribution around that mode. As the exponential rate constants ranged across both 
positive and negative values, the modal (cohort-level) values were sampled on the log-
modulus-transformed scale [21], defined here as ( ) = | | × log	(100 × | | + 1). 
 
Importance Resampling 
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Following initial Latin hypercube sampling [22], importance resampling [23] was 
used to generate Bayesian posteriors for each parameter as described below. A joint 
likelihood function was generated to describe probable values of the clinical 
characteristics of a cohort of TB cases from the pre-chemotherapy era [9]. The case-
fatality ratio likelihood was modeled as a binomial distribution with p=0.55 and 
parameters = ℙ ( ) > 	, = ℙ ( ) >  populated from 
values of each realized simulation. The likelihood for the median disease duration of a 
cohort was modeled as a symmetric beta distribution ( = 0.5	, = 8) scaled to a 
range [1 , 5] years (modal equivalent of 3 years). This concentration value was used to 
define a broad likelihood function around the median duration (standard deviation of 8 
months). The likelihood of the proportion of cases which self-resolve was modeled as a 
uniform distribution on the interval [0.1, 1.0]. Each parameter set was weighted 
according to the quotient of the set’s joint likelihood, L(θi ; x), and the marginal 
likelihood of all sets:  
= ( ; )∑ ;  (8) 
Each parameter value was then resampled from the Latin hypercube according to its 
weight to construct its posterior distribution.  
 
Diagnosis and Treatment 
 To simulate the potential impact of diagnosis and treatment on the cumulative 
disease burden and time spent symptomatic among patients in a cohort, we compare 
various scenarios using the maximum likelihood parameter set identified above. 
Diagnosis and treatment is conceptualized as a weekly probability of detection, 
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dependent upon disease burden. If a patient initiates treatment at time t (Dt=1), she is 
removed from the infectious cohort before time t+1. The weekly probability of initiating 
treatment, Pr(Dt=1 | Nt), is set equal to zero at any disease burden below the symptom 
threshold. This probability increases logarithmically to a maximum pmax (defined as 
Pr(Dt=1|Nt=δ)) when the disease burden equals the death threshold such that: 
Pr( = 1| ) = 	 ×  (9) 
This disease-dependent probability of detection ensures that patients with nearly 
asymptomatic disease are unlikely to be diagnosed while patients near death are most 
likely to be diagnosed. 
 
 When the cohort is simulated with the introduction of diagnosis and treatment 
(each patient with a possibility of being detected and starting on treatment [Pr(Dt(p)=1)] 
at each time t), the case detection proportion (commonly called the “case detection rate”, 
or CDR) of the entire cohort can be defined as the proportion of symptomatic patients 
detected prior to death or self-resolution:  
(ℙ) = |{ℙ|	 	( ( )) }|
ℙ ( )
 (10) 
Values for pmax (weekly probability of initiating treatment at the time of maximum 
symptom burden) were sampled randomly from a uniform distribution on the log10 scale 
from 10-5 to 1.0 (median: 1.0% probability of detection per week), and one cohort of 
1,000 patients each was simulated for each of the 1,000 pmax values sampled (holding all 
other parameters constant at their maximum likelihood values). The pseudo-likelihood 
associated with each value for pmax was calculated using the estimated 2015 global CDR 
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of 59% [95% CI: 50-70%] [24]. The pseudo-likelihood function was parameterized as a 
normal distribution with a mean of 59% and a standard deviation of 5.1%.  
 The potential impact of treatment initiation was then estimated by comparing the 
cumulative burden-time of the cohort with and without detection and treatment. For each 
patient, the total burden-time is defined as the area under the curve of (disease burden 
above the symptom threshold) versus time (see Figure S1.4 for a graphical 
representation). If the time of symptom onset for a given patient p is a=[min(t|t∈N 
,Nt≥σ)] and the time of exit from the cohort (due to death, cure, detection, or end of 
follow-up) is b, then the patient’s total burden-time is: 
( ) = ∫ 	 − ∫  (11) 
The cumulative burden-time for a population of P symptomatic patients can then be 
calculated as ∑ ( ).  
  





Of the 2,000,000 simulated patient cohorts (each containing 1,000 patients), 
76,544 (3.8%) had no TB patients who progressed to symptomatic disease within 5 years 
of infection. In an additional 34,596 cohorts (1.7%), all symptomatic TB cases suffered 
symptoms for at least five years before death or resolution; these cohorts were excluded 
from further analysis. Of the remaining cohorts, the epidemiological characteristics of TB 
were highly varied with case fatality ratios ranging from 0%-100% [Interquartile range 
(IQR): 7.5%, 80%] and median durations ranging from 1 week to 5 years [IQR:0.48 
years, 1.3 years]. After applying the joint likelihood function to differentially weight 
plausibly realistic cohorts from discernibly unrealistic cohorts, 551,100 cohorts (28% of 
the total) had results consistent with historical estimates of the natural history of TB (joint 
likelihoods greater than zero). Amongst these plausible cohorts, the median case fatality 
ratio was 42.5% [IQR: 18%, 67%] and the median duration of disease for the 50th 
percentile of cohorts was 1.5 years [IQR:1.2 years, 1.9 years]; however, amongst those 
cohorts accounting for 90% of total likelihood mass (n=20,770), the median duration of 
disease was substantially longer at 2.3 years [IQR:1.9 years, 2.7 years]. Notably, these 
results indicate a closer recapitulation of historical case fatality ratio estimates (target: 
55%; posterior IQR: 54-56%) than disease duration estimates (target: 3.0 years; posterior 
IQR: 2.1-2.8 years). This suggests that, in the simplified modeling approach used here, 
cohorts with case fatality proportions that are most similar to the reported values (i.e., 
highest likelihood cohorts) have mean disease durations that are somewhat shorter than 
those reported. In other words, a disease process that results in 55% case fatality in our 
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simplified model generally progresses more rapidly than would be expected if the mean 
disease duration were actually 3.0 years. Further work is justified to discern whether this 
discrepancy is more likely a reflection of the simplified modeling framework utilized 
here (e.g., if addition of further model complexity would result in less of a discrepancy) 
or whether this apparent discrepancy may suggest actual measurement error in pre-
chemotherapy studies that relied largely on reported symptoms for their estimates of 
disease duration. 
Of the 1,000 cohorts simulated with detection and treatment initiation, 6.2% 
demonstrated case detection proportions consistent with global estimates (median: 59%; 
95% CI: 50-70%). After importance resampling, the median posterior CDR in these 
simulated cohorts was 57.2% (95% UR: 47.9-69.8%). In the absence of detection and 
treatment, mortality using the maximum likelihood parameter set identified above was 
53.2%. When the maximum likelihood estimate of the weekly detection probability 
(1.4% per week) was applied, mortality in this cohort dropped to 17.2% (omitting 
possible deaths during treatment). Although mortality was not calibrated to data from 
patients receiving treatment, this estimate was nevertheless very similar to the reported 
2015 global mortality rate of 17.3% [24]. 
 
  
   
190 
 
Figure S1.1: Values of the Symptom Window Width Consistent with Observed 




The symptom width window was used to define the symptom threshold by determining the difference 
between the death threshold (δ) and the symptom threshold (σ). Model input values (prior distributions) 
were sampled uniformly on the log-transformed scale between reasonable bounds selected on an a priori 
basis (denoted by vertical dashed lines). Histogram densities show the proportion of 2 million weighted 
parameter values that were most consistent with observed cohort data from the pre-chemotherapy era 
(posterior distributions). 
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The symptom threshold parameter was derived as the difference between the log-transformed death 
threshold and symptom window width. Therefore, the model input values (prior distribution) for the 
symptom threshold parameter was not uniformly sampled, but was derived from two uniformly sampled 
parameters (the death threshold and the symptom window width). Input values for the symptom threshold 
are depicted in darker shades behind the weighted values most consistent with observed data (depicted in 
lighter transparent shades). Input values for the death threshold were sampled uniformly on the log-
transformed scale between the displayed bounds, and weighted values most consistent with observed cohort 
are depicted in green.   
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Figure S1.3: Values of the Probability of Transition to Progression Consistent with 




Model input values (prior distributions) were sampled uniformly on the log-transfomred scale between the 
defined bounds (depicted as vertical dashed lines). Histogram densities depict the proportion of 2 million 
weighted parameter values most consistent with observed cohort data from the pre-chemotherapy era 
(posterior distribution). Probabilities of transition from the recovery phase to the progression phase are 
depicted on weekly and annualized scales. 
  




Without diagnosis and treatment initiation, the cohort’s cumulative burden-time 
was 11.0 log(unit-weeks). When the maximum likelihood probability of detection and 
treatment initiation was applied (from above), the burden-time was reduced to 10.5 
log(unit-weeks), a 4.5% reduction in cumulative burden time (on the log10 scale). We 
then explored the potential impact of improved diagnosis using Xpert® MTB/RIF over 
sputum microscopy (assuming that the probability of diagnosis and treatment is 
proportional to the sensitivity of the assay used). When the probability of weekly 
detection was increased 1.4-fold (to represent the improved sensitivity of Xpert® 
MTB/RIF over sputum microscopy [25,26]), the log burden-time was further reduced to 
10.3 log(unit-weeks). This reduction represents a 6.3% reduction in cumulative burden-
time compared with no detection and treatment but only a 1.9% reduction in burden-time 
compared with detection and treatment based on the existing standard of care. To the 
extent that cumulative burden-time also reflects cumulative transmission potential 
(especially if expressed on the log scale as in our model), these results may illustrate why 
improvements in detection and treatment can yield important reductions in mortality 
without dramatically impacting incidence – as has been seen both with the scale-up of 
DOTS in the 1990s and more recently projected for the scale-up of Xpert® MTB/RIF 
over the past five years [27,28]. 
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Figure S1.4: Evaluating the Impact of Detection and Treatment on TB Morbidity 
 
The impact of detection and treatment was evaluated by comparing a cohort’s cumulative burden-time in 
the absence or presence of an intervention. (A) A representative cohort in which no patients are detected 
and treated, as described in the Methods and Figure 2.2. Emphasized are the disease trajectories of three 
patients (labeled 1-3). (B) The results of the same cohort when each patient has a weekly probability of 
detection and treatment, dependent on his or her disease burden in each week. Patients who are detected 
and treated before surpassing the death threshold (or self-resolution or the end of follow-up) are depicted in 
violet, with the times of detection/treatment overlaid as purple points. (C) Comparison of the trajectories of 
Patients 1-3 in the absence and presence of detection and treatment. Patient 1 does not receive treatment 
before surpassing the death threshold. Patients 2-3 are detected and treated and are removed from the 
infectious cohort at the time of detection and treatment. (D) Cumulative burden-time is calculated as the 
sum of the areas under each patient’s disease burden curve (above the symptom threshold). Shaded areas 
(of any color) denote this cumulative burden-time for each patient in the absence of detection and 
treatment. Red shaded areas represent each patient’s burden-time prior to the point of detection and 
treatment. Green shaded areas represent the burden-time averted through detection and treatment. 
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APPENDIX B:  
SUPPLEMENTARY INFORMATION FOR CHAPTER 4 
 
  







TB Natural History 
 Populations in our model are categorized and described by core states of TB 
infection and substates of resistance status (DS-TB or MDR-TB), TB treatment history 
(new or previously-treated), and HIV status (Figure 4.1).  
TB infection results from a density-dependent transmission process. Upon initial 
infection, populations may progress rapidly to incipient/preclinical/asymptomatic TB 
(hereafter referred to as early-active TB) or may develop latent infection; those latently 
infected may reactivate to early-active TB at a constant rate. Individuals in states of 
early-active TB, symptomatic active TB, ineffectively treated TB, or diagnosed-untreated 
TB contribute infectious person-time to transmission (with reduced infectiousness and 
mortality associated with early-active or ineffectively treated TB). Self-cure (with return 
to the susceptible state) may occur at a constant rate during early-active or active TB. 
When TB patients develop fully symptomatic active TB, they may initiate first-
line or (in cases of MDR-TB) second-line treatment. Upon initiating treatment, TB 
patients are separated into states of effective or ineffective treatment; those who complete 
effective treatment regimens experience culture conversion by the end of the treatment 
duration. (In the absence of DST, MDR-TB patients can only initiate ineffective first-line 
treatment). After effective treatment, TB patients may either achieve durable cure 
(becoming susceptible again) or may eventually relapse; after ineffective treatment, 
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patients may either immediately re-initiate treatment or return to symptomatic active TB. 
During any TB treatment state, patients may be lost to follow-up; all those lost from 
ineffective treatment return to active TB, while those lost from effective treatment may 
return to active TB or (having received a sufficiently curative treatment before default) 
may achieve durable cure.  
MDR-TB infections may result from transmission of MDR-TB or from 
acquisition of drug resistance during treatment of DS-TB. MDR-TB may develop from 
transmission in populations who are susceptible to TB or (as a superinfection) in 
populations who are latently infected with DS-TB. (Similarly, populations latently 
infected with MDR-TB may be subsequently superinfected with DS-TB.) MDR-TB may 
be acquired during first-line treatment (including ineffective treatment, as well as 
effective treatment with future relapse). 
TB treatment history influences several of the dynamics described above. TB 
patients with a history of first-line treatment have an increased probability of acquiring 
MDR-TB upon retreatment. Similarly, they have a reduced probability of receiving 
effective first-line treatment and a reduced probability of durable cure following effective 
first-line treatment. Among patients with MDR-TB who have received DST and initiated 
second-line therapy, those who are treated with second-line therapy unsuccessfully 
become treatment-ineligible (as we assume that an attempted second-line treatment may 
include changes in drug regimen if treatment fails to resolve symptoms). 
HIV status also affects a variety of the dynamics of TB infection. HIV infected 
populations have higher rates of TB-independent mortality, and those with low CD4 
status concurrent with active (untreated) TB experience an additional mortality associated 
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with HIV/TB interactions. The probability of rapid TB progression upon initial infection 
is increased in HIV-infected populations, while the probability of TB self-cure is reduced. 
In populations latently infected with TB, HIV co-infection increases the rate of TB 
reactivation and reduces the degree of protection against a rapidly progressing 
superinfection. The infectiousness of each TB disease state is somewhat lower in 
populations with HIV co-infection than in their HIV-uninfected counterparts. Finally, due 
to more rapid disease progression and more frequent encounters with the health system, 




 TB transmission occurs as a function of time-varying transmission efficiency 
coefficients and the size of the infectious TB population. As previously described, we 
define the transmission efficiency of each strain (DS-TB vs. MDR-TB) as the number of 
new infections which would develop in a susceptible population from each infectious 
person-year contributed by prevalent infectious DS-TB or prevalent infectious MDR-TB, 
respectively. An initial coefficient β  is used to define the equilibrium transmission 
efficiency of DS-TB cases. Due to secular trends in overall TB incidence in recent years, 
we allow for the overall transmission of DS-TB β ( ) to decline at an annual geometric 
rate d  after the year t . In Vietnam, we define t  as the first year with data used to 
calibrate our epidemics ( = 1996). In South Africa, due to the HIV/TB co-epidemic 
over 1995-2010, we felt there was insufficient evidence for secular declines in DS-TB 
transmission in HIV-uninfected populations starting in the first year of survey data 
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(2001). Instead, we assumed any such declines would not occur until 2010 ( = 2010). 
Therefore, we define the transmission efficiency of DS-TB as follows: 
β ( ) = β ×
1 if	 <
(1 + ) if	 ≥  (1) 
 In all MDR-TB scenarios we examined, the transmission efficiency of MDR-TB, 
β ( ), is initialized at the start of the modern MDR-TB epidemic (in the year ) with an 
initial value determined by the initial transmission efficiency of DS-TB β  and a relative 
efficiency term . In the Shrinking Efficiency Deficit scenario, the transmission 
efficiency of MDR-TB is allowed to increase annually (through an annual percentage 
increase  in the relative efficiency coefficient) beginning in the year . (The rate of 
increase term  is set equal to zero in both the No Efficiency Deficit and Constant 
Efficiency Deficit scenarios, and the relative efficiency term  is set equal to one in the 
No Efficiency Deficit scenario.) Therefore, the transmission efficiency of MDR-TB is 
defined as: 
β ( ) = β ×
0 if	 <
if	 ≤ <
+ ( − ) if	 ≥
 (2)  
In this way, any declines in DS-TB secular transmission efficiency (after time ) are not 
necessarily mirrored by MDR-TB, as trends in the transmission efficiency of DS-TB and 
MDR-TB are likely to occur through different processes (though β ( ) is never permitted 
to exceed β ( )).  
 
Drug Sensitivity Testing and Second-line Treatment 
 The probability of MDR-TB cases receiving DST and initiating second-line 
therapy, DST(t), is defined as a country-specific time-varying quantity that depends on 
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the availability of DST and individualized second-line regimens. We assume that DST is 
not widely available prior to 2006. We then separately define the probability of receiving 
DST during two time intervals: from 2006 to the time of Xpert® MTB/RIF adoption by 
national TB programs tXpert (modeled as 2011 in South Africa and 2013 in Vietnam); and 
from tXpert to 2016. At tXpert, we use WHO estimates of each country’s provision of DST 
among all TB cases (data was not yet stratified by new and retreatment cases) and the 
proportion of detected MDR-TB cases that initiated treatment to estimate DST coverage, 
( ). We modeled the availability of DST and the initiation of second-line 
treatment as a linear increase in DST(t)from DST(2006)=0 to the value of ( ) 
that we estimated from WHO data. We similarly used WHO estimates of each country’s 
DST provision (stratified by new and retreatment cases) and treatment initiation of 
detected MDR-TB cases to estimate (2016). Again, we modeled the availability of 
DST as a linear increase from the estimated ( ) to (2016) and (2016). 
We then assumed the linear trends of DST availability will each continue into the future 
beyond 2016 until eventually reaching 100% coverage. These trends are plotted 










0 if	 < 2006
( ) ( − 2006) if	2006 ≤ <
min[	100%	, if	 ≥
( ) ( ) ( − ) + ( )]
 (3) 
 







( ) if	 <
min[100%, if	 ≥
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Each line represents the time-varying probability of DST for MDR-TB cases after TB diagnosis. Points 
represent country-specific estimates in DST availability over time drawn from WHO reports. From 2006 to 
2011 in South Africa and 2013 in Vietnam, estimates of only overall (cumulative) DST were reported and 
therefore used for both new and previously-treated cases. Dashed lines represent current trends in DST 
extrapolated into the future until reaching 100% coverage. 
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Births and Deaths 
We make a simplifying assumption of a steady-state population size. “Births” 
(entry of new 15-year olds into the population) are forced to equal cumulative deaths due 
to TB, HIV, and background mortality. New adults are added to treatment-naïve 
susceptible or latently infected states. The proportions of new adults which enter into 
latent TB states are determined by the cumulative TB forces of infection over the 
preceding 15 years (approximated by an exponential distribution using the transmission 
efficiencies of TB at the midpoint 7.5 years prior and the current prevalence of infection; 
see differential equations below). These new latently-infected adults are divided between 
DS-TB and MDR-TB infections according to the ratio of each strain’s approximate force 
of infection over the preceding 15 years.  
 
HIV Infection and ART Initiation 
Our model does not attempt to replicate the complex dynamics and partner 
networks which characterize transmission in HIV epidemics. To capture macro trends in 
the HIV epidemics of South Africa and Vietnam, we fitted our model to reported 
UNAIDS estimates of the prevalence of HIV among adults in yearly intervals from 1990 
to 2016 (Figure S2.2.2A below) in the following manner. At any time t1, the prevalence 
of HIV infections in our fixed population of 100,000 is calculated as the sum of 
individuals in any HIV-infected substate V(t) divided by the total population size: 
( ) = ∑ ( ) (5) 
After a time interval from [t1,t2), the prevalence of HIV survivors (without new 
incident infections) 0 ( 2) would equal the prevalence at t1 minus the number of deaths 
   
209 
 
(based on the state-specific cumulative mortality rates ) from all HIV-infected states 
during the time interval: 
0 ( 2) = ( 1) −
∑ ( 1)  (6) 
For reference, we use UNAIDS country-specific estimates of the prevalence of 
HIV among adults 15 years and older ( ) for the discrete time points ∈
{1990, 1991, … , 2016}. The expected HIV prevalence at time t2 is then calculated by 
linear interpolation between the two time points nearest in time to t2 (the maximum Y less 
than t2 and the minimum Y greater than t2): 
( ) = ( ( | ≤ ))
+ ( ( | )) ( ( | ))
( ( | )) ( ( | ))
× ( − ( ( | ≤ )))
 (7) 
To reach the necessary ( 2) between [t1,t2), the number of new HIV infections 
in this interval ( 1, 2) must therefore equal the expected prevalence minus the 
prevalence of surviving HIV infections multiplied by the population size: 
( 1, 2) = ( ( 2) − 0 ( 2)) ×   (8) 
The rate of new HIV infections during the interval is determined by the number of new 
HIV infections needed and the size of currently HIV-uninfected populations in states XU: 
( , ) = ( , )
∑ ( )
 (9) 
All incident HIV infections are modeled as transitions from an HIV-uninfected 
state to a state of HIV infection with a High CD4 count. After 2016, the expected rate of 
change in HIV prevalence is assumed to equal that of 2015-2016. At no time is the rate of 
new HIV infections allowed to become negative. 
Prior to 2004, we assume that antiretroviral therapy (ART) is not widely 
available. Between 1990 and 2004, individuals in High CD4 substates gradually progress 
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to Low CD4 substates where they remain until death. Between 2004 and 2010, we 
assume that ART is available only to those with Low CD4 counts. During this time, the 
time-varying rate of ART initiation is derived such that the proportion of HIV-infected 
patients receiving ART are consistent with UNAIDS estimates (Figure S2.2B below).  
The rate of ART initiation is fitted to UNAIDS estimates in a similar manner used 
to fit HIV prevalence. We define the proportion of HIV-infected individuals receiving 
ART at any time A(t) as equal to the cumulative size of ART substates XA divided by the 
cumulative size of all HIV-infected substates V: 
( ) = ∑ ( )
∑ ( )
 (10) 
After a time interval from [t1,t2), the number of survivors continuing to receive 
ART , ( ) would equal the number receiving ART at t1 minus the number of deaths 
(based on the state-specific cumulative mortality rates ) from all ART substates 
during the time interval:  
∑ , ( ) = ∑ ( )(1 − ) (11) 
The total ART coverage (continued and newly initiated) expected at time t2 is 
again fitted to UNAIDS estimates. Based on the shape of UNAIDS estimates of this 
quantity (Figure S2.2B), we used nonlinear (weighted) least squares regression to fit a 
sigmoid function (assuming ART coverage approaches a future asymptote A  at 60%) 
of the form: 
ˆ ( ) =  (12) 
To reach this new level of ART coverage, the number of new ART initiations 
during the interval ( 1, 2) can be calculated as the number of total individuals 
receiving ART at t2 minus the number continuing to receive ART: 
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( , ) = ^ ( )∑ ( ) − ∑ , ( ) (13) 
The time-varying rate of ART initiation ( , ) is derived according to the 
number of required new patients initiating ART ( 1, 2) and the population eligible to 
receive ART at time t2. Between 2004 and 2010, all new ART initiation is restricted to 
Low CD4 populations XL. After 2010, we allow for ART initiation to occur in both Low 
CD4 and High CD4 populations XH to reflect improved access to HIV care and changing 
national guidelines for ART provision. However, ART initiation in High CD4 
populations occurs at a lower rate than initiation in Low CD4 populations, according to 
an initiation coefficient kH (that is, for every one High CD4 patient, there are only kH 
High CD4 patients eligible for ART). Therefore, the time-varying rate of ART initiation 
is defined as follows: 





⎧0 if	 ≤ 2006
( , )
∑ ( )
if	2006 < ≤ 2010
( , )
∑( ( ) ( ))
if	 > 2010
 (14)  
Finally, among HIV-infected patients receiving TB treatment, this rate of ART 
initiation is increased by a factor ktb to reflect increased HIV screening in patients 
diagnosed with TB. Therefore, the total rate of ART initiation in TB treatment states 
equals ktb ( , ). 
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Figure S2.2: Modeled Trends in HIV Incidence and ART Coverage 
 
 
Plots present country-specific trends in HIV prevalence or ART coverage. (A) The prevalence of HIV 
among adults 15 years and older. Points represent UNAIDS estimates of prevalence at yearly intervals, 
while lines represent our interpolation/extrapolation of incidence rates from those data. (B) The proportion 
of persons living with HIV currently receiving ART. Points represent ART coverage from UNAIDS 
estimates. These estimates were used to fit sigmoid functions with ART coverage approaching a maximum 
of 60%. Lines represent the fitted functions which were used to model ART coverage. Dashed lines 
represent current trends extrapolated into the future.  




Notation and Conventions 
Core TB states are defined according to the following abbreviations: 
S = susceptible 
L = latently infected 
E = early-active TB (incipient TB, not yet seeking care) 
A = symptomatic active TB 
B1e = on effective first-line treatment (leading to culture conversion) 
B1i = on ineffective first-line treatment (remaining infectious) 
W = post-treatment, will relapse 
B2e1 = on effective second-line treatment (the initial six months of MDR-TB 
treatment, remaining partially infectious) 
B2e2 = on effective second-line treatment (the continuation phase of MDR-TB 
treatment, leading to culture conversion after 14 months) 
B2i = on ineffective second-line treatment (remaining infectious) 
Z = post second-line treatment, will relapse 
F = post second-line treatment, active MDR-TB 
C = diagnosed untreated MDR-TB 
X = any state above 
I = any infectious state above {E, A, B1i, B2e1, B2i, F, C} 
G = any diagnosis/treatment state above {B1e, B1i, B2e1, B2e2, B2i, C} 
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Populations in any of the above core TB states are additionally categorized using 
the following subscripts and superscripts (some combinations may be null): 
T = treatment status (a value of N indicates TB treatment-naïve; a value of P 
indicates previously-treated for TB) 
D = drug sensitivity status (a value of S indicates DS-TB infections; a value of R 
indicates MDR-TB infections) 
V = HIV status (a value of U indicates HIV-uninfected; a value of H indicates 
HIV-infected with High CD4 counts; a value of L indicates a HIV-
infected with Low CD4 counts; a value of A indicates HIV-infected and 
receiving ART) 
As described above, several rates and probabilities of core TB states are modified 
by TB treatment history and HIV status. Unless otherwise noted, parameter values with a 
superscript of naught (“0”) represent the rate/probability in HIV-negative, treatment-
naïve patients; values with a superscript of ∈ { , , , } reflect the multiplicative 
factor associated with each respective HIV substate; and values with a superscript of 
∈ { , } reflect the multiplicative factor associated with each respective category of 
TB treatment history. Thus, if ρ  represents the probability of rapid progression in HIV-
uninfected populations, then ρ ρ  represents the probability of rapid progression in HIV-
infected populations with a High CD4 count. (Multiplicative factors with superscripts of 
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Populations Susceptible to TB Infection 
The total population is initiated at a size of 100,000 and forced to remain at 
steady-state. The size of newly added populations is forced to equal the number of deaths 
in the population at any time, defined by the rates of background mortality (µ ), HIV-
associated mortality (µ ), and active-TB associated mortality (µ  , reduced by factors  
associated with early/incompletely treated active TB): 
( ) = ∑ ∑
 
∈
( )( + + ) + ∑
 
∉
( )( + )  ∈{ , , , }  (15) 
All newly added populations are divided between susceptible and latently infected 
states (described above). We define the forces of infection applied to individuals before 
entering the population at age 15 as using the approximate forces of infection distributed 
over the preceding 7.5 years: 
ˆ ( − 7.5) = ∑ ∑
 
∈{ }
( ( ) ( − 7.5))  ∈{ , , , }  (16) 
These approximate forces of infection are used to determine the number of new 
15-year olds entering the population as susceptible to TB infection. Newly added 
susceptible populations SN occur to replace deaths (excluding those latently infected) and 
those who self-cure (according to the rate of self-cure ( )) without treatment. 
Transitions from the susceptible state occur due to new infection (dependent on the time-
varying forces of infection ( ( )), described below) and death: 
= ( ) ∑ ˆ ( . )
 
∈{ , } + ∑
 
∈{ , }
( ) + ( ) − ( ) +
∑
∈{ , }
( )  (17) 
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All newly susceptible 15-year olds are modeled as initially HIV-uninfected 
(ignoring contributions from perinatal infection). In HIV-infected populations, new 
susceptible populations occur only through TB self-cure: 




( ) + ( ) − ( ) + + ∑
 
∈{ , }
( )  (18) 
Transitions into the previously-treated susceptible state SP occur as the result of 
self-cure ( ) of previously-treated patients with early-active EP (due to new infection 
after previous cure) or active TB AP (after failed treatment or new infection after previous 
cure).  
Effective first-line treatment B1eS can result in also durable cure (returning to the 
susceptible state SP) after treatment has been completed (duration τ = 6 months) 
without the acquisition of MDR during treatment (based on the probability of MDR 
acquisition during treatment α α ) in two ways: a) treatment is completed without loss to 
follow-up (based on the probability of loss during first-line treatment δ ) and without 
subsequent relapse (based on the probability of relapse among those with DS-TB who 
complete first-line treatment ω ω ); or b) treatment is not completed due to loss to 
follow-up but after a sufficiently curative treatment has been received (based on the 
proportion of those lost during first-line treatment who remain culture positive at the time 
of loss η ). Durable cure can also be achieved after the continuation phase of effective 
second-line B2e2 treatment (duration τ = 14 months) if relapse does not occur 
(probability 1 − ω ). Transitions out of the previously-treated susceptible state occur due 
to death or new infection. 






( ) + ( )
+ ∑  ∈{ , } ( ) ((1 − )(1 − ) + (1 − ))





Transmission of TB Infection 
New latently infected populations LN may result from the addition of previously-
infected 15-year olds (all assumed to be HIV-uninfected), new infections, or 
superinfection of already latently-infected populations. The total number of new 15-year 
olds is equal to the number of deaths M(t) as above, and the proportion that enters with a 
previous latent infection is determined by an exponential distribution of the cumulative 
estimated force of infection over 15 years (∑ ˆ ( − 7.5)  ∈{ , } ); these latent 
infections are divided between DS-TB and MDR-TB weighted by the strain-specific 
force of infection during this period ( ˆ ( − 7.5)).  
New infections from susceptible states S occur based on the current force of 
infection ( ) and the probability that new infections do not progress rapidly to 
early-active TB (1 − ρ ). The time-varying force of infection for a given TB strain 
( ) describes the cumulative, state-adjusted infectious person-time contributed by 
all TB cases. For a given infectious state , the population size of ( ) is reduced by 
the relative infectiousness of the core TB state ix (associated with early-active disease or 
incomplete/ineffective treatment) and the relative infectiousness of the HIV substate iV, 
and multiplied by the transmission efficiency β ( ) (defined above). 
( ) = ∑ ∑
 
∈{ }
( ( ) ( ))  ∈{ , , , }  (20) 
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Transitions between MDR-TB and DS-TB latent states (e.g., LNS to LNR) occur 
due to exogenous superinfections which do not progress rapidly (1 − ). Additional 
protection against rapid infection is afforded by an existing latent infection (based on the 
reduced probability of rapid progression in latently infected populations 1 − λ ). The 
proportions of superinfections which change state (e.g., latent DS-TB to latent MDR-TB) 
are weighted by the strain-specific transmission efficiencies such that, if β ( ) = β ( ), 
then half of reinfected latent DS-TB patients will transition to latent MDR-TB patient and 
vice versa.  
Transitions out of the new, latently infected state occur due to background 
mortality, reactivation to early-active TB (based on the constant rate of reactivation ( )), 
or reinfection followed by rapid progression (despite the protection afforded by an 
existing latent infection ((1 − λ )ρ )).  
( ) = ( )
ˆ ( . )
∑ ˆ ( . )  ∈{ , }
1 − ∑ ˆ ( . )
 
∈{ , }
+ (1 − ) ( )
+(1 − (1 − )) ( )
( ) ( )
( ) ( ) −
( )
( ) ( )
( ) ( )
− ( )( + ) − (1 − ) ( ) ∑ (  ∈{ , } ( ))
 (21) 
As described above, all new 15-year olds are assumed to be initially uninfected. 
Therefore, new additions to HIV-infected latent states occur due to new infections of 
susceptible populations and superinfections of latent populations. Losses occur in the 
same manner as HIV-uninfected latent populations. 
For	V	 ∈ { , , }:
= (1 − ) ( )
+(1 − (1 − )) ( )
( ) ( )
( ) ( ) −
( )
( ) ( )
( ) ( )
− ( )( + + ) − (1 − ) ( ) ∑ (  ∈{ , } ( ))
 (22) 
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Among previously-treated populations, latent infections LP result from new 
infections of previously-treated TB susceptible populations and superinfections of 
previously-treated, latently infected populations in the same manner as above. (Newly 
added 15-year olds are assumed to have negligible previous TB treatment history and are 
excluded from these populations upon initial entry.) 
( ) = (1 − ) ( )
+(1 − (1 − )) ( )
( ) ( )
( ) ( ) −
( )
( ) ( )
( ) ( )
− ( )( + + ) − (1 − ) ( ) ∑ (  ∈{ , } ( ))
 (23) 
 
Progression into early-active states E occur from a) a susceptible state S according 
to the force of infection and the proportion of infections which progress rapidly (ρ ρ ); 
b) from a latent state L due to reactivation of endogenous infection according to the rate 
of reactivation ( ); or c) from rapid progression of a recent, exogenous superinfection 
according to the proportion of infections which progress rapidly, reduced by the 
protection afforded by an existing latent infection ((1 − λ λ )ρ ρ ). Transitions from the 
early-active state occur due to death, spontaneous resolution, or progression to active TB. 
= ( ) ( ) + + (1 − ) ( ) ∑ ( )∈{ , }




Transitions into the symptomatic, active TB states A occur from the progression 
of early-active TB E according to the duration of early-active TB a. Transitions from the 
active disease state occur due to death, spontaneous resolution, or treatment initiation. 
= ( ) − + + + +  (25) 
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In those previously treated, active disease AP may additionally result from: a) 
relapse among those who will relapse W after the mean time to relapse (τ ); b) loss to 
follow-up (δ ) during ineffective first-line treatment B1i ; c) loss to follow-up during 
effective treatment B1e provided that culture conversion has not yet occurred (δ η ); or d) 
failing ineffective first-line therapy provided that treatment has been completed without 
loss to follow-up (1 − δ ) after treatment duration τ = 6 months and that care is not 
immediately reinitiated (1 − γ). 
= ( ) + ( )(1/ )
+ ∑ (1 − ) ( ) + ( )( + (1 − )(1 − ))  ∈{ , }
− ( ) + + + +
 (26) 
In those with MDR-TB, active disease APR may also result from the new 
acquisition of drug resistance during ineffective first-line therapy B1iS based on the 
probability of MDR acquisition during first-line treatment α α . (Patients with 
preexisting MDR-TB only initiate ineffective first-line treatment B1iR, described below.) 
= + ( )(1/ )
+ ∑ + ( )  ∈{ , } ( + (1 − )(1 − ))
− ( ) + + + +
 (27) 
Among those with MDR-TB who have been diagnosed and received DST, some 
may be lost before linkage to appropriate second-line therapy while others may not 
receive second-line therapy based on the specific drug resistance pattern (e.g., extensively 
drug resistant TB) and available drug regimens. These patients enter in the diagnosed 
active but untreated MDR-TB state C. These patients must first receive DST (with 
probability ( ), described above) at the time of diagnosis or re-evaluation (after a 
delay in diagnosis – duration x x  – or at the completion of a failed first-line regimen – 
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duration τ = 6 months). MDR-TB patients eligible to receive DST are those with 
active, untreated TB AR; those with pre-existing MDR-TB at the completion of an 
ineffective first-line regimen; or those with DS-TB who acquire MDR-TB during first-
line therapy B1eS with (probability α α ). Those receiving a first-line therapy are eligible 
for a DST re-evaluation provided they complete the first-line regimen without loss to 
follow-up (1 − δ ) and reinitiate care immediately upon completion (γ). After receiving 
DST, these patients are lost/declined second-line treatment with probability b. Losses 
from C occur due to death. 
= ∑ ( ) ( ) + ( ) ( ) + ( )  ∈{ , }
− ( )( + + )
 (28) 
MDR-TB patients who have initiated second-line treatment without successful 
completion enter the failed second-line therapy state F. These transitions include those 
who initiate successful treatment B2e1 but are subsequently lost to follow-up with 
probability δ ; those who experience treatment failure B2i (due to ineffective second-line 
therapy after duration τ = 6 months); or those complete treatment but subsequently 
relapse ZR (after a mean time to relapse τ ). Losses from F occur due to death. 
= ( ) + ( ) + ( ) − ( )( + + ) (29) 
 
TB Treatment 
Upon the initiation of treatment, TB patients are separated between effective and 
ineffective TB treatment states based on the probability of culture conversion among 
those who complete treatment (σ σ  for first-line therapy and σ  for second-line 
therapy). 
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Transitions into the effective first-line therapy B1e occur from the symptomatic 
active TB states A according after a mean delay before diagnosis (duration x x ). 
Transitions out of B1e occur due to death or ending treatment. 
= ( ) − ( )( + + 1/ ) (30) 
 Among those previously treated, effective first-line therapy B1eP may also be 
initiated following the failure of a previous first-line treatment regimen B1i. This only 
occurs provided the previous regimen was completed (after duration τ = 6 months) 
without loss to follow-up (1 − δ ), that retreatment is started immediately upon 
completion of the previous regiment (γ), and that MDR-TB was not acquired during the 
previous regimen (1 − α α )).  
= ( ) + ∑
 
∈{ , }
( )(1 − )(1 − )
− ( )( + + 1/ )
 (31) 
Among DS-TB patients, transitions into the state of ineffective first-line therapy 
B1iS occur from the same sources of effective first-line therapy above (according to the 
probability that treatment will not be successful 1 − σ σ ).  
= ( ) − ( )( + + 1/ ) (32) 
= (1 − ) ( ) + ∑
 
∈{ , }
( )(1 − )(1 − )
− ( )( + + 1/ )
 (33) 
In those with MDR-TB, all first-line therapy is ineffective. Transitions into B1iR 
occur from treatment initiation or re-initiation based on the proportion of cases which do 
not receive DST (1 − ( )).  
= ( ) − ( )( + + 1/ ) (34) 
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= ( ) ( ) + ∑ ( )(1 − ( ))(1 − )(1 − )  ∈{ , }
− ( )( + + 1/ )
 (35) 
 As with first-line therapy, TB patients initiating second-line therapy are separated 
between effective and ineffective TB treatment states based on the probability of culture 
conversion among those who complete treatment ( ). Those who enter the effective 
second-line treatment state begin with the initiation phase B2e1 (duration = 6 months) 
followed by the continuation phase B2e2 (duration = 14 months) upon completion of 
the initiation phase. Those who enter the ineffective second-line treatment state B2i will 
only receive treatment for a duration of τ  before treatment is withdrawn. 
Transitions into the initiation phase of effective second-line therapy B2e1 occur as 
the result of: a) symptomatic active MDR-TB which, after a delay (duration  ) 
before diagnosis, has received DST and was not lost before treatment initiation (( ) 
(1 − )); b) failure of ineffective first-line treatment for pre-existing MDR-TB B1iR or 
DS-TB (B1iS ) which subsequently acquired MDR-TB (with probability α α ). In the case 
of failure, patients must have completed treatment (duration τ = 6 months) without loss 
to follow-up followed by immediate retreatment(1 − )  . Transitions from B2e1 occur 
due to death or finishing the initiation phase. 
= (1 − ) ∑ ( ) ( ) + ( ) (1 − ) ( ( ) + ( ))  ∈{ , }
− ( )( + + + 1/ )
 (36) 
Transitions into ineffective second-line therapy for MDR-TB B2i occur from the 
same states as above.  
= (1 − )(1 − ) ∑ ( ) ( ) + ( ) (1 − ) ( ( ) + ( ))∈{ , }
− ( )( + + + 1/ )
 (37) 
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Transitions into the continuation phase of effective second-line therapy for MDR-
TB B2e2 occur only after completion of the initiation phase B2e1 (duration τ = 6 
months), provided patients were not lost to follow-up (1 − ). Transitions from this state 
occur due to death or finishing treatment (duration τ = 14 months). 
= ( ) − ( )( + + + 1/ ) (38) 
After Treatment 
Among those who complete effective first-line therapy B1e (culture negative at the 
end of treatment), a proportion ω  will eventually relapse to active TB A. Between the 
completion of first-line treatment and the time of relapse, these populations occupy an 
asymptomatic state W for a mean duration of τ . Transitions into W occur following 
completion of effective first-line therapy (after duration τ ) with or without the 
acquisition of MDR during treatment (based on the probability of acquisition α α ) 
leading to eventual relapse with DS-TB (WS) or MDR-TB (WR), respectively. Losses 
from these states occur due to death or relapse.  
= ∑ (1 − ) ( )  ∈{ , } − ( )( + + 1/ ) (39) 
= ∑ ( )∈{ , } − ( )( + + 1/ ) (40) 
Among those who complete effective second-line therapy B2e2 (culture negative at 
the end of treatment), a proportion ω  will eventually relapse to chronic (untreated) 
MDR-TB C. Between the completion of second-line treatment and the time of relapse, 
these populations occupy an asymptomatic state Z for a mean duration of τ . This 
population differs from that of WR through a history of attempted second-line therapy; 
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afterwards, those who relapse from Z will be ineligible for retreatment with second-line 
therapy. Losses from this state occur due to death or relapse. 
= ( ) − ( )( + + 1/ ) (41) 
 
HIV Infection 
 In addition to the rates of change across states of TB infection (and births/deaths) 
described above, transitions between HIV substates occur due to initial HIV infection 
(Uninfected to High CD4), gradual immunosuppression (High CD4 to Low CD4), or 
ART initiation. Interactions between TB state and HIV substate influence HIV mortality 
(excess mortality rates in Low CD4 patients with active, untreated TB; see Table S2.1) 
and the rate of ART initiation (HIV patients receiving TB treatment initiate ART at an 
increased rate).  
New High CD4 infections XH occur based on the fitted HIV force of infection 
(described above); prior to 2010, transitions from the High CD4 substate occur only due 
to immunosuppression or death. (In our notating convention, HIV-associated mortality is 
presented in differential equations of TB transitions above and is therefore not duplicated 
here.) After 2010, transitions from the High CD4 substate may occur due to death or 
ART initiation. 
New Low CD4 infections XL occur solely due to immunosuppression based on the 
rate of CD4 decline, with an approximate duration of 1/ϕ  between initial infection and 
decline below 250 CD4 cells/mL. Prior to 2006, transitions from the Low CD4 substate 
occur solely due to death; after 2006, transitions from the Low CD4 substate may occur 
due to death or ART initiation. 
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HIV-infected populations are assumed to be unable to access ART before at least 
2006. After 2006, Low CD4 populations become eligible for ART at a time-varying rate 
( ) described in detail above. After 2010, High CD4 populations also become eligible 
for ART at a rate lower than that among Low CD4 populations (determined by the 
relative proportion of new ART initiations from patients with High CD4 counts kH). For 
populations in any TB treatment state G, ART initiation occurs at an amplified rate 
( Ω( )). These dynamics are summarized as follows: 
For	X	 ∉ :  =
( ) ( ) − ( ) if	 < 2010
( ) ( ) − ( )( ( ) + ) if	 ≥ 2010
  
=
( ) if	 < 2006
( ) − ( ) ( )         if	 ≥ 2006
 (42) 
For	X	 ∈ : =
( ) ( ) − ( ) if	 < 2010
( ) ( ) − ( )( ( ) + ) if	 ≥ 2010
  
=
( ) if	 < 2006









0 if	 < 2006
( ) ∑
∉
( ( )) + ∑
∈
( ( )) if	2006 ≤ < 2010
( ) ∑
∉
( ( ) + ( )) + ∑
∈
( ( ) + ( )) if	 ≥ 2010
 (44) 
 
Sampling & Calibration 
 To enrich our projections using simulated TB epidemics which were most 
consistent with empirical estimates of TB epidemics in South Africa and Vietnam, we 
implemented a two-stage semi-Bayesian Sampling/Importance-Resampling algorithm 
[1]. In the first stage of calibration, parameter sets were composed of a single value for 
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each DS-TB or HIV parameter (drawn using Latin hypercube sampling [2], Tables S2.1-
2.2 below) while values for MDR-TB parameters (Table S2.3) were set to zero. Each 
parameter set was then assigned a likelihood value based on the DS-TB/HIV epidemic 
the set produced. Joint likelihoods were defined by the each epidemic’s pseudo-
likelihood of absolute TB incidence (per 100,000) in 2005, 2010, and 2015 (from WHO 
country estimates [3] ) as well as the proportion of incident TB cases infected with HIV. 
Targets for HIV calibration were taken from a 2012 national TB drug resistance survey in 
South Africa [4]; comparable data from surveys in Vietnam were unavailable, thus the 
most recent WHO estimate of incident HIV-infected TB cases (in 2015) was used. 
Targets were modeled as independent beta distributions with bounds set equal to the 95% 
confidence limits of estimated TB incidence; bounds were set equal to 85% and 115% of 
the HIV point estimate. (All calibration targets are presented in Table S2.4 below.) The 
product of each simulation’s pseudo-likelihoods was used as the joint likelihood of the 
corresponding DS-TB parameter set. Each parameter set was weighted then weighted 
according to the quotient of the set’s joint likelihood L(θi ; y) and the cumulative 
likelihood of all sets:  
= ( ; )∑ ;  (45) 
 DS-TB parameter sets were then resampled (with replacement) proportional to the 
weights assigned above. In the second stage of calibration, each resampled DS-TB 
parameter set was paired with a new MDR-TB parameter set (again drawn using Latin 
hypercube sampling, Table S2.3 below). Each new parameter set was then used to 
simulate a DS-TB epidemic to a time equal to the value of the MDR-TB parameter . 
After this time, MDR-TB epidemics were simulated forward to 2040. Each epidemic was 
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then assigned a new joint likelihood defined by the epidemics pseudo-likelihood of the 
proportion of recent TB diagnoses with MDR-TB among new and previously-treated 
cases.  




Table S2.1: TB Natural History Parameter Prior Distributions 
 Description Median Sampling Range† Distribution References 
μ0 Baseline mortality rate for ages 15+ (per year) 0.017 (0.015-0.018) Lognormal [5] 
μtb Added mortality rate of untreated symptomatic TB in HIV- populations (per year) 0.15 (0.07-0.3) Lognormal [3,6] 
ρ0 Probability of rapid progression after initial TB infection in HIV- populations 0.14 (0.07-0.25) Logit-normal [7] 
λ0 Protection by latent infection: reduction in rapid progression after second infection event in HIV- populations 0.5 (0.1-0.9) Logit-normal [7,8] 
r0 Reactivation rate, latent to early (asymptomatic) active TB in HIV- populations (per year) 0.001 (0.0005-0.002) Lognormal [8–11] 
a Duration of asymptomatic (preclinical) TB if no death or spontaneous resolution (years) 0.6 (0.36-1.0) Lognormal [12,13] 
iE 
Infectiousness and mortality of asymptomatic (preclinical) TB, relative to 
symptomatic TB in HIV- populations 0.22 (0.1-0.4) Logit-normal [14,15] 
ν0 Rate of spontaneous resolution of untreated active TB in HIV-populations (per year) 0.13 (0.08-0.2) Lognormal [6] 
x0 Time to TB diagnosis and treatment initiation (with pretreatment loss to follow up incorporated for DS-TB) in HIV- populations (years) 1 (0.67-1.5) Lognormal [3,12,16] 
σ10 
First-line treatment success (fraction of new DS-TB patients who will successfully 
complete treatment if adherent; includes those who may relapse with or without 
acquired resistance) 
0.98 (0.96-0.99) Logit-normal [3,17–19] 
σ1P 
Reduction in first-line treatment success for previously treated DS-TB patients 
(multiplicative factor) 0.95 (0.9-1.0) Uniform [3,20] 
 
†Sampling ranges represent the 2.5th to 97.5th percentiles of unbounded distributions and lower to upper bounds of uniform distributions.  
 
 




Table S2.1 (Continued): TB Natural History Parameter Prior Distributions 
ω10 
Relapse risk after first-line therapy (if no acquired drug resistance), new DS-TB 
patients 0.04 (0.026-0.06) Logit-normal [21,22] 
ω1P 
Increase in relapse risk after first-line therapy, retreatment DS-TB patients 
(multiplicative factor) 2 (1-3) Uniform [20,21] 
τω Median time to relapse, among patients who will relapse (years) 1.5 (0.9-2.5) Lognormal [21] 
δ1 Probability of loss to follow up during first-line therapy 0.06 (0.035-0.10) Logit-normal [3] 
η1 
Probability of returning to active TB after loss to follow-up during effective first-line 
treatment of DS-TB 0.4 (0.16-0.7) Logit-normal [23,24] 
Γ Probability of immediate retreatment after DS-TB treatment failure 0.92 (0.85-1.0) Uniform Model Assumption 
iA 
Infectiousness and mortality of TB on ineffective treatment, relative to 
untreated active TB 0.5 (0-1) Uniform 
Model 
Assumption 














Table S2.2: HIV and TB/HIV Parameter Prior Distributions 
 
†Sampling ranges represent the 2.5th to 97.5th percentiles of unbounded distributions and lower to upper bounds of uniform distributions.  
 Description Median Sampling Range Distribution References 
μH Added mortality rate of HIV+, High CD4 populations (per year) 0.05 (0.03-0.07) Lognormal  [25] 
μL Added mortality rate of HIV+, Low CD4 populations (per year) 0.27 (0.23-0.33) Lognormal [25] 
μA Added mortality rate of HIV+, receiving ART populations (per year) 0.01 (0.008-0.013) Lognormal [26] 
μtbL 
Excess added mortality rate of HIV+, Low CD4 individuals infected with untreated active 
TB (per year) 0.8 (0.5-1.3) Lognormal [27] 
φH Rate of transition from HIV+, High CD4 to HIV+, Low CD4 (per year) 0.2 (0.15-0.26) Lognormal [28,29] 
kH 
Reduced probability of initiating ART for HIV+, High CD4 populations relative HIV+, 
Low CD4 populations (after 2006 only) 0.33 (0.11-1.0) Logit-normal [30] 
ρH Relative increase in the probability of rapid progression of TB in HIV+, High CD4 populations 2.9 (1.8-4.7) Lognormal [27] 
ρL Relative increase in the probability of rapid progression of TB in HIV+, Low CD4 populations 8 (6.3-10.1) Lognormal [27] 
ρA Relative increase in the probability of rapid progression of TB in HIV+, on ART populations 2.9 (1.8-4.7) Lognormal [27] 
λH Relative reduction in the probability of protection against rapid progression upon reinfection in HIV+, High CD4 populations 0.25 (0-0.5) Uniform [31] 
λL Relative reduction in the probability of protection against rapid progression upon reinfection in HIV+, Low CD4 populations 0.25 (0-0.5) Uniform [31] 
λA Relative reduction in the probability of protection against rapid progression upon reinfection in HIV+, on ART populations 0.25 (0-0.5) Uniform [31] 
rH Relative increase in the rate of reactivation in HIV+, High CD4 populations 34 (20-60) Lognormal [32,33] 








rL Relative increase in the rate of reactivation in HIV+, Low CD4 populations 67 (31-158) Lognormal [32,33] 
rA Relative increase in the rate of reactivation in HIV+, on ART populations 34 (20-60) Lognormal [32,33] 
νH Relative reduction in the rate of spontaneous resolution in HIV+, High CD4 populations 0.5 (0-1) Uniform Model Assumption 
νL Relative reduction in the rate of spontaneous resolution in HIV+, Low CD4 populations 0.25 (0-0.5) Uniform Model Assumption 
νA Relative reduction in the rate of spontaneous resolution in HIV+, on ART populations 0.5 (0-1) Uniform Model Assumption 
iH Relative reduction in the infectiousness of HIV+, High CD4 populations 0.89 (0.53-0.98) Logit-normal [34,35] 
iL Relative reduction in the infectiousness of HIV+, Low CD4 populations 0.5 (0.12-0.88) Logit-normal [34] 
iA Relative reduction in the infectiousness of HIV+, on ART populations 0.89 (0.53-0.98) Logit-normal [34,35] 
ktb 
Relative increase in the rate of ART initiation in HIV+ TB patients receiving any form of 
TB treatment 2.4 (1.0-5.6) Lognormal [36] 
xA Relative reduction in the duration before TB treatment initiation in HIV+ TB patients receiving ART 0.43 (0.3-0.6) Lognormal [37] 




Table S2.3: MDR-TB Parameter Prior Distributions 
 Description Median Sampling Range Distribution References 
tR0 Time since emergence of modern MDR-TB strains (years) 30 (20-45) Lognormal [38,39] 
α0 Risk of acquired multidrug-resistance during first-line therapy, new DS-TB patients 0.004 (0.0015-0.01) Logit-normal [22] 
αP Increase in risk of acquired multidrug resistance, retreatment DS-TB patients (multiplicative factor) 2 (1-3) Uniform [20,40] 
b Pre-treatment loss to follow up after MDR-TB diagnosis 0.05 (0.025-0.10) Logit-normal [3,16] 
σ2 
MDR-TB treatment success (fraction of MDR-TB patients who successfully complete 
treatment if adherent; includes those who may relapse) 0.77 (0.66-0.85) Logit-normal [41–43] 
i2 
Infectiousness during the first six months of effective MDR-TB therapy, relative to 
untreated active TB 0.1 (0-0.2) Uniform [42,44] 
δ1 Probability of loss to follow up during MDR-TB therapy 0.11 (0.04-0.25) Logit-normal [41,45] 
ω2 Relapse risk after successful completion of conventional MDR-TB treatment 0.04 (0.015-0.1) Logit-normal [42,46] 
ER 
Transmissibility of drug-resistant strain, relative to drug-susceptible strain at the time 
of MDR emergence 0.6 (0.38-0.94) Lognormal [47–49] 
dR 
Annual rate of increase in MDR-TB Transmission coefficient (in the Shrinking Deficit 




Year of start of increase in MDR-TB Transmission coefficient (as a percentile of [tR0, 




†Sampling ranges represent the 2.5th to 97.5th percentiles of unbounded distributions and lower to upper bounds of uniform distributions.  




Table S2.4: Calibration Targets  
 




MDR-TBd in New 
Cases (%) 
MDR-TBd in Previously-
Treated Cases (%) 
Year Median (Range) Year Median (Range) Year 
Mean 
(Range) 
Year Mean (Range) 
South 
Africa 
2005 932 (603-1331) 2012 63.2 (62.2-64.2) 2002 1.6 (1.1-2.1) 2002 6.6 (4.9-8.2) 
2010 948 (710-1219)   2013 2.1 (1.5-2.7) 2013 4.6 (3.2-6.0) 
2015 834 (539-1190)       
Vietnam 
2005 176 (114-252) 2015 4.3 (4.0-4.6) 1996 2.3 (1.3-3.8) 1996 18.2 (11.9-24.5) 
2010 155 (114-202)   2002 2.3 (1.1-3.6) 2002 19.3 (14.0-25.0) 
2015 137 (110-166)   2005 2.7 (2.0-3.7) 2005 23.3 (16.7-29.9) 
    2011 4.0 (2.5-5.4) 2011 18.2 (11.9-24.5) 
 
aIncidence estimates were taken from WHO country reports (as published with the 2016 Global TB Report) [3].  
bThese estimates were modeled as independent beta distributions with bounds defined by the estimated 95% confidence intervals. 
cHIV targets represent the proportion of HIV-infected populations among all incident TB cases. Estimates were taken from the 2012 TB drug resistance survey in 
South Africa [4] and the 2016 WHO estimate in Vietnam. dMDR-TB targets represent the proportion of MDR-TB cases among all recent TB diagnoses (defined 
as any population transitioning from a state of active, untreated TB to a state of TB diagnosis/treatment). Estimates were taken from national drug resistance 
surveys in South Africa [4,50] and Vietnam [51]. These estimates were modeled as independent normal distributions with two standard deviations set equal to 
half the widths of the estimated 95% confidence intervals.
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Recent TB diagnoses were used (instead of incident TB cases) to recapitulate the 
sampling methodologies used in national drug resistant surveys: a representative 
sampling of prevalent TB cases who have recently submitted sputum specimens to public 
health facilities at the time of the survey. (Not all incident TB cases may be captured by 
survey methods; for example, due to delays between the onset of symptomatic TB and 
the time of presentation at a clinical center.) In our model, we define recent diagnoses as 
any populations transitioning from a state of active, untreated TB A into any treatment 
state G, regardless of whether appropriate/effective treatment is initiated afterwards.  
Targets for MDR-TB diagnoses were drawn from national drug resistance survey 
data in each country. To date, results from two such surveys in South Africa have been 
published (2002 and 2013) [4,50] while results from one such survey in Vietnam has 
been published (2011) [51]. Results from three additional surveys (1996, 2002, and 2005) 
have been provided to us by Dr. Nguyen Binh Hoa of the Vietnam National TB Program. 
(The 1996 survey only assessed MDR-TB in new TB patients.) Each MDR-TB 
calibration target was modeled as an independent normal distribution with means set 
equal to survey point estimates and standard deviations set equal to half the estimated 
95% confidence interval divided by Z=1.96. Joint likelihoods were calculated as the 
product of pseudo-likelihoods for each simulated epidemic, and weights were assigned in 
the same manner as above. Simulated MDR-TB epidemics were resampled (with 
replacement) proportional to these weights to create posterior distributions of epidemics 
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Bayesian Model Comparison 
 To compare the performance of our model scenarios, we calculated a Bayes 
Factor for each pair of scenarios in each country. A Bayes Factor is traditionally defined 
as the posterior odds to prior odds ratio [52]. For posterior distributions from any two 
models ( | ) and ( | ) and data y (our empirical calibration targets), a Bayes 
Factor can be defined as: 
= ( | )/ ( )
( | )/ ( )
 (46) 
(In this notation, ( ) and ( ) represent the prior distributions of each model.) As with 
common Monte Carlo approximations to Bayesian inference, if independent samples are 
drawn from ( ) and ( ), the BF may be consistently estimated by [52]: 
∑ ( ; )
∑ ( ; )
 (47) 
In our approach, the number of independent simulations run in each scenario’s 
prior distribution was equal ( = ). Therefore, the BF is approximated by the ratio of 
the sums of likelihood values for the n prior simulations (before resampling) in each 
scenario (∑ ( ; )). When presented in the text, the Constant Deficit scenario is 
used as the denominator model ( | ) in calculating a BF unless noted otherwise. 
 
Replication of Previous Findings 
 After review of our primary results, we noted important discrepancies in our 
projections of the MDR-TB epidemic in South Africa under the No Deficit scenario and 
those published in a similar study by Sharma and colleagues in which the transmission 
efficiency of DS-TB and MDR-TB were assumed to be identical [53]. Notably, their 
work projected the relative incidence of MDR-TB in South Africa to be 5.7% (95% UR: 
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3.0-7.6%) by 2040, significantly lower and with less variance than our estimates. In an 
attempt to reconcile these projections, we undertook to identify the source(s) of these 
discrepancies in our approach. 
 In reviewing the methodology of the previously published study, we identified 
several parameters with comparable surrogates in our model where our values diverged. 
Whereas our colleagues parameterized the 5-year probability of latent TB reactivation 
with a median of 2.9%, we parameterized the rate of TB reactivation r0 with a median of 
0.1 per 100 person-years (equivalent to a 5-year probability of 0.5%). Additionally, they 
parameterized the median probabilities of acquiring active TB and latent TB from an 
infectious index case as 3.3% and 51%, respectively. It follows that, among those who 
acquire a new TB infection, approximately 6% would bypass the latent state 
(3.3/(51+3.3). We parameterized the comparable median probability of rapid progression 
upon acquiring a new TB infection ρ0 as 14%. Finally, our colleagues’ approach to the 
rate of treatment initiation used a case detection rate of 75% with a wide prior 
distribution (3-98%) for the probability that TB patients will initiate effective treatment 
following detection. The posterior of this distribution is significantly narrower (6-26%) 
with a low median value (11.3%). This implies that only 8% of DS-TB patients would 
initiate effective TB treatment in South Africa; equivalently, the mean time between TB 
onset and treatment initiation would be 11 years. By comparison, we parameterized the 
mean delay between TB onset and treatment initiation as 12 months. 
 To replicate these previously published results, we altered our parameter priors in 
a stepwise manner. First, in our Slower Epidemic scenario, we decreased the prior 
probability of rapid progression ρ0 upon new infection from 14% (95% range: 7-25%) to 
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4% (95% range: 1-15%) and increased the range for the rate of latent TB reactivation r0 
from 0.05-0.2 per 100 person-years to 0.01-1.0 per 100 person-years and executed our No 
Deficit scenario as before. Afterwards, in our Delayed Treatment scenario, we 
additionally increased the prior duration of time between TB onset and treatment 
initiation from 12 months (95% range: 8-18 months) to 10 years (95% range: 7.5-12.5 
years). To assess model performance, we calculated Bayes Factors comparing these two 
new scenarios with our No Deficit scenario and our Constant Deficit scenario. 
 
Sensitivity Analyses 
 We implemented two strategies in our sensitivity analyses. For each parameter in 
each scenario, we calculated the partial rank correlation coefficient (PRCC) between the 
parameter’s posterior values and two primary outcomes of interest generated from 
simulations with those values: the absolute 2040 MDR-TB incidence and the fold change 
in the relative MDR-TB incidence (as a proportion of all TB) between 2016 and 2040. 
This multivariate analysis evaluates the strength of rank correlation between a parameter 
input value and the associated outcome value, adjusting for all other parameters. 
Additionally, in a univariate approach, we stratified outcome values across quintiles of 
parameter values. Briefly, for each parameter in each scenario, posterior simulations were 
ordered by parameter value (least to greatest). The bottom 20% of simulations (those with 
the lowest parameter values) and the top 20% of simulations (those with the highest 
parameter values) were identified and outcomes of simulations in each quintile were 
plotted. In cases where a parameter is highly influential on an outcome, a clear separation 
is expected between the distributions of the outcome in the lowest and highest quintiles of 
   
239 
 
the parameter’s value. In cases where a parameter is not influential, the distribution of 
outcomes is not expected to differ significantly between quintiles of the parameter’s 
value.  
 
Sensitivity to Conditions at Initiation 
 All simulations were initiated under the same initial conditions: in a population of 
100,000 members, 49.5% were latently infected (in state LNSU), 0.3% were in a state of 
early-active TB (state ENSU), 0.2% were in a state of active TB (state ANSU), and the 
remaining 50% were uninfected (state SNU). Simulations were initiated 150 years before 
the present and run without interruption until the introduction of MDR-TB (sampled 
between 1971 and 1996) or the introduction of HIV (1990 in all simulations). To evaluate 
the behavior of the ODE system under different initial conditions, the parameter set 
producing the maximum likelihood DS-TB simulation under these initial conditions was 
subsequently used to simulate epidemics following a variety of alternative initial 
conditions. For these alternative conditions, the prevalence of active DS-TB cases was 
varied between 0.001% and 90% and the prevalence of latent TB infection among those 
without active TB was varied between 0% and 99%; these simulations were again 
initiated 150 years before the present and run without interruption until the introduction 
of MDR-TB or HIV.  
 
  







 As described in the Methods, our scenarios were calibrated in a two-stage semi-
Bayesian algorithm. The results of the second stage of calibration – using empirical 
estimates of MDR-TB incidence – are presented in Chapter IV (Figure 4.3). The results 
of the first stage of calibration – using estimates of absolute TB incidence and HIV 
among incident TB cases – are presented in Figure S2.3. All Bayes Factors calculated 
between the three primary scenarios examined are presented in Table S2.5. Posterior 
distributions of parameter values resampled during calibration in the Constant Deficit and 
Shrinking Deficit scenarios are compared with the prior distributions used for Latin 
hypercube sampling in Figures S4-S6 (South Africa) and in Figures S7-S9 (Vietnam). 
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Figure S2.3: TB and HIV Incidence Calibration Results 
A – South Africa 
 
B – Vietnam 
 
 
Simulated epidemics are weighted according to how well each reproduced empirical calibration targets 
(historical estimates of absolute TB incidence and the proportion of incident TB cases infected with HIV). 
Red points represent median values and bounds for calibration targets drawn from WHO estimates and 
national survey data. IQR represents 25th to 75th percentiles and the 90% range represents the 5th to 95th 
percentiles of posterior simulations. 
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Table S2.5: Model Comparison with Bayes Factors 








No Efficiency Deficit 67,380,983 3354 
Constant Efficiency 
Deficit 
Shrinking Efficiency Deficit 2.6 2.1 
Shrinking Efficiency 
Deficit 
No Efficiency Deficit 25,868,566 1607 
 
aThe model used in the numerator of the calculation of the Bayes Factor (i.e., ( | ) in Equation 47 
above). 
bThe model used in the denominator of the calculation of the BF (i.e., ( | ) in Equation 47 above). 
cThe BF corresponding to the performance of the numerator model relative to the denominator model in 
South Africa. 
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Figure S2.4: TB Natural History Parameter Distributions – South Africa 
 
The probability distribution function used to sample initial values for each parameter (the prior distribution) 
is illustrated in Black in each plot. (Identical prior distributions were used to sample parameter values in 
both Constant Deficit and Shrinking Deficit scenarios.) The distribution of values for each parameter after 
resampling in the Constant Deficit scenario is illustrated in Blue in each plot. The distribution of values for 
each parameter after resampling in the Shrinking Deficit scenario is illustrated in Red in each plot. See 
Table S2.1 for full descriptions, sampling ranges, and references for each parameter and prior distribution. 
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Figure S2.7: TB Natural History Parameter Distributions – Vietnam 
 
 
The probability distribution function used to sample initial values for each parameter (the prior distribution) 
is illustrated in Black in each plot. (Identical prior distributions were used to sample parameter values in 
both Constant Deficit and Shrinking Deficit scenarios.) The distribution of values for each parameter after 
resampling in the Constant Deficit scenario is illustrated in Blue in each plot. The distribution of values for 
each parameter after resampling in the Shrinking Deficit scenario is illustrated in Red in each plot. See 
Table S2.1 for full descriptions, sampling ranges, and references for each parameter and prior distribution. 
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 The primary outcomes of interest in our study were the projected changes 
absolute and relative incidences of MDR-TB over time. Results of these outcomes in the 
Constant Deficit and Shrinking Deficit scenarios are presented in Chapter IV. Here, we 
present results of these outcomes in the No Deficit scenario in Figure S2.10.  
 Additionally, we investigated several secondary outcomes of interest in all 
scenarios. Projections of the absolute TB incidence (used to calculate the relative MDR-
TB incidence presented in Chapter IV) are illustrated in Figure S2.11. The proportion of 
incident MDR acquired during recent first-line therapy is presented in Figure S2.12. 
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Figure S2.10: Projections of the MDR-TB Burden in the No Deficit Scenario 
 
 
Simulated MDR-TB epidemics were projected from 2010 to 2040. Panels A and B demonstrate the 
projected absolute MDR-TB incidence in each country, while Panels C and D demonstrate MDR-TB as a 
proportion of all incident TB. The 2040 projected median (IQR) values are included in the upper right of 
each panel. IQR represents 25th to 75th percentiles and the 90% range represents the 5th to 95th percentiles 
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Figure S2.11: Projections of the Absolute Burden of TB 
 
 
Simulated MDR-TB epidemics were projected from 2010 to 2040, and the absolute incidence of all forms 
of TB (DS-TB and MDR-TB) are illustrated. Panels A and D represent projections in the Constant Deficit 
scenario in each country; panels B and E represent projections in the Shrinking Deficit scenario; panels C 
and F represent projections in the “Equal Transmission Efficency” scenario. The 2040 projected median 
(IQR) values are included in the upper right of each panel. IQR represents 25th to 75th percentiles and the 
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Figure S2.12: Projections of Acquired Drug Resistance 
 
 
In our model, the acquisition of drug resistance (ADR) is defined as occurring at the time any population 
exits a DS-TB treatment state (B1eS or B1iS) and enters a state of symptomatic MDR-TB, will relapse with 
symptomatic MDR-TB, or initiates MDR-TB treatment (APR , B1iPR, WR, B2e1, B2i, or CR). The transmission 
of drug resistance (in the calculation of proportion ADR) is defined as occurring at the time any 
asymptomatic, treatment-naïve population experiences the first onset of detectable MDR-TB (from S or LR 
to ER). The projected proportion of all recent-onset MDR-TB due to ADR is illustrated above. Panels A and 
D represent projections in the Constant Deficit scenario in each country; panels B and E represent 
projections in the Shrinking Deficit scenario; panels C and F represent projections in the No Deficit 
scenario. The 2040 projected median (IQR) values are included in the upper right of each panel. IQR 











Replication of Previous Findings 
 In our modeling approach, posterior simulations in the No Deficit scenario were 
poorly supported by empirical data and projections of the relative incidence of MDR-TB 
in South Africa estimated that MDR-TB would composed 22% (IQR: 11-51%; Figure 
S2.10 above) by 2040, significantly higher than the estimate of 5.7% (95% UR: 3.0-
7.6%) published by Sharma and colleagues using a comparable model [53]. In our 
attempt to replicate their results using our No Deficit scenario, we first altered prior 
distributions for two parameters – the probability of rapid progression upon initial TB 
infection and the rate of reactivation upon latent infection – such that simulated TB 
epidemics were driven less by rapidly progressing TB and driven more by the 
reactivation of latent TB, leading to a more slowly developing TB epidemic. The 
calibration results of this Slower Epidemic scenario are presented in Figure S2.13, in 
comparison with the results of our Constant Deficit and No Deficit scenarios. This 
Slower Epidemic scenario was supported even less by empirical data relative to our No 
Deficit scenario (BF=24). As the Slower Epidemic becomes driven by reactivation, a 
high proportion of incident TB cases are among those living with HIV; this higher than 
expected proportion of HIV in TB cases performs poorly to our calibration of HIV/TB 
coinfection targets. In the Slower Epidemic scenario, we project MDR-TB will account 
for 17% of all incident TB by 2040 (see Figure S2.14).  
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Simulated epidemics are weighted according to how well each reproduced empirical calibration targets. 
Red points represent median and 95% confidence intervals for calibration targets drawn from national 
survey data. For comparison, results from the Constant Deficit scenario and the No Deficit scenario (Figure 
4.3) are reproduced here. IQR represents 25th to 75th percentiles and the 90% range represents the 5th to 
95th percentiles of posterior simulations. 
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Simulated MDR-TB epidemics in South Africa were projected from 2010 to 2040. Panels in the top row 
illustrate the projected absolute MDR-TB incidence, while panels in the lower row illustrate MDR-TB as a 
proportion of all incident TB. For comparison, results from the Constant Deficit scenario (Figure 4.4) and 
the No Deficit scenario (Figure S2.10 above) are reproduced here. The 2040 projected median (IQR) values 
are included in the upper right of each panel. IQR represents 25th to 75th percentiles and the 90% range 
represents the 5th to 95th percentiles of posterior simulations. 
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 These results were still meaningfully higher than the estimates published by 
Sharma and colleagues. We therefore adjusted this scenario further by increasing the 
prior distribution of the duration of delay between the onset of TB and the initiation of 
care from a median of 12 months to a median of 10 years, comparable to the posterior 
probability of effective DS-TB treatment initiation published by Sharma and colleagues. 
In this Delayed Treatment scenario, few TB patients (DS-TB or MDR-TB) receive 
treatment of any kind, having died of TB or self-cured before treatment begins. As a 
result, MDR-TB exerts little competitive advantage over DS-TB (through lower 
probabilities of cure and longer durations of symptomatic, infectious disease). With this 
additional adjustment, the Delayed Treatment scenario was better supported by empirical 
data than the Slower Epidemic scenario (BF>106) but still more poorly supported relative 
to our Constant Deficit scenario (BF=0.08); calibration results of this model are presented 
in Figure S2.15.  
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Simulated epidemics are weighted according to how well each reproduced empirical calibration targets. 
Red points represent median and 95% confidence intervals for calibration targets drawn from national 
survey data. For comparison, results from the No Deficit scenario (Figure 4.3) and the Slower Epidemic 
scenario (Figure S2.13 above) are reproduced here. IQR represents 25th to 75th percentiles and the 90% 
range represents the 5th to 95th percentiles of posterior simulations. 
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In the Delayed Treatment scenario, we project that MDR-TB will account for 6% 
(IQR: 5-7%) of incident TB in South Africa by 2040 (see Figure S2.16), comparable to 
the estimate published by Sharma and colleagues. This implies that the discrepancies 
between our primary results and those previously published may not be due to 
fundamental differences in model structures or statistical approaches but can be explained 
largely by differences in the selection of parameter priors. Parameter selection is a 
delicate task and even minor differences in prior distributions may affect long-term 
projections [54]. A number of epidemiological studies have examined primary 
progressive TB and TB reactivation, with some variation in estimates between studies 
and between demographic groups within studies [7,9,8,10,11]. These estimates may be 
parameterized in several ways, and the values used in our Slower Epidemic scenario may 
be consistent with this body of literature.  
More uncertainty exists around the probabilities and timing of care seeking, 
diagnosis, referral, and treatment initiation in South Africa, and parameterizing these 
processes is complex. Nonetheless, WHO estimates of treatment initiation indicate that 
54% (95% confidence interval: 40-78%) of incident TB cases in South Africa were 
diagnosed in 2016 [3], and measured total delays in Africa before treatment initiation 
may be 1-2 orders of magnitude shorter than our modified median prior value of 10 years 
[55–57]. Therefore, while our Delayed Treatment scenario may perform well statistically, 
it is unlikely to be an accurate or informative representation of the current MDR-TB 
epidemic in South Africa. 
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Simulated MDR-TB epidemics in South Africa were projected from 2010 to 2040. Panels in the top row 
illustrate the projected absolute MDR-TB incidence, while panels in the lower row illustrate MDR-TB as a 
proportion of all incident TB. For comparison, results from the No Deficit scenario and the Slower 
Epidemic scenario (Figure S2.14 above) are reproduced here. The 2040 projected median (IQR) values are 
included in the upper right of each panel. IQR represents 25th to 75th percentiles and the 90% range 








 As described in the Supplementary Methods, we performed multivariate 
sensitivity analyses using PRCCs and univariate sensitivity analyses using parameter 
quintiles associated with two primary outcomes: the absolute incidence of MDR-TB in 
2040 and the fold change in the relative incidence of MDR-TB between 2016 and 2040. 
Results of sensitivity analyses around the absolute MDR-TB incidence in 2040 for all 
parameters in South Africa are presented in Figures S2.17-S2.22, and results of analyses 
around the fold change in relative incidence are presented in Figures S2.22-S2.28. 
Results of sensitivity analyses around the absolute MDR-TB incidence in 2040 in 
Vietnam are presented in Figures S2.29-S2.34, and results of analyses around the fold 
change in relative incidence are presented in Figures S2.35-S2.40. 
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Figure S2.17: Sensitivity Analysis – PRCCs of TB Natural History Parameters and 
Absolute MDR-TB Incidence – South Africa 
 
Each bar represents the partial rank correlation coefficient of the association between each model parameter 
and the the primary outcome (the incidence of MDR-TB in 2040), adjusting for all other parameters in the 
model. Beneath each parameter label is the sampling range from which parameter values were sampled. 
 
Figure S2.18: Sensitivity Analysis – Absolute MDR-TB Incidence by TB Natural 
History Parameter Quintiles – South Africa 
 
Each boxplot represents the distribution of values for the primary outcome (the incidence of MDR-TB in 
2040) within a given set of simulations. Pairs of boxplots represent groups of simulations categorized by 
values of a single input parameter: red boxplots represent the outcomes of those simulations with parameter 
values in the upper 20% of all simulations; blue boxplots represent the outcomes of those simulations with 
parameter values in the lower 20% of all simulations. More influential parameters demonstrate a greater 
separation of the distributions of outcome between simulations in the upper quintile and simulations in the 
lower quintile of parameter values. To the left of each panel are included the input parameter values 
corresponding to the accompanying quintile. In black is represented the overall distribution of the outcome 
across all simulations and the median estimate is drawn as a vertical dotted line. Boxes represent the 
median, 25th, and 75th percentiles of the distribution of outcomes; whiskers represent the 5th and 95th 
percentiles of the distribution of outcomes. In the Constant Deficit model, parameters involving the 
increase in MDR-TB transmission efficiency are excluded. 




Figure S2.17: Sensitivity Analysis – PRCCs of TB Natural History Parameters and Absolute MDR-TB Incidence – South 
Africa 




Figure S2.18: Sensitivity Analysis – Absolute MDR-TB Incidence by TB Natural History Parameter Quintiles – South Africa 
 




Figure S2.18 (Continued): Sensitivity Analysis – Absolute MDR-TB Incidence by TB Natural History Parameter Quintiles – 
South Africa 




Figure S2.19: Sensitivity Analysis – PRCCs of HIV and HIV/TB Parameter and Absolute MDR-TB Incidence – South Africa 
 




Figure S2.20: Sensitivity Analysis – Absolute MDR-TB Incidence by HIV and HIV/TB Parameter Quintiles – South Africa 
 




Figure S2.20 (Continued): Sensitivity Analysis – Absolute MDR-TB Incidence by HIV and HIV/TB Parameter Quintiles – 
South Africa 
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Figure S2.21: Sensitivity Analysis – PRCCs of MDR-TB Parameters and Absolute 
MDR-TB Incidence – South Africa 
 




Figure S2.22: Sensitivity Analysis – Absolute MDR-TB Incidence by MDR-TB Parameter Quintiles – South Africa 




Figure S2.23: Sensitivity Analysis – PRCCs of TB Natural History Parameters and Change in Relative MDR-TB Incidence – 
South Africa 
 




Figure S2.24: Sensitivity Analysis – Change in Relative MDR-TB Incidence by TB Natural History Parameter Quintiles – 
South Africa 
 




Figure S2.24 (Continued): Sensitivity Analysis – Change in Relative MDR-TB Incidence by TB Natural History Parameter  
Quintiles – South Africa 




Figure S2.25: Sensitivity Analysis – PRCCs of HIV and HIV/TB Parameter and Change in Relative MDR-TB Incidence – 
South Africa 




Figure S2.26: Sensitivity Analysis – Change in Relative MDR-TB Incidence by HIV and HIV/TB Parameter Quintiles – South 
Africa 
  




Figure S2.26 (Continued): Sensitivity Analysis – Change in Relative MDR-TB Incidence by HIV and HIV/TB Parameter 
Quintiles – South Africa 
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Figure S2.27: Sensitivity Analysis – PRCCs of MDR-TB Parameters and Change in 
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Figure S2.28: Sensitivity Analysis – Change in Relative MDR-TB Incidence by MDR-TB Parameter Quintiles – South Africa 
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Figure S2.29: Sensitivity Analysis – PRCCs of TB Natural History Parameters and Absolute MDR-TB Incidence – Vietnam 
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Figure S2.30: Sensitivity Analysis – Absolute MDR-TB Incidence by TB Natural History Parameter Quintiles – Vietnam 
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Figure S2.30 (Continued): Sensitivity Analysis – Absolute MDR-TB Incidence by TB Natural History Parameter Quintiles – 
Vietnam 
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Figure S2.31: Sensitivity Analysis – PRCCs of HIV and HIV/TB Parameter and Absolute MDR-TB Incidence – Vietnam 
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Figure S2.32: Sensitivity Analysis – Absolute MDR-TB Incidence by HIV and HIV/TB Parameter Quintiles – Vietnam 
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Figure S2.32 (Continued): Sensitivity Analysis – Absolute MDR-TB Incidence by HIV and HIV/TB Parameter Quintiles – 
Vietnam 
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Figure S2.33: Sensitivity Analysis – PRCCs of MDR-TB Parameters and Absolute 
MDR-TB Incidence – Vietnam 
 




Figure S2.34: Sensitivity Analysis – Absolute MDR-TB Incidence by MDR-TB Parameter Quintiles – Vietnam 
 




Figure S2.35: Sensitivity Analysis – PRCCs of TB Natural History Parameters and Change in Relative MDR-TB Incidence – 
Vietnam 
 




Figure S2.36: Sensitivity Analysis – Change in Relative MDR-TB Incidence by TB Natural History Parameter Quintiles – 
Vietnam 
 




Figure S2.36 (Continued): Sensitivity Analysis – Change in Relative MDR-TB Incidence by TB Natural History Parameter 
Quintiles – Vietnam 
 




Figure S2.37: Sensitivity Analysis – PRCCs of HIV and HIV/TB Parameter and Change in Relative MDR-TB Incidence – 
Vietnam 
 




Figure S2.38: Sensitivity Analysis – Change in Relative MDR-TB Incidence by HIV and HIV/TB Parameter Quintiles – 
Vietnam 
 




Figure S2.38 (Continued): Sensitivity Analysis – Change in Relative MDR-TB Incidence by HIV and HIV/TB Parameter 
Quintiles – Vietnam 
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Figure S2.39: Sensitivity Analysis – PRCCs of MDR-TB Parameters and Change in 









Figure S2.40: Sensitivity Analysis – Change in Relative MDR-TB Incidence by MDR-TB Parameter Quintiles – Vietnam 
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Sensitivity to Conditions at Initiation 
 To evaluate the behavior of the epidemic system of equations with varying initial 
conditions, the set of DS-TB parameters which produced the maximum likelihood 
simulation under standard conditions was used as a “base case” to compare the system’s 
behavior. The incidence of DS-TB and the prevalence of TB infection in this “base case” 
simulation under standard initial conditions are presented in Figure S2.41.  
Alternative simulations using the same parameter set were initiated under a 
variety of different conditions. The prevalence of active DS-TB was varied between 
0.001% and 90%, and the prevalence of latent TB among those without active TB was 
varied between 0% and 99%. The behavior of the system was compared by examining 
time-trends in TB incidence (Figure S2.42) and the total prevalence of infection (Figure 
S2.43) in these alternative simulations before the introduction of MDR-TB or HIV. For 
reference the “base case” epidemic is plotted in red in each panel. While early behavior 
of the system is quite variable, in the decades preceding the introduction of MDR-TB and 
HIV all simulations approach the same equilibrium values of TB incidence 
(approximately 379 per 100,000) and prevalence of infection (approximately 71%). 
Additionally, the population of each state in each simulation in 1989 was compared to the 
population of each state in the “base case” simulation in 1989. Relative differences 
between the populations of each compartment in each simulation and those of the “base 
case” simulation are presented in Table S2.6. Regardless of the initial conditions of the 
system, the size of each compartment was within 7% of the value of the “base case” 
simulation by 1989, indicating that the differential equation system is stable with regard 
to the conditions of the system at the time of initiation. 
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Figure S2.41: Behavior of the “Base Case” DS-TB Simulation after Initiation  
 
 
The parameter set which produced the maximum likelihood DS-TB epidemic (see Sampling & Calibration) 
was selected as a “Base Case” to evaluate the behavior of the ODE system under varying initial conditions. 
Here, the maximum likelihood epidemic was simulated using standard initial conditions (50% uninfected, 
45.5% latently infected, 0.3% active TB, 0.2% early-active TB). The epidemic was initiated 150 years 
before the present and run without interruption until the introduction of either MDR-TB or HIV. 
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Plots represent the annual incidence of DS-TB cases since the time of simulation initiation (150 years 
before the present) until the introduction of MDR-TB or HIV. Curves in blue represent the behavior of the 
system under different combinations of the prevalence of active TB and latent TB infection at initiation. 
For comparison, in each panel the behavior of the “base case” simulation with standard initial conditions is 
plotted in red. 
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Figure S2.43: Impact of Initial Conditions on the Prevalence of TB Infection  
 
 
Plots represent the prevalence of all types of DS-TB infection and disease since the time of simulation 
initiation (150 years before the present) until the introduction of MDR-TB or HIV. Curves in blue represent 
the behavior of the system under different combinations of the prevalence of active TB and latent TB 
infection at initiation. For comparison, in each panel the behavior of the “base case” simulation with 
standard initial conditions is plotted in red.




Table S2.6: Percent Difference in State Sizes between Base Case and Alternative Initial Conditions in1989 
Alternative Initial Conditions  
(150 years before the present) 
SN SP LN LP EN EP AN AP B1eN B1eP B1iN B1iP W 
0.001% Active TB, 0% Latent TB 4.10 0.37 0.68 3.00 0.02 0.01 0.01 0.01 0.01 <0.01 <0.01 <0.01 <0.01 
0.001% Active TB, 10% Latent TB 0.24 0.02 0.35 0.56 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
0.001% Active TB, 50% Latent TB 0.07 0.01 0.23 0.28 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
0.001%Active TB, 75% Latent TB 0.04 0.02 0.27 0.29 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
0.001% Active TB, 99% Latent TB 0.01 0.02 0.33 0.32 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
0.1% Active TB, 0% Latent TB 0.17 0.01 0.21 0.37 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
0.1% Active TB, 10% Latent TB 0.11 0.01 0.16 0.27 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
0.1% Active TB, 50% Latent TB 0.05 0.01 0.18 0.22 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
0.1% Active TB, 75% Latent TB 0.03 0.02 0.24 0.25 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
0.1% Active TB, 99% Latent TB 0.01 0.02 0.31 0.29 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
1% Active TB, 0% Latent TB 0.08 0.03 0.47 0.52 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
1% Active TB, 10% Latent TB 0.07 0.02 0.41 0.45 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
1% Active TB, 50% Latent TB 0.04 0.01 0.17 0.20 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
1% Active TB, 75% Latent TB 0.03 <0.01 0.04 0.07 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
1% Active TB, 99.% Latent TB 0.03 0.01 0.07 0.03 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
10% Active TB, 0% Latent TB 0.33 0.08 2.30 2.60 0.01 0.01 0.01 0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
10% Active TB, 10% Latent TB 0.32 0.08 2.30 2.50 0.01 0.01 0.01 0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
10% Active TB, 50% Latent TB 0.30 0.08 2.10 2.30 0.01 0.01 <0.01 0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
10% Active TB, 75% Latent TB 0.28 0.07 1.90 2.10 0.01 0.01 <0.01 0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
10% Active TB, 99.% Latent TB 0.27 0.07 1.80 2.00 0.01 0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
90% Active TB, 0% Latent TB 0.75 0.19 6.40 6.90 0.02 0.02 0.01 0.02 0.01 0.01 <0.01 <0.01 <0.01 
90% Active TB, 10% Latent TB 0.75 0.19 6.40 6.90 0.02 0.02 0.01 0.02 0.01 0.01 <0.01 <0.01 <0.01 
90% Active TB, 50% Latent TB 0.75 0.19 6.40 6.90 0.02 0.02 0.01 0.02 0.01 0.01 <0.01 <0.01 <0.01 
90% Active TB, 75% Latent TB 0.75 0.19 6.40 6.90 0.02 0.02 0.01 0.02 0.01 0.01 <0.01 <0.01 <0.01 
90% Active TB, 99% Latent TB 0.75 0.19 6.40 6.90 0.02 0.02 0.01 0.02 0.01 0.01 <0.01 <0.01 <0.01 
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